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The Human Epidermal Growth Factor Receptor (EGFR or HER) family consists of four 
members (ErbB or HER1-4) and belongs to the super-family of receptor tyrosine kinase 
(RTK). Mutation and/or over-expression of these receptors are implicated in various 
cancer types and they have been subject of intense research for anti-cancer therapies. 
However, effectiveness of current targeted therapeutics, either treatment with tyrosine 
kinase inhibitors (TKIs) or antibodies (and even a combination of both) differs from 
patient to patient. Even in cases when these therapies are initially effective, the disease 
returns back exploiting its complexity (EGFR signalling through different pathways) or 
other defence mechanism (e.g. altered signalling via EGFR mutations). A better 
understanding of EGFR structure and TKIs mechanism of action are therefore 
imperative to understand the function of the receptor during treatment and for 
improving the efficiency of future therapeutics. 
In order to address some of the aforementioned unknown aspects, I require tools and 
methods that would allow me to investigate the structure of the receptor on cells in basal 
and EGF activated states as well as the conformational changes induced by TKI 
binding. 
Following the development of methods previously reported by my group to probe the 
structure of the ECD, I have developed a range of different fluorescently labelled TKIs 
(fTKIs) for labelling the ICD of the receptor in vitro. These fTKIs are comprised of the 
pharmacophore and of the fluorophore and target the ATP-binding site of receptor 
which is the “heart” of the ICD. Characterization of fTKIs’ binding by confocal 
microscopy showed their ability to be used as reporters of receptor’s activation state. 
For the ECD labelling, I have used existing fluorescent probes (non-activating 
molecules and activating ligands) and have employed a combination of advanced 
single-molecule methods (Single-Particle Tracking and Fluorescence Localization 
Imaging with Photobleaching) and FRET measurements (Distance Of Closest 
Approach). The current investigation revealed new information regarding the 
architecture and the oligomerization of EGFR in cells as well as insight into TKIs 
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1 General Introduction 
 
1.1 Receptor Tyrosine Kinases 
Many important cell processes such as proliferation, survival, differentiation, 
function and motility rely on the communication of the extracellular with the 
intracellular environment. The transduction of the information across the plasma 
membrane is performed by cell surface receptors. Amongst other receptors, the 
Receptor Tyrosine Kinase (RTK) super-family has been associated with many of the 




Figure 1-1: Receptor Tyrosine Kinase Families. All RTKs consist of an extracellular and an intracellular kinase 
domain. In all cases, receptor activation requires growth factor binding which leads to C-tail phosphorylation of the 




The RTK superfamily consists of 58 proteins which can be classified into 20 sub-
families as illustrated in Figure 1-1. All of receptors share the same structural 
architecture consisting of an extracellular domain (ECD), a transmembrane segment 
(TM) and an intracellular domain (ICD) with kinase activity. The signal transducing 
function of most RTKs in healthy cells depends on stimulation by growth factors which 
bind to an epitope on the ECD. Although dimerization of RTKs was first thought to be a 
common step during activation, more recent studies have shown that some receptors 
exist as pre-dimers
2
. Moreover, higher order oligomers have also been proposed as 
important in signalling of some RTKs
3,4
. Despite the differences in organization on the 
cell surface in the basal state, an activated signalling unit requires non-monomeric 
ligand-bound receptors. Phosphorylation of RTKs allows activation of different 
downstream signalling pathways for regulating cell processes. The first characterised 
protein of the RTK super-family was the Epidermal Growth Factor Receptor (EGFR). 
 
1.2 The EGFR Family of Receptors: History, Importance and 
Current Therapeutics 
The history of the EGFR family of receptors started more than 50 years ago in 1962 
when Stanley Cohen isolated and characterised the protein responsible for inducing 
anatomical changes in new-born mice and rats
5
. This finding was a result of a research 
which had started a few years earlier and led to the discovery of the nerve growth factor 
(NRG) by Cohen and Levi-Montalcini
6
 which also initiated the research on growth 
factors. The isolated protein was named epidermal growth factor (EGF) due to its ability 
to stimulate epidermal proliferation
7
. The EGF receptor (or ErbB1 or HER1) was first 
reported in 1980 by Cohen et al.
8
 after investigations to find the target of the EGF 
ligand by using a radiolabelled EGF molecule (
125
I-EGF). Subsequently after Cohen’s 
discovery, the identification of the rest of the family members (ErbB or HER 2-4) was 
followed by different groups
9
. Since then, these receptors have been the target of a 
significant amount of cancer research due to their identification in different cancers
10
 
and have become one of the most studied RTK systems. 
24 
 
The EGFR family consists of 4 homologous receptors with the same structural (ECD, 
TM and ICD) and functional features (activation through ligand binding and 
dimerization-oligomerization) mentioned previously for RTKs (Figure 1-2). To date, 
approximately 13 ligands are known to bind and regulate ErbB family members 
signalling
11
, however none of them bind ErbB2 (also referred as neu). ErbB3 is also 
distinct from the others as it is catalytically inactive or has low activity, even though it 
is competent to bind ATP
12
. As a consequence, activation of these two receptors occurs 
only through hetero-dimerization with the other members of the family as well as with 
each other. 
 
Figure 1-2: The ErbB family members and their ligands. All EGFR members share a similar architecture 
consisting of an extracellular domain, a helical transmembrane domain, and an intracellular domain. The main 
differences between them are that there are no known ligands for ErbB2 and that ErbB3 is catalytically inactive (red 
X on the kinase domain). Common ligands between EGFR and ErbB4 receptors have blue coloured letters and 
between ErbB3 and ErbB4 with green. Ligands coloured with black (EGFR and ErbB4) are specific to the respective 
receptors. 
 
Activation through homo- or hetero-dimerization of ErbBs leads to tyrosine 
phosphorylation of their C-terminal tails which are being used as docking sites for 
downstream effectors with Src Homology 2 (SH2) or PhosphoTyrosine Binding (PTB) 
domain
13
. Association of these effector molecules activates a complex signalling 
network which regulates a variety of essential biological processes. The most common 
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signalling pathways are: the Mitogen-Activated Protein (MAP) kinase cascade, the 
Phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), the Phospholipase-Cγ 
(PLCγ) and the Signal Transducers and Activators of Transcription (STAT) pathways 
(Figure 1-3). 
 
Figure 1-3: The most common signalling pathways of the EGFR family. Phosphorylation of ErbB homo- and 
hetero-dimers results in the recruitment of downstream effectors which propagate the signal through different 
pathways such as MAP, PI3K/AKT, PLCγ and STAT (Adapted from Qiagen website). 
 
The ErbB family of receptors plays a prominent role in many cancer histotypes, 
expect from their physiological roles in cells (regulate apoptosis, cell cycle progression, 
differentiation, development, and transcription). The association of ErbB family of 
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receptors in the pathogenesis of cancer was first reported in 1985 when Thompson et 
al.
14
 provided evidence for the correlation of EGFR overexpression and cancer. This 
correlation also consists the first example for a relationship between receptor 
overexpression and cancer
15
. Since then, dysregulation of the physiological function of 
these receptors either by mutation or gene amplification (or both simultaneously) is 
implicated in the development of many types of cancer including lung, breast, stomach, 




For these reasons, ErbBs are key targets of cancer therapies. The most used 





 and in some cases where a patient develops resistance, 
a combination of both
18–21
. TKIs are small-molecule drugs that target the Tyrosine 
Kinase Domain (TKD) of a protein and block its phosphorylation by competing with 
ATP, thereby preventing the downstream signalling cascade
22
. On the other hand, mAbs 
bind to the ECD and their mode of action for, indirectly, blocking receptor 
phosphorylation varies. Some mAbs compete with and block ligand (e.g. EGF) binding 
(and subsequent dimerization)
23
 whereas others prevent dimerization by “locking” the 
receptor in the inactive conformation
24
. Table 1-1 below summarizes the approved 
drugs as well as some targeted therapeutics currently in clinical trials.  
 
Table 1-1: Table of ErbB family members targeted therapeutics. 
Therapy Trade name Target Cancer Type Status 
Monoclonal Antibodies 
Cetuximab Erbitux® EGFR 
Colon and Head & Neck 
cancers 
Approved 
Panitumumab Vectibix® EGFR 
Colon and Head & Neck 
cancers 
Approved 
Nimotuzumab - EGFR Glioma, pancreatic, SCC Approved 




Advanced solid tumors Clinical trials 
Trastuzumab Herceptin® ErbB2 
ErbB2 
Breast cancer Approved 
Pertuzumab Perjeta® Breast cancer Approved 
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Seribantumab - ErbB3 Heregulin positive NSCLC Clinical trials 
Tyrosine Kinase Inhibitors 
     
Gefitinib Iressa® EGFR NSCLC Approved 
Erlotinib Tarceva® EGFR NSCLC Approved 
Lapatinib Tykerb® EGFR, ErbB2 Breast cancer Approved 
Afatinib Giotrif® EGFR, ErbB2 NSCLC Approved 
Dacomitinib - EGFR, ErbB2 SCC, NSCLC Clinical trials 




Breast cancer Clinical trials 
Osimertinib Tagrisso® T790M EGFR T790M positive NSCLC Approved 
BI 1482694 - T790M EGFR T790M positive NSCLC Approved 
Rociletinib - T790M EGFR T790M positive NSCLC Clinical trials 
 
NSCLC: Non-Small Cell Lung Cancer, SCC: Squamous Cell Carcinoma 
 
Despite the development of various anticancer therapeutics for all ErbB members, 
their effectiveness differs from patient to patient. Even in cases when these therapies are 
initially effective, the disease returns back exploiting mainly resistance mechanisms 
such as somatic mutations on ErbBs’ TKD25–28 and altered downstream signalling 
thourgh homo- and heterodimerizations
29–32
. Improving the efficiency of future 
therapeutics is therefore tighly associated with our understanding of both the 
mechanism of activation and drug resistance of these receptors at a molecular level. 
Such an understanding could potentially allow scientists to better design drugs (either 
TKIs or mAbs) which would more accurately and efficiently inhibit ErbB members’ 
activation. 
 
1.2.1 Structural Analysis of ErbBs 
ErbB receptors are type I transmembrane glycoproteins and each member consists of 
an ECD, a helical TM, a juxtamembrane segment (JM), a TKD and the C-terminal tail 




Figure 1-4: Structure of ErbB receptors. The ECD can be divided into four sub-domains 
(I-IV). Domains I and III are involved in ligand binding and domain II, which contains the 
dimerization arm, in dimerization. The TM, JM and TKD are also involved in the 
dimerization whereas the phosphorylated C-tail is served as a docking site for downstream 
signalling (the amino acid numbering of each region is referred to EGFR). 
 
The ECD consists of approximately 600 amino acids and can be further divided into 
four sub-domains (I-IV): the leucine-rich sub-domains I (L1) and III (L2) and the 
cysteine-rich sub-domains II (CR1) and IV (CR2). Even though an early study, using 
titration calorimetry and X-ray scattering, had suggested that the formation of the ECD 
dimer occurs through direct interaction of two EGFR molecules
33
, deeper insights into 
the active dimeric ECD form as well as the inactive-active transition were obtained a 
few years later from crystal structures
34–36
. In the inactive state, the receptor exists in a 
tethered-like state (Figure 1-5A) where CR1 and CR2 interact with each other in an 
auto-inhibitory conformation
36
. Ligand binding to the epitope between sub-domains I 
and III triggers conformational changes that interrupt the auto-inhibited interactions and 
allow dimerization by exposing the dimerization arm (sub-domain II)
34,35
 as is shown in 
Figure 1-5B. Both crystal structures of ECD dimers revealed a 2:2 ligand:ECD 
complexes (one structure with TGFα34 and the other with EGF35) in a back-to-back 




Figure 1-5: Crystal structures of the tethered and monomeric and dimeric extended conformation of the ECD 
of EGFR. EGF-EGFR complex of the tethered state (A, PDB: 1NQL) and the extended state (B, PDB: 3NJP). In C 
the extended ECD dimer of EGFR is depicted (PDB: 3NJP). Colours: blue for sub-domain I, green for sub-domain 
II, red for sub-domain III, grey for sub-domain IV and cyan for EGF. 
 
Crystal structures of both ErbB3 and ErbB4 in the tethered conformation have also 
been resolved
37,38
 and showed a similar configuration as in EGFR. The same it is not 
true for ErbB2 as the residues responsible for the intramolecular interaction between 
CR1 and CR2 are not conserved
39
. Therefore, the receptor always adopts the extended 
conformation
40,41
. This structure resembles the “active” extended conformation seen for 
EGFR and for ErbB4 bound to NRG1β42 but with the equivalent epitope being 
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unoccupied. The fact that the receptor only exists in one state allows it to be poised for 
interacting with the other members without the need of any conformational change. 
 
The TKD of ErbB receptors is much smaller in size than the ECD and consists of 
two lobes; the N-lobe which is constituted by β-sheets and the C-lobe which is mainly 
helical. The role of the TKD is to bind ATP, upon activation of the receptor by ligand 
binding, in the catalytic cleft located between the two lobes and to catalyze the transfer 
of the γ-phosphatase of ATP to tyrosine residues on the C-terminal tail which in turn 
will be served as a docking site for downstream effectors. Some features important for 
receptor activation are: the αC-helix on the N-lobe, which coordinates with a key 
residue (K721) within the cleft to stabilize ATP binding, the activation loop (A-loop) on 
the C-lobe and the conserved Asp-Phe-Gly (DFG) motif located on the N-terminus of 
the A-loop. 
Questions regarding the activation mechanism of these receptors where first raised 
when Gotoh et al.
43
 showed that phosphorylation of the A-loop of ErbB receptors is not 
required for catalytic activity. For the rest of the members of the RTK superfamily, 
however, the phosphorylation of the A-loop is essential for activation, as the receptors 
cannot be released from their cis-autoinhibited state without it
1
. It is worth noting that 
even though the mutation of Tyr845 (located on the A-loop) of EGFR to Phe did not 
abolish kinase activation
43
, it has been found to be important for cell proliferation and 
transformation in breast cancer cells
44
 as well as for EGF-induced DNA synthesis
45
. 
The same observation regarding the A-loop-independent activation of ErbB1 was 
also made later on when the first crystallographic structure of EGFR TKD was resolved 
by Stamos et al.
46
. Despite the fact that the TKD of EGFR was in an active-like 
conformation and structural features resembled those seen in other RTKs, the A-loop 
was not phosphorylated. The notion that the mechanism of ErbBs activation might be 
distinct from the other RTKs was further supported by yet another structure. In that 
structure, the TKI Lapatinib was co-crystallized with the EGFR TKD and revealed a 
novel conformation
47
 which has been previously observed for the inactive state of both 
cyclin-dependent kinases (CDKs) and proto-oncogene tyrosine-protein kinases (Src)
48
. 
The aforementioned structures suggested that the TKD, as the ECD, exists in two 
different states as depicted in Figure 1-6. In the inactive conformation (Figure 1-6A), 
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the αC-helix is displaced away (αC helix-out) from the ATP binding pocket by the small 
helical DFG motif. Furthermore, the flexible A-loop also points out in order to allow 
substrate (C-terminal tail) binding to the binding site which is located just outside of the 
cleft. In the active conformation (Figure 1-6B), the helical structure of the DFG motif 
no longer exists allowing αC-helix to be positioned in a close proximity with K721 and 
stabilize the active conformation. 
 
Figure 1-6: Crystal structures of the inactive and active conformation of the TKD of EGFR. (A) Crystal 
structures of wt EGFR bound to Lapatinib in the inactive conformation (PDB: 1XKK). (B) Crystal structure of wt 
EGFR in the active conformation (PDB: 1M14). In both structures, the ATP-site (green framerwork), the αC-helic 
(red), the DFG motif (light-blue framework) and the A-loop (blue) are denoted. 
 
These findings, along with several other structural and biochemical studies which 
untangled the mechanistic aspects of the activation of EGFR family
49–53
, suggested an 





Upon ligand binding to the ECD, dimerization is promoted which brings the kinase 
domains of each monomer in close proximity and results in conformational changes 
allowing the formation of an asymmetric dimer between them. This dimer presents a 
head-to-tail configuration, where the C-lobe of one kinase (“activator” or “donor”) 
interacts with the N-lobe (“receiver” or “acceptor”) of the other kinase (Figure 1-7A). 
These hydrophobic interactions between the TKDs cause disruption of the cis-
autoinhibitoty interactions of the receiver (αC-helix in, extension of the A-loop and 
deformation of the helical structure of the DFG motif) which can now bind ATP and 
catalyse the transfer of the phosphate group. In this dimer, the “activator” molecule is in 
the inactive conformation as in Figure 1-6A whereas the “receiver” in the active 
(Figure 1-6B). Importantly, the crystal structure of the asymmetric dimer showed that 
the C-terminal tail of the activator was positioned at the active site of the receiver, 
indicating phosphorylation in trans
49
. 
In contrast to the ECD, the inactive TKD has been crystallized in a dimeric 
arrangement
49,54
 (in addition to the monomeric form shown above). This symmetric 
back-to-back dimer comprises TKDs which are both in the inactive-like state as none of 
the interactions  which are crucial for activation take place (Figure 1-7B) and does not 
contribute to the phosphorylation of the receptor
49
. It should be noted that in the 
structure reported by Jura et al.
54
, the symmetric interface interaction is mediated by the 
small AP-2 helices (residues 969-978), formed at the beginning of the C-terminal tail of 
each monomer (Figure 1-7B), suggesting an auto-inhibitory role of the tail
1
. 







 have been resolved, ErbB3 has never been crystallized in that state. 
Perhaps the reason for that is that ErbB3 N-lobe (asymmetric dimer interface) residues 
are divergent from those of the other members
56
 and this prevents its TKD from acting 
as receiver in the asymmetric dimer. However, since the phosphorylation of ErbB 
receptors occurs in trans and the TKD of ErbB3 can function as an activator (C-lobe 
sequence is very similar to other receptors) when it heterodimerizes, ErbB3 is found 
phosphorylated in cells. On the other hand, its inactive conformation
56
 is the same as the 






Figure 1-7: Crystal structures and cartoon representations of the asymmetric and symmetric TKD dimer. In 
the head-to-tail interaction of the asymmetric dimer (A, PDB: 3GOP), the JM (orange) latches the C-lobe of the 
activator (light yellow). In the symmetric dimer (B, PDB: 3GT8) the back-to-back interaction between the monomers 
is mediated by the small helices of their C-tail (orange). 
 
Another structural feature that has been highlighted to be indispensable to the 
allosteric activation described above is the JM
53,54,58
. The JM can be separated in two 
regions: the JM-A (residues 645–657) which is helical and the more flexible JM-B 
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(residues 658–671). In the inactive state (monomers or symmetric dimers), JM-A has 
been predicted to be embedded in the inner leaflet of the membrane, possibly by 
interacting with membrane components such as Phosphatidylinositol 4,5-bisphosphate 
(PIP2)
59–61
, and to be monomeric
62,63
. Upon activation, ECD conformational 
rearrangements cause its release from the membrane and subsequently the formation of 
an anti-parallel helical dimer which contributes to the stabilization of the asymmetric 
dimer. It has also been demonstrated that different ligands induce distinct JM-A 
dimers
64
, further underlying their importance in activation. On the contrary, JM-B is 
directly involved in the asymmetric dimer: the JM-B of the receiver cradles the C-lobe 
of the activator as it is shown in Figure 1-7A. Mutations that disrupt the interaction 
between the JM-B and the C-lobe or deletion of the JM completely abrogate 
phosphorylation of EGF. 
 
1.2.2 Activation Mechanism of ErbBs in Cells 
Even though the organization of both inactive and active receptors, as well as their 
architecture on cells is yet to be defined, a simplified mechanism summarizing the 
aforementioned findings on the inactive-active transition of ErbBs is illustrated in 
Figure 1-8A. 
In the basal state, the receptors (apart from ErbB2) adopt the tethered conformation 
on the ECD with an inactive-like TKD conformation. While results from some studies 
question the existence of inactive pre-dimers
62,65
, others have shown that ErbBs not only 
pre-dimerize even in the absence of ligand
66–68
 but they may also form higher order 
oligimers
69–71
. Based on these contradicting results, the inactive receptor is represented 
in equilibrium between a tethered monomer and a tethered dimer with a symmetric 
TKD configuration. The presence of the tethered receptor in the inactive pre-dimers was 
recently demonstrated by Nevoltris et al.
72
 using novel nanobodies which recognize the 
tethered conformation. It is also worth mentioning that the observed inactive dimers 
where heterodimers of EGFR (tethered) and ErbB2 which is an extended-only receptor. 
In the activated state, ligand binding to monomers or pre-dimers leads to an extended 
2:2 ligand-bound ECD dimer which promotes the formation of the asymmetric dimer on 
the intracellular and allows signal propagation. As for the basal receptor, 





The existence of higher order oligomers might also explain how ErbB2 can be 
phosphorylated in a ErbB2-ErbB3 system since the phosphorylation occurs in trans and 




Figure 1-8: Mechanism of activation ErbB members and TM-JM dimerization crossings on cell surface. (A) In 
the basal state, receptors exist as either monomers or inactive pre-dimers. Upon ligand binding, ECD is released from 
the tethered conformation, dimerized and allow the asymmetric KD dimer formation. (B) Conformation of TM-JM in 
the basal (left: C-terminal crossing) and the activated (right: N-terminal crossing) state of dimeric receptor (Adapted 
from Bragin et al, J Mol Biol, 201675). (C) Proposed alternative conformation of TM-JM in the basal dimeric receptor 
(Adapted from Bragin et al, J Mol Biol, 201675). 
 
The structural component responsible for the conformational coupling between the 
ECD and ICD is the TM domain. The TM is approximately 20 amino acid long with a 
helical structure and its association, in both homo- and hetero-dimers, has been 
suggested to contribute to dimer stabilization and activation
76–80
. All ErbB members 
have conserved motifs in both the N- and C-terminal of the TM (apart from ErbB3 
which lacks the C-terminal motif) consisting of a GG4-like (GxxxG) sequence
15
 which 
are involved in both asymmetric and symmetric dimer, respectively. In the companion 
articles by Endres at al.
62
 and Arkhipov et al.
63
, the authors employed in silico, Nuclear 
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Magnetic Resonance (NMR) and mutational studies to determine the TM-JM dimer 
conformation in both the unliganded-symmetric and extended-asymmetric dimers. 
According to this model, the TMs of the inactive dimers interact with each other at the 
C-terminus (C-crossing) of each monomer whereas in the active form it is a N-crossing 
(Figure 1-8B) conformation. In the former configuration the JMs are kept apart and 
embedded into the membrane while in the latter the N-crossing conformation causes 
release of JMs from the membrane and also favours the formation of the anti-parallel 
JM-A dimer. 
A third, distinct, conformation of the TM-JM dimer in the inactive receptor was 
proposed earlier this year by Bragin et al.
75
 (Figure 1-8C). In this structure, the crossing 
of TMs is slightly shifted, compared to C-crossing, towards the middle which results in 
a much smaller crossing angle. This TM crossing also affects the JM conformation 
which, in contrast to the previous model, can now dimerize in a parallel fashion with a 
part of it buried in the plasma membrane. The authors also state that this alternative 
inactive conformation is reminiscent of other receptors and that its transition to the 
active is relatively easier compared to the C-crossing.  
Despite these fundamental discoveries in the last 15 years, the ErbB system still 
remains a complex network with many unknown aspects which need to be addressed for 
more accurate and efficient therapies. For instance, the role and the importance of the 
TM in the activation have been highlighted very recently by different studies
22
. 
Moreover, features such as higher-order oligomers, the role of the C-terminal tail and 
the conformation of the receptor in the different states are still unclear. Chemical 
biology approaches for developing novel probes along with fluorescent microscopy 
techniques comprise a promising combination to further explore such systems. 
 
1.3 Fluorescence Microscopy 
Fluorescence microscopy is a powerful imaging tool for modern biology and 
medicine. It is a variation of the conventional light microscopy and its principle relies 
on molecules, known as fluorophores, that when excited with light of appropriate 
wavelength re-emit light (fluorescence emission) at longer wavelength. This allows the 
fluorescence emission to be separated from the excitation and specific labelling of 
targets with fluorophore allow these to be distinguished within a sample (Figure 1-9A). 
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A fluorescent microscope requires: a light source for producing photons with energy 
capable of exciting a specific fluorophore, an objective lens for focusing the light as 
well as for collecting the emitted light, a detector for the emitted photons and a filter(s) 
for splitting the excitation and emission lights. There are three categories of 
fluorophores that are most usually used for visualization of a protein of interest as 
illustrated in Figure 1-9B: fluorescent proteins which can be fused onto other proteins, 
small organic dyes and quantum dots for tagging biomolecules. 
 
Figure 1-9: Jablonski energy diagram for fluorescence principle (A) and types of fluorophores (B). 
 
Fluorescent microscopy techniques allow imaging of both fixed and live biological 
specimens and can provide insight on biological processes. These techniques are very 
sensitive to low numbers of labelled molecules, changes in the environment, etc. and 
enable scientists to conduct experiments under physiological conditions (e.g. 
temperature), directly detect a protein of interest (single-molecule imaging) in complex 






The two types of fluorescent microscopes used in the present study are scanning 
illumination (confocal) and surface illumination (total internal reflection fluorescence 
(TIRF)) which will be briefly described in the following two sections. 
 
1.3.1 Confocal Laser Scanning Microscopy and Fluorescence 
Lifetime Imaging 
The basic principles of confocal imaging were introduced by Marvin Minsky in 
1955
82
. Although modern confocal microscopes have been highly evolved from the 
‘prototype’, the principles they follow remain the same. 
Confocal laser scanning microscopy (CLSM) is an advanced optical technique for 
visualization of a specimen with the use of fluorescent molecules and it has proved a 
powerful tool in cell biology as well as in other research fields. Confocal microscopy is 
based on the principle that out-of-focus glare can be eliminated or rejected by placing a 
pinhole in front of the detector (Figure 1-10A). The laser beam comes from the side, is 
filtered by the dichroic splitter in order to give the desired wavelength, reflected via the 
objective and excites the specimen. The emitted light from the specimen then returns 
back, is de-scanned and ends up through the pinhole to the detector. The construction of 
an image is made pixel by pixel and line by line as the laser scans the specimen. This 
pinhole is the core difference between confocal and conventional wide-field microscopy 
where the entire field is excited. This point-wise excitation and detection offers several 
advantages such as: rejection of out of focus fluorescence, scanning in x-y planes with 
different depths which allows imaging of thick samples without the need of physical 




Figure 1-10: Principle of Confocal laser scanning microscopy. Illustration of the principles of (A) CLSM and 
(B) reconstruction of 3D image. 
 
In biological sciences CLSM is used, but not limited to, for visualization of both live 
and fixed samples, localization and co-localization of proteins, quantitative analysis 
(e.g. binding studies), visualization of cell processes (cell division) and 
immunofluorescence. Many fluorescence imaging techniques are compatible with 
CLSM including: Fluorescence Recovery After Photobleaching (FRAP) for measuring 
diffusion of both cell membrane and interior components, Förster (or Fluorescence) 
Resonance Energy Transfer (FRET) for studying protein interactions, Fluorescence 
Lifetime Imaging (FLIM) which overcomes some limitation of intensity-based FRET 
and is sensitive to environment changes (e.g. pH) and Stimulated Emission Depletion 




FRET is a process whereby the energy from one excited fluorophore (donor) is 
transferred to another (acceptor). As it can be used as a biophysical measurement for 
determining molecular proximity within ~10 nm distance
83
, FRET is most commonly 
used to study protein-protein (or -ligand) interaction and protein conformation
84
. The 
principle of FRET is shown in Figure 1-11. When an excited donor fluorophore is in 
close proximity to an acceptor fluorophore, the energy of the donor before returning to 
the ground state can be transferred to the acceptor and excite it. The efficiency of the 
FRET process between an isolated donor and acceptor depends upon the donor quantum 
yield, relative orientation of the donor and acceptor dipoles, the overlap between the 
donor emission and the acceptor spectra and the distance between and acceptor. 
FRET can be quantified by measuring the reduction in the donor fluorescence 
intensity and sensitised acceptor emission, depolarization of fluorescence emission or 
by the apparent reduction of the fluorescence lifetime of the donor
85
. The fluorescent 
lifetime (τ) of a fluorophore is the mean time a molecule stays in the excited state before 
returning to the ground state. Measurement of fluorescence lifetimes can be done either 
in the frequency domain or the time domain
86
. The frequency domain approach is 
compatible with widefield microscopy methods and the time domain is compatible with 
point scanning microscopy. Determining the fluorescence lifetime at every pixel of a 
fluorescence image is known as Fluorescence Lifetime Imaging Microscopy (FLIM). 
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The advantages of using FLIM to quantify FRET (FLIM-FRET) over intensity-based 
FRET are that only the donor is monitored
87
 and that artefacts from signal cross-




Figure 1-11: Förster resonance energy transfer principle. 
 
1.3.2 Single Molecule Imaging using Total Internal Reflection 
Fluorescence (TIRF) Microscopy 
Imaging of single molecules was first reported nearly 30 years ago by two 
independent groups who visualized solid crystals
89,90
. However, the need for aqueous 
media for single-molecule imaging of biological samples set a barrier to this method
90
. 
To overcome this problem, Funatsu et al.
91
 exploited TIRF microscopy which had been 
earlier introduced by Axelrod et al
92
. 
TIRF microscopy is widely used for imaging the membranes cultured cells and thin 
samples. TIRF can be operated on a wide-field epi-fluorescence microscope with the 
use of an objective lens with a high Numerical Aperture (NA). The laser beam is 
focused onto the back aperture of the objective lens so that it emerges from the lens as a 
collimated beam. By translating the position of the beam away from the centre of the 
back aperture, the beam will emerge from the objective at an angle. Once the angle is 
large enough the beam will be totally internally reflected (TIR) at an interface of media 
with different refractive indexes e.g. glass-sample medium (Figure 1-12). The critical 
angle for TIR depends upon the refractive index mismatch. The sample is then 
illuminated by the evanescent wave generated by TIR that penetrates the sample to a 





Figure 1-12: Schematic representation of Total internal reflection fluorescence (TIRF) microscopy (Adapted 
from Y. Sako and T. Yanagida, Nat. Rev. Mol. Cell Biol., 200393).  
 
Single-molecule methods, either using confocal
45
 or TIRF microscopy
94
, allow one 
to visualize, detect and analyse individual labelled particles. This feature of SMMs 
enables scientists not only to extract information regarding the mean behaviour of a 
certain property of the system under study but to examine the heterogeneity of a system 
as even rare events are reported
95
. Furthermore, the development of single-molecule 
localization algorithms
70,96
 and the use of Charge-Coupled Device (CCD) cameras, 
allows the localization of molecules with a precision below the diffraction limit of light 
and the detection of molecule movement, or other events, with millisecond time 
resolution. The most commonly used single molecule methods compatible with TIRF 
are: single-particle tracking (SPT) for studying protein dynamics, localization-based 
methods for extracting information regarding the geometry and stoichiometry of protein 
complexes and single-molecule FRET (smFRET) for studying intra- and inter-
molecular dynamics and kinetics
97
. 
SPT is a live-cell imaging method for studying protein dynamics by tracking the 
lateral movement of molecules and protein-protein interactions when 2- or 3-colour 
experiments are employed. Parameters that can be extracted from SPT are the diffusion 
coefficients of the particles, the confinement of the movement and the frequency and 
duration of colocalization events
95,98
. The main advantage of SPT over other methods 
for studying protein dynamics (such as fluorescence recovery after photobleaching 
(FRAP)
99
 or fluorescence correlation spectroscopy (FCS)
100
) is, as mentioned above, the 
detection of events with spatial and temporal resolution
95
. SPT method has also been 







, activation mechanism of EGFR cancer mutant
103
, to name a 
few. 
Single-molecule localization methods on the other hand take place in either 
immobilized, on a glass surface, molecules or in fixed cells and provide information 
regarding the stoichiometry of molecules. The method that is employed herein is the 
Fluorophore Localization Imaging with Photobleaching (FLImP) method which has 
been developed by Martin-Fernandez’s group70,104 for determination of oligomer size 
and distribution. This super-resolution technique requires fixed samples and allows the 
measurement of the distribution of the separations between pairs of molecules with ~6 
nm resolution. The advantage of FLImP over other super-resolution techniques such as 
photoactivated localisation microscopy (PALM)
105
, stochastic optical reconstruction 
microscopy (STORM)
106
 and stimulated emission depletion (STED)
107
 is that it allows 
to measure inter-molecular distances in the range of ~10-60 nm as it has been 




1.4 Labelling Techniques for Intracellular Targets 
The use of fluorescent microscopy techniques for studying biological systems 
requires specific labelling of the protein(s) of interest. Moreover, the labelling must not 
perturb the conformation of the protein, should ideally be compatible with live cell 
imaging and, ideally, be sensitive enough to monitor conformational changes. Even 
though the aforementioned requirements for labelling an extracellular target are met by 
many methods or probes, the same is not true for intracellular targets. 
The study of the conformation of ErbBs kinase domains in a cellular context with 
imaging techniques is significantly hindered by the lack of suitable probes. The most 




Figure 1-13: Most commonly applied labelling techniques. A protein of interest can be tagged by fluorescently 
labelled ligands (left) or genetically modified to be expressed with either unnatural amino acid for click chemistry 
(middle) or fused protein (right). 
 
Antibodies (IgG) are proteins which are used in many imaging applications due to 
their high affinity (low nanomolar or even at the picomolar range
108
) and specificity but 
also because they are widely available commercially. However, an intact IgG protein 
has a molecular weight of ~150 kDa (similar to full-length EGFR) and is further 
modified by glycosylation on different sites, a modification which is essential for its 
functions
109
. Due to their size, they are unable to pass the cell membrane and therefore 
labelling of intracellular proteins is only possible after cell fixation and 
permeabilization, which limits their use. Besides, conformation-sensitive antibodies are 
hard to produce and select, even though they have been successfully developed for some 
targets
110
. Intracellular expression of non-antibody high affinity binders such as 
nanobodies and monobodies, which are much smaller in size, has been performed in 
some studies
111–113
. However, their applications in imaging require fusion to fluorescent 
proteins (FP) which increases their size. Moreover these reagents still need to be 
produced and selected on-demand for each new protein target. 
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Incorporation of unnatural amino acids in the sequence of a protein is an emerging 
method for specific labelling
114–116
. The side chains of the unnatural amino acids, which 
can be introduced by expanding the genetic code
117
, bear a functional group capable of 
participating in exceptionally specific reactions with high kinetics rates (bioorthogonal 
chemistry) in vitro, under mild conditions
118
. This approach, however, requires the 
introduction of two plasmids (mutant protein and modified tRNA) and the 
supplementation of the culture with an unnatural amino acid bearing the reactive group 
to ensure the insertion of the tag in the desired position. While this approach can 
guarantee high labelling specificity, insertion sites need to be carefully planned in order 
to avoid disrupting important interaction interfaces. Another more critical challenge is 
the low efficiency of the incorporation of unnatural amino acids
119
 and hence the 
labelling efficiency. Moreover, this technique is only suitable for the study of 
ectopically expressed kinases and therefore not ideal for the study of primary samples. 
The same caveats apply to the production of fusion constructs labelled with 
fluorescent proteins or other tags (based on enzyme-labelled substrate interaction), with 
the additional concern that the size and position of the tag might compromise the 




1.4.1 Site-specific Labelling Using Small-molecule Probes 
The limitations of the available labelling techniques for intracellular targets have led 
scientists to explore alternative methods. Such a method is site-specific labelling by 
small-molecule probes. 
Small-molecule imaging probes are low-molecular weight compounds which can be 
very specific to their primary target protein and allow the visualization of the protein of 
interest. The development of such probes was inspired by the emerging field of activity-
based protein profiling (ABPP)
122
, pioneered by Benjamin Cravatt
123
. Probes for both 
applications (imaging and ABPP) share the same principle in terms of their design and 
structure; they consist of a reactive warhead, a linker and a tag (Figure 1-14A, top)
124–
126
. The reactive warhead is responsible for the recognition of the target whereas the 
choice of the tag (a dye or an affinity label) depends on the application (labelling or 
chemical proteomics respectively). The role of the linker (PEG, amino acid chain or 
cleavable linkers) is to keep apart the tag from the warhead so they do not interfere with 
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each other, as such an interference would likely alter the specificity of the probe. Such 
probes can be either synthesized with tag attached (Figure 1-14A, top) 
124–126
 or 
prepared with a functional end (e.g. clickable linker) on a, usually, shorter linker which 
can be tagged in situ (bioorthogonal reaction, Figure 1-14A, bottom)
127,128
. An 
advantage of the latter (bioorthogonal probes) is that they can be used for both labelling 
and affinity-based pull-down experiments as the choice of the tag takes place after 
binding of the probe. Bioorthogonal probes have been also used in order to circumvent 




Figure 1-14: General structure of small-molecule probes and their applications. (A) Small-molecule probe 
consists of a warhead which allows specific binding in a target, a linker and a fluorescent dye or an affinity group. 
These probes can be either synthesized with the tag attached (top) or prepared with a functional group which can be 
participated in bioorthogonal reactions (bottom). (B) Their main application after labelling of the target are 
visualization using Imaging techniques (left) or in Gel analysis (right). 
 
The two main techniques where such probes have been used are ABPP and imaging 
(Figure 1-14B). Applications of both methods offer information in a variety of studies 











, to name a few. Apart from in vitro experiments, 





This alternative labelling approach for studying biological processes with fluorescent 
microscopy seems to be promising, especially due to its suitability for labelling 
intracellular targets. Among the few examples in literature reporting the development of 
such probes for imaging, only a small number of them have reported novel biological 
information regarding their target protein, while most concerned the characterization of 
the recognition element of the probe. Therefore, this new method may offer new 





2 Aim of Thesis 
The main objectives of this project were: 1) the desing and synthesis of fluorescent 
TKIs (fTKIs) for ErbB family members (Chapter 4), 2) their evaluation and the 
development of methods for the use of fTKIs in fluorescence microscopy (Chapter 5) 
and 3) their applications in order to get a better insight into the drugs mechanism of 
action in cell-based assays and the basal EGFR architecture on cells (Chapter 6 & 7) 
(Figure 2-1). 
 
Figure 2-1: Schematic representation of project’s aim. 
 
To achieve the first objective, I have performed a literature review on ErbBs’ TKIs in 
order to identify the most potent and selective compounds as well as to help me 
rationally design the synthesis of the labelled compounds. The modified compounds 
were synthesized based on the reported synthesis of the parent compounds. In terms of 
the second objective, I have evaluated the suitability of the synthesized fTKIs for use as 
imaging probes (binding affinity, cell permeability, specificity, etc) and have developed 
and validated methods for their use in different fluorescence microscopy techniques. 
Finally, for the third objective I have exploited one of the developed methods and 
combined it with methods for probing the EGFR ECD structure (previously reported by 
my group
70,71,136,137
) in order to investigate both drugs sensitivity/resistance mechanism 





3 Materials and Methods 
 
3.1 Chemistry 
3.1.1 General experimental 
All reagents, chemicals and solvents (HPLC grade) were purchased from Sigma-
Aldrich, Alfa Aesar, Fisher Scientific, Fluka or Invitrogen and used without any further 
purification. 
Standard syringe techniques were applied for transfer of air/moisture sensitive 
reagents and dry solvents. Reaction temperatures were monitored and controlled with an 
electronic contact thermometer on the outside wall of the reaction vessels. Reaction 
times refer to hold times at the indicated temperatures.  
Chromatographic purification was carried out on Biotage Isolera flash 
chromatography using normal and reverse-phase Biotage SNAP cartidges. Thin-layer 
chromatography (TLC) analysis was performed with Kieselgel 60 F254 (Merck) plates 




C NMR spectra were recorded on Bruker Advance DPX 2500 or DRX 500 
instrument using deuterated solvents. Chemical shifts (δ) on 1H spectra are referred to 
tetramethylsilane (TMS) and given in parts per million (ppm). Coupling constants are 
referred given in Hz. DEPT, COSY and HMQC measurements were also used to aid the 
peak assignment. 
Analytical HPLC-MS was performed on Shimadzu LCMS-2010EV systems using 
reverse phase Atlantis dC18 columns (3 μm, 2.1 x 50 mm), gradient 5-100% B (A = 
water/ 0.1% formic acid, B = acetonitrile/ 0.1% formic acid) over 3 min, injection 
volume 3 μL, flow = 1.0 mL/min. UV spectra were recorded at 215 nm using a Waters 
2788 dual wavelength UV detector. Mass spectra were obtained over the range m/z 150 
to 850 or 150 to 1300 at a sampling rate of 2 scans per second using Waters LCT or 
analytical HPLC-MS on Shimadzu LCMS-2010EV systems using reverse phase Water 
Atlantis dC18 columns (3μm, 2.1 X 100 mm), gradient 5-100% B (A = water/ 0.1% 
formic acid, B = acetonitrile/ 0.1% formic acid) over 7 min, injection volume 3 μL, flow 
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= 0.6 mL/min. UV spectra were recorded at 215 nm using a Waters 2996 photo diode 
array. 
High resolution mass spectrometry (HRMS) was performed at the Mass 
Spectrometry Facility (King’s College London). Samples were flow injected in positive 
ESI mode. The mobile phase used was A: 0.1% formic acid in water (HPLC grade) and 
A: 0.1% formic acid in MeCN (HPLC grade) with flow rate 200ul/min. 
 
3.1.2 Compounds synthesis 
3.1.2.1 Synthesis of Gef-linker 
 






: In a sealed tube containing 4-Chloro-6-[3-(4-
morpholinyl)propoxy]-4-quinazoline (1) (1.0 g, 2.97 mmol) in  i-PrOH (15 ml), 3-
chloro-4-fluoro-aniline (2) (645 mg, 4.46 mmol) was added. The mixture was refluxed 
until precipitate was formed (approx. 3.5 h) and then cooled to an iced bath. The 
precipitate was collected by filtration, washed with chilled i-PrOH and dried over air to 
afford a white powder. The collected filtrate was evaporated in vacuo up to 10 ml and 
the above procedure was repeated 2-3 times. The filter cakes were collected together 
(1.0 g, 2.97 mmol, 85%) and the product was used in the next step without further 
purification (>95% purity). The 
1
H NMR data for the compound (3) are identical to 
literature data
139
. MS (C18, ES
+
) 447.1 [M + H]
+
, C22H24ClFN4O3 requires M 446.1521; 
1
H NMR (500 MHz, DMSO) δ 9.90 (s, 1H), 8.55 (s, 1H), 8.20 (dd, J = 6.7, 2.3 Hz, 1H), 
8.06 (s, 1H), 7.92 – 7.86 (m, 1H), 7.46 (t, J = 9.1 Hz, 1H), 7.25 (s, 1H) 4.24 (t, J = 5.8 
Hz, 2H), 4.02 (s, 3H), 3.81 (t, J = 4.41 Hz, 4H), 2.46 (t, J = 7.1 Hz, 2H), 2.39 (s, 4H), 
1.99 (p, J = 6.7 Hz, 2H).
 
 
Compound 5: Method I
140
. To a sealed tube containing Gefitinib (0.4 g, 0.89 mmol) in 
anhydrous DMF (5 ml) lithium chloride (188 mg, 4.47 mmol) was added and the 
mixture was refluxed overnight. Then the mixture was cooled to room temperature and 
water (10 mL) was added. The mixture was extracted by EtOAc (3 × 10 ml), washed 
with brine (saturated solution of NaCl in water), dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product. Purification by column 
chromatography (10-40% EtOAc in heptane) gave the compound 5 as a white powder 
(42.4 mg, 0.10 mmol, 11%). 
Method II
141
. The above procedure was repeated but the reaction was performed in a 
microwave oven for 9 h. The yield of the reaction was 42%.  
Method III
142
. A sealed tube containing Gefitinib (0.5 g, 1.12 mmol) and an excess of 
pyridinium hydrochloride (4) was heated to 165°C for 55-60 min. Then water was 
added (8 ml) carefully to the hot mixture and left to cool at room temperature for 1.5 h. 
The precipitate was collected by filtration, washed with water and dried to afford a 
dark-grey solid (360 mg, 0.83 mmol, 74%) which was used to the next step without 
further purification (>95% purity).  The 
1
H NMR data for the compound (5) are 
identical to literature data
140
. MS (C18, ES
+
) 433.1 [M + H]
+





H NMR (500 MHz, DMSO) δ 8.45 (s, 1H, Ar), 8.02 (dd, J = 6.7, 2.6 Hz, 
1H, Ar), 8.06 (s, 1H, Ar), 7.73 – 7.65 (m, 2H, Ar), 7.27 (t, J = 9.0 Hz, 1H, Ar), 7.17 (s, 
1H, Ar), 4.26 (t, J = 5.8 Hz, 2H), 3.58 (m, 4H), 2.69 – 2.64 (m, J = 15.0 Hz, 2H), 2.57 
(s, 4H), 2.16 – 2.09 (m, 2H). 
 
Compound 7 (tetraethylene grycol linker)
143
: To a solution of tetraethylene glycol di-
p-tosylate 6 (3.50 g, 6.97 mmol) in anhydrous DMF (4 ml) di-tert-butyl 
iminodicarboxylate (Boc2NH, 1.97 g, 9.06 mmol) and potassium carbonate (0.96 g, 
6.97 mmol) were added. The resulting mixture was stirred at 60 °C for 4 h and then left 
to cool to room temperature, followed by addition of EtOAc (4 ml) and water (4 ml). 
The mixture was transferred to a separating funnel and the organic layer was washed 
with 1N HCl, water and brine. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product. Purification by column 
chromatography (10-30% EtOAc in heptane) gave the compound 7 as colorless oil (0.92 
g, 1.67 mmol, 24%). The 
1
H NMR data are identical to data reported previously by 
Shreder et al
143
. MS (C18, ES
+
) 548.1 [M + H]
+
, C25H41NO10S requires M 547.2451; 
1
H 
NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 4.08 (dd, 
J = 9.1, 4.1 Hz, 2H), 3.71 (dd, J = 11.5, 5.2 Hz, 2H), 3.63 – 3.59 (m, 2H), 3.55 – 3.46 






To a solution of compound 5 (100 mg, 0.23 mmol) in 
anhydrous DMF (8 ml) compound 7 (253 mg, 0.46 mmol) and potassium carbonate 
(128 mg, 0.92 mmol) were added. The resulting mixture was stirred at 60 °C overnight 
and then left to cool to room temperature, followed by addition of EtOAc (4 ml) and 
water (4 ml). The mixture was transferred to a separating funnel and the organic layer 
was washed with 1N HCl, water and brine. The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product. Purification by column 
chromatography (20-80% EtOAc in heptane) gave the compound 8 as yellowish oil (87 
mg, 0.11 mmol, 47%). Rf = 0.61 (10% MeOH in DCM).; 
1
H NMR (500 MHz, MeOD) δ 
8.45 (s, 1H), 8.02 (dd, J = 6.7, 2.6 Hz, 1H), 7.72 (s, 1H), 7.69 (ddd, J = 8.9, 4.0, 2.7 Hz, 
1H), 7.27 (t, J = 9.0 Hz, 1H), 7.17 (s, 1H), 4.36 – 4.29 (m, 2H), 4.26 (t, J = 6.1 Hz, 2H), 
3.98 – 3.94 (m, 2H), 3.76 (ddd, J = 16.5, 8.4, 4.6 Hz, 8H), 3.68 (dd, J = 5.6, 3.8 Hz, 
52 
 
2H), 3.64 – 3.60 (m, 2H), 3.61 – 3.55 (m, 4H), 2.69 – 2.65 (m, 2H), 2.57 (s, 4H), 2.16 – 
2.09 (m, 2H), 1.49 (s, 18H).; 
13C NMR (500 MHz, MeOD) δ 156.91, 155.65, 154.71, 
153.22, 152.69, 152.41, 149.17, 146.10, 136.22, 136.19, 124.26, 122.38, 122.32, 
119.95, 119.76, 116.08, 115.86, 109.16, 106.81, 102.59, 82.34, 70.60, 70.35, 70.27, 
70.03, 68.52, 67.09, 65.87, 55.23, 53.19, 45.15, 26.91, 25.37.; HRMS (ESI) 808.3678 
[M + H]
+
, C39H55ClFN5O10 requires M 807.3621; 
 










: A solution of compound 9 (10 g, 38.02 mmol) in 80 ml of formamide 
10 was heated under reflux for 3 h at 120-125°C and then at 145°C overnight. Upon 
cooling, the product was precipitated and collected by filtration. Finally, the crude solid 
was recrystallized from EtOH to give 8.95 g of compound 11 as light brown solid 
(yield, 85%). The 
1





) 272.3 [M + H]
+
, C8H5IN2O requires M 271.9447; 
1
H NMR (500 MHz, 
DMSO) δ 1H NMR (500 MHz, DMSO) δ 12.40 (s, 1H), 8.39 (d, J = 2.1 Hz, 1H), 8.13 





: To a flask containing compound 11 (8.95 g, 32.9 mmol) thionyl 
chloride (SOCl2, 200 ml) was added dropwise at 0 °C. Catalytic amount of DMF (5-6 
drops) was also added and the resulting mixture was heated under reflux for 3 hrs. 
Thionyl chloride was then removed under reduced pressure and the resulting residue 
was washed by slow addition of saturated Na2CO3. The product was extracted with 
EtOAc (3 × 100 mL) and the organic layers were dried over Na2SO4 and concentrated in 
vacuo to give the crude solid, yellowish needles, which was used to the next step 
without further purification (6.82 g, 23.5 mmol, 71%). The 
1
H NMR data of compound 
12 are identical to literature data
146
. MS (C18, ES
+
) 290.7 [M + H]
+
, C8H5ClIN2 requires 
M 289.9108; 
1
H NMR (500 MHz, DMSO) δ 1H NMR (500 MHz, DMSO) δ 9.07 (d, J 








: In a flask containing compound 12 (6.8 g, 23.4 mmol) in i-PrOH 
(160 ml), compound 13 (5.8 g, 4.46 mmol) was added. The mixture was refluxed for 4 h 
and then at room temperature overnight. The precipitate was collected by filtration, 
washed with acetone and dried to afford a light yellow solid (10.9 g, 21.5 mmol, 92%). 
The 
1
H NMR data of compound 14 are identical to literature data
148
. MS (C18, ES
+
) 
505.85 [M + H]
+
, C21H14ClFIN3O0 requires M 504.9854; 
1
H NMR (500 MHz, DMSO) δ 
11.70 (s, 1H), 9.34 (s, 1H), 8.95 (s, 1H), 8.36 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 2.3 Hz, 
1H), 7.76 (d, J = 8.7 Hz, 1H), 7.67 (dd, J = 8.9, 2.3 Hz, 1H), 7.47 (dd, J = 14.1, 7.9 Hz, 





: In a flask containing compound 14 (10.5 g, 20.8 mmol) and 
compound 15 (3.75 g, 27 mmol) Pd(PPh3)2Cl2 (695 mg, 5% mmol), DME (70 ml), 
EtOH (42 ml) and 2M Na2CO3 (70 mL) were added and the resulting mixture was 
heated at 70 °C for 2 h. The reaction was then cooled to room temperature and the 
product was precipitated as yellow solid. The solid was filetred, washed with water and 
dried under vacuum overnight to yield the pure product (7.5 g, 15.8 mmol, 76%). The 
1
H NMR data for the compound 16 are identical to literature data
149
. MS (C18, ES
+
) 
474.01 [M + H]
+
, C26H17ClFN3O3 requires M 473.0942; 
1
H NMR (500 MHz, DMSO) δ 
10.13 (s, 1H), 9.69 (s, 1H), 8.99 (s, 1H), 8.61 (s, 1H), 8.32 (dd, J = 8.7, 1.5 Hz, 1H), 
8.00 (d, J = 2.5 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.76 (d, J = 3.7 Hz, 1H), 7.72 (dd, J = 
8.9, 2.5 Hz, 1H), 7.48 (dd, J = 14.0, 8.0 Hz, 1H), 7.43 (d, J = 3.7 Hz, 1H), 7.37-7.25 (m, 





: To a solution of commercial available 2-mercaptoethanol 17 (7 g, 
31.3 mmol) and compound 18 (2.19 ml, 31.3 mmol) in EtOH (70 ml) was added a 
solution of NaOMe in MeOH (30%, 7 ml) at room temperature. The mixture was stirred 
at room temperature overnight and then concentrated under reduced pressure. To the 
residue, water (60 ml) was added, followed by EtOAc (60 ml). The organic layer was 
washed with water and saturated brine, dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. The crude product was purified by column chromatography 
(10-80% EtOAc in heptane) to give the title compound 19 as a colorless oil (5.75 g, 26 
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mmol, 83%). The 
1





) 222.10 [M + H]
+
, C9H19NO3S requires M 221.1106; 
1
H NMR (500 
MHz, CDCl3) δ 5.06 (br s, 1H), 3.73 (t, J = 6.0 Hz, 2H), 3.31 (d, J = 6.1 Hz, 2H), 2.72 





: To a solution of compound 19 (5.7 g, 25.8 mmol) in DCM (250 mL) 
mCPBA (70%, 12.7 g, 51.6 mmol) was added at 0°C. The mixture was stirred at 0°C 
for 2 h and then aqueous N2S2O3 solution was added to the reaction mixture, and the 
mixture was stirred at room temperature for 30 min. The mixture was extracted with 
EtOAc, and the organic layer was washed with saturated NaHCO3, brine, dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified 
by column chromatography (0-50% EtOAc in heptane) to give the title compound 20 as 
a colorless oil (4.31 g, 17.03 mmol, 66%). The 
1
H NMR data for the compound (20) are 
identical to literature data
150
. MS (C18, ES
+
) 254.40 [M + H]
+
, C9H19NO5S requires M 
253.0984; 
1
H NMR (500 MHz, CDCl3) δ 5.26 (br s, 1H), 4.12 – 4.10 (m, 2H), 3.64 (dd, 




: 6N HCl (30 ml) was added to a solution of compound 20 (4.3 g, 
16.98 mmol) in THF (105 ml) at room temperature. The mixture was then stirred at 
60°C for 1.5 h, and concentrated under reduced pressure. EtOH was added to the 
residue and the mixture was concentrated again. The residue was purified by column 
chromatography (30-100% EtOAc in heptane) to give the title compound 21 as 
colorless oil (2.34 g, 15.3 mmol, 90%). The 
1
H NMR data for the compound 21 are 
identical to literature data
150
. MS (C18, ES
+
) 254.10 [M + H]
+
, C4H11NO3S requires M 
153.0460; 
1
H NMR (500 MHz, DMSO) δ 5.37 (br s, 1H), 3.79 (t, J = 5.5 Hz, 2H), 3.54 
– 3.51 (m, 2H), 3.38 – 3.36 (m, 2H), 3.22 – 3.19 (m, 2H). 
 
Compound 22 (Modified Lapatinib)
19
: Compound 16 (6.33 g, 12.53 mmol) and 
compound 21 (2.3 g, 15.03 mmol) were dissolved in DCM (105 ml) containing 
molecular sieves (5Å) and the reaction mixture was heated at 40
o
C for 3 h. Then, AcOH 
(43 ml) and NaBH (OAc)3 (4.3 g, 16.98 mmol) were added and the mixture was stirred 
at room temperature overnight. After filtration to remove the molecular sieves, the 
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mixture was concentrated under reduced pressure and the residue was purified by 
column chromatography (0-20% MeOH in DCM) to give the title compound 22 as a 
yellow-orange solid (3.75 g, 6.13 mmol, 49%). Rf= 0.48 (10% MeOH in DCM). 
1
H 
NMR (500 MHz, DMSO) δ  9.94 (s, 1H), 8.78 (s, 1H), 8.54 (s, 1H), 8.14 (dd, J = 8.7, 
1.6 Hz, 1H), 8.04 (d, J = 2.5 Hz, 1H), 7.79 (m, 2H), 7.74 (dd, J = 9.0, 2.6 Hz, 1H), 7.46 
(td, J = 8.0, 6.0 Hz, 1H), 7.35-7.10 (m, 4H), 7.06 (d, J = 3.3 Hz, 1H), 6.49 (d, J = 3.4 
Hz, 1H), 5.25 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.86 – 3.78 (m, 4H), 3.31 (dd, J = 13.0, 
6.7 Hz, 2H), 3.02 (t, J = 6.7 Hz, 2H).; 
13C NMR (126 MHz, DMSO) δ 163.49, 161.79, 
158.94, 153.07, 152.92, 152.40, 150.64, 149.08, 136.01, 131.06, 130.97, 129.15, 
129.09, 124.72, 123.80, 123.78, 121.23, 116.79, 115.26, 115.04, 114.75, 114.60, 
114.39, 110.01, 108.34, 69.86, 56.25, 55.39, 54.10, 45.62, 41.99; HRMS (ESI) 
611.1521 [M + H]
+
, C30H28ClFN4O5S requires M 610.1526.
 
 
Compound 24 (triethylene glycol linker)
143
: To a solution of triethylene glycol di-p-
tosylate 23 (4.52 g, 9.87 mmol) in anhydrous DMF (55 ml) di-tert-butyl 
iminodicarboxylate (Boc2NH, 2.25 g, 10.86 mmol), Cs2CO3 (3.62 g, 11.8 mmol) and 
NaI (10% mol, 162 mg, 0.99 mmol) were added. The resulting mixture was stirred at 75 
°C overnight and then left to cool to room temperature, whereby EtOAc (4 ml) and 
water (4 ml) were added. The mixture was transferred to a separating funnel and the 
organic layer was washed with 1N HCl, water and brine. The organic layer was dried 
over Na2SO4, filtered and concentrated in vacuo to give the crude product. Purification 
by column chromatography (20-50% EtOAc in heptane) gave compound 24 as 
colourless oil (1.32 g, 2.62 mmol, 27%). MS (C18, ES
+
) 504.2 [M + H]
+
, C23H37NO9S 
requires M 503.22; Rf= 0.52 (40% EtOAc in heptane).  
1
H NMR (500 MHz, CDCl3) δ 
7.81 (d, J = 8.3 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 4.17 – 4.14 (m, 1H), 3.78 (t, J = 6.2 
Hz, 1H), 3.70 – 3.66 (m, 1H), 3.58 (t, J = 6.1 Hz, 1H), 3.55 (s, 4H), 2.46 (s, 3H), 1.50 
(s, 18H).; 
13
C NMR (126 MHz, CDCl3) δ 152.64, 144.82, 132.95, 129.83, 128.00, 
82.33, 70.73, 70.13, 69.31, 69.23, 68.70, 45.12, 28.05, 21.65. 
 
Compound 25 (Lap-linker): To a solution of compound 22 (1.32 g, 2.18 mmol) in 
anhydrous DMF (55 ml), NaH (60 % dispersion in mineral oil, 87.2 mg, 2.18 mmol) 
was added at 0
o
C and stirred for 15 min. In another flask, compound 24 (1.3 g, 2.61 
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mmol) and NaI (10% mol, 36 mg, 0.99 mmol) were added. The resulting mixture of 
compound 24 was slowly added to compound 22 mixture at 0 °C and then left to warm 
to room temperature and stirred overnight. At this point, EtOAc (4 ml) and water (4 ml) 
were added. The organic layer was washed with 1N HCl, water and brine. The organic 
layer was dried over Na2SO4, filtered and concentrated in vacuo to give the crude 
product. Purification by column chromatography (0-30% MeOH in DCM) afforded 
compound 25 as dark yellow oil (860 mg, 0.91 mmol, 42%). Rf= 0.54 (10% MeOH in 
DCM).;  
1
H NMR (500 MHz, DMSO) δ  9.86 (s, 1H), 8.73 (s, 1H), 8.56 (s, 1H), 8.16 
(dd, J = 8.8, 1.5 Hz, 1H), 8.01 (d, J = 2.5 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.75 (dd, J 
= 9.0, 2.5 Hz, 1H), 7.50 – 7.42 (m, 1H), 7.31 – 7.28 (m, 3H), 7.20 (td, J = 8.6, 2.5 Hz, 
1H), 7.07 (d, J = 3.2 Hz, 1H), 6.56 – 6.55 (d, J = 3.3 Hz, 1H), 5.27 (s, 2H), 5.13 (t, J = 
4.8 Hz, 1H), 3.84 - 379 (m, 4H), 3.65 – 3.60 (m, 2H), 3.56 – 3.45 (m, 10H), 3.39 – 3.35 
(m, 2H), 3.01 (t, J = 6.7 Hz, 2H), 2.71 (t, J = 5.7 Hz, 2H), 1.41 (s, 18H).; 
13
C NMR (126 
MHz, DMSO) δ 163.89 161.47, 158.05, 153.30, 152.58, 152.40, 150.27, 149.34, 
140.16, 140.09, 133.50, 131.09, 131.00, 129.09, 128.97, 124.82, 123.82, 123.80, 
123.02, 121.53, 117.00, 115.07, 114.78, 114.62, 114.40, 111.96, 108.27, 82.16, 70.13, 
69.97, 69.86, 69.16, 68.83, 56.24, 55.46, 52.84, 51.77, 50.32, 47.24, 45.37, 28.01;  
HRMS (ESI) 942.3501 [M + H]
+
, C46H57ClFN5O11S requires M 941.3448; 
 
3.1.2.3 Attempted syntheses of irreversible TKIs scaffold 
Compound 27-36: Experimental procedures for compound 27–36 shown in Scheme 
4-7 and Scheme 4-8 (both in Section 4.4.3) are not included as the desired compounds 
were not synthesized and alternative compounds for the synthesis of the irreversible 




3.1.2.4 Syntheses of Pel-linker and Ner-linker compounds 
 
 






: Compound 37 (10.5 g, 67.31 mmol) was dissolved in a 1:1 mixture 
of MeOH-THF (l80 ml), followed by addition of an excess of 1N KOH. The reaction 
mixture was heated under reflux overnight. The solution was cooled down to room 
temperature and treated with 10% aq HCl. After addition of EtAO the organic layer 
washed with water and brine, dried, filtered and concentrated. Purification by column 
chromatography afforded the compound 38. The 
1
H NMR data of compound 38 are 
identical to literature data
152
. MS (C18, ES
+
) 168.9 [M + H]
+
, C7H8N2O3 requires M 
168.0535; 
1
H NMR (500 MHz, DMSO) δ 7.82 – 7.79 (d, J = 9.1 Hz, 1H), 6.26 (s, 1H), 




: Compound 38 (9 g, 53.54 mmol) and compound 29 (18.1 g, 107.08 
mmol) were dissolved in toluene (l00 ml) and refluxed overnight. The reaction mixture 
was then cooled down to 0
o
C, filtered and washed with MTBE three times. The solid 
was dried to give compound 39 as a mixture of cis-trans isomers (14.5 g, 49.80 mmol, 
93%) which was used without further purification. MS (C18, ES
+
) 292.1 [M + H]
+
, 





: Compound 39 (13.5 g, 46.39 mmol) was added to refluxing (255
o
C) 
Dowtherm A (375 ml) and the reaction mixture was refluxed for 4 h. After completion 
of the reaction, the mixture was cooled to room temperature and diluted with MTBE 
(350 ml), filtered and washed with MTBE three times. The solid was dried to give 
compound 36 (9.36 g, 38.20 mmol, 82%) which was used without further purification. 
The 
1
H NMR data of compound 36 are identical to literature data
138
. MS (C18, ES
+
) 
245.3 [M + H]
+
, C11H7N3O4 requires M 245.0437.; 
1
H NMR (500 MHz, DMSO) δ 





: Compound 36 (7.0 g, 28.57 mmol) was dissolved in POCl3 (40 ml)) 
and stirred under refluxe until completion of the reaction (5 h). The reaction mixture 
was cooled to room temperature and slowly poured into ice/water (~400 ml) and left 
overnight. The solid was filtered off and washed with water to afford compound 40 (6.6 
g, 25.10 mmol, 88%). The 
1





. MS (C18, ES
+
) 263.1 [M + H]
+
, C11H6ClN3O3 requires M 263.0098.; 
1
H NMR 




: In a flask containing compound 40 (2.8 g, 10.65 mmol) in i-PrOH 
(47 ml), 3-chloro-4-fluoro-aniline (2) (2.24 mg, 4.46 mmol) was added. The mixture 
was refluxed for 4 h and then cooled in an iced bath. The precipitate was collected by 
filtration, washed with chilled i-PrOH and dried to afford a white powder (3.15 g, 8.47 
mmol, 80%) and the product was used to the next step without further purification. The 
1
H NMR data for the compound 42a are identical to literature data
153
. MS (C18, ES
+
) 
373.2 [M + H]
+
, C17H10ClFN4O3 requires M 372.0425; 
1
H NMR (500 MHz, DMSO) δ 




: A flask containing compound 40 (2.8 g, 10.65 mmol), aniline 41 
(3.55 g, 15.13 mmol) and compound 4 (1.77 g, 15.13 mmol) in i-PrOH (45 ml) was 
refluxed for 3 h. This was then cooled in an iced bath and the precipitate was collected 
by filtration, washed with waster, MTBE and dried to afford the product which was 
used in the next step without further purification (4.63 g, 10.04 mmol, 94%). MS (C18, 
ES
+
) 462.0 [M + H]
+
, C23H16ClN5O4 requires M 461.0891; 
1
H NMR (500 MHz, DMSO) 
δ 9.42 (s, 1H), 8.91 (s, 1H), 8.71 (d, J = 4.5 Hz, 1H), 8.10 (td, J = 7.8 Hz, 1.6 Hz, 1H), 
7.76 – 7.72 (m, 2H), 7.62 (d, J = 2.0 Hz, 1H), 7.57 (dd, J = 6.8 Hz, 5.3 Hz, 1H), 7.43 – 
7.34 (m, 2H), 5.43 (s, 2H), 4.10 (s, 3H).; 
13
C NMR (126 MHz, DMSO) δ 159.71, 
159.67, 159.39, 158.86, 158.00, 152.62, 144.86, 144.44, 136.67, 133.25, 131.74, 
129.29, 127.87, 127.74, 126.88, 120.14, 119.58, 116.79, 112.61, 91.80, 75.23, 62.68.
 
 
Compound 43a: A flask containing compound 42a (3.0 g, 8.07 mmol) and an excess of 
compound 4 was placed in a thermo-block pre-heated at 170°C. The progress of the 
reaction was monitored every min. Upon completion (5 min), the mixture was left to 
slowly cool to room temperature with slow addition of water. The precipitate was 
filtered, washed with water and dried to afford the crude product. Purification by 
column chromatography (0-40% EtOAc in heptane) afforded compound 43a as a grey 
solid (2.65 mg, 7.40 mmol, 91%). Rf= 0.49 (15% EtOAc in heptane).; MS (C18, ES
+
) 
359.3 [M + H]
+
, C16H8ClFN4O3 requires M 358.0269; 
1H NMR (500 MHz, DMSO) δ 
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9.28 (s, 1H), 8.83 (s, 1H), 7.70 (dd, J = 6.6 Hz, 2.4 Hz, 1H), 7.59 (s, 1H), 7.51 (d, J = 
8.9 Hz, 1H), 7.46 – 7.39 (m, 1H).; 13C NMR (126 MHz, CDCl3) δ 154.89, 154.45, 
153.81, 143.68, 139.68, 128.34, 127.19, 127.08, 123.26, 117.95, 117.59, 115.69, 
111.56, 106.35, 86.63. 
 
Compound 43b: This compound was prepared from 42b (4.5 g, 9.76 mmol) and 
pyridinium hydrochloride (4) using the method described above for 43a. Purification by 
column chromatography (0-60% EtOAc in heptane) afforded compound 43b as a grey 
solid (3.11 mg, 6.96 mmol, 71%). Rf = 0.45 (15% EtOAc in heptane).; MS (C18, ES
+
) 
448.2 [M + H]
+
, C22H14ClN5O4 requires M 447.0734; 
1H NMR (500 MHz, DMSO) δ 
9.26 (s, 1H), 8.77 (s, 1H), 8.64 – 8.62 (m, 1H), 7.83 (td, J = 7.7 Hz, 1.8 Hz, 1H), 7.63 – 
7.58 (m, 2H), 7.53 (s, 1H), 7.42 (dd, J = 7.5 Hz, 5.0 Hz, 1H), 7.35 – 7.34 (m, 2H), 5.35 
(s, 2H).; 
13
C NMR (126 MHz, DMSO) δ 155.60, 155.52, 154.90, 153.65, 153.37, 
148.72, 139.41, 138.91, 131.39, 128.74, 127.26, 124.10, 123.64, 122.59, 122.09, 
114.83, 114.74, 110.86, 109.28, 86.16, 71.06. 
 
Compound 44a: To a solution of compound 43a (200 mg, 0.56 mmol) and K2CO3 (154 
mg, 1.12 mmol) in anhydrous DMF (4 ml), tetraethylene glycol linker 7 (153 mg, 0.28 
mmol) and a catalytic amount of NaI were added. The resulting mixture was stirred at 
75°C overnight and then left to cool to room temperature, followed by addition of water 
(4 ml) and extraction with EtOAc (4 ml). The organic extracts were combined, dried 
over MgSO4, filtered and concentrated in vacuo to give the crude product. Purification 
by column chromatography (00-50% EtOAc in heptane) gave the compound 44a as 
yellowish oil (100 mg, 0.14 mmol, 25%). Rf = 0.59 (15% EtOAc in heptane).;  MS 
(C18, ES
+
) 734.4 [M + H]
+
, C16H8ClFN4O3 requires M 733.2526; 
1
H NMR (500 MHz, 
DMSO) δ 9.11 (s, 1H), 8.67 (s, 1H), 7.66 (s, 1H), 7.63 (dd, J = 6.9 Hz, 2.1 Hz, 1H), 
7.53 – 7.46 (m, 1H), 7.40 – 7.34 (m, 1H), 4.48 – 4.44 (m, 2H), 3.85 – 3.82 (m, 2H), 3.66 
– 3.60 (m, 4H), 3.55 – 3.46 (m, 8H), 1.43 (s, 18H). 
 
Compound 44b: This compound was prepared from 43b (250 mg, 0.56 mmol), 
potassium carbonate (154 mg, 1.12 mmol), compound 7 (153 mg, 0.28 mmol) and a 
catalytic amount of NaI in anhydrous DMF (4 ml) using the method described above for 
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44a. Purification by column chromatography (00-50% EtOAc in heptane) gave the 
compound 44b as yellowish oil (105 mg, 0.13 mmol, 23%). Rf = 0.48 (15% EtOAc in 
heptane).; MS (C18, ES
+
) 823.5 [M + H]
+
, C40H47ClN6O11 requires M 822.2991; 
1
H 
NMR (500 MHz, DMSO) δ 9.13 (s, 1H), 8.63 – 8.60 (m, 2H), 7.92 – 7.85 (m, 1H), 7.65 
(s, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.53 (s, 1H), 7.41 – 7.36 (m, 1H), 7.32 – 7.31 (m, 2H), 
5.32 (s, 2H), 4.47 – 4.44 (t, J = 4.2 Hz, 2H), 3.85 – 3.82 (dd, J = 4.5 Hz, 3.8 Hz, 2H), 
3.65 – 3.66 (m, 4H), 3.55 – 3.46 (m, 8H), 1.43 (s, 18H). 
 
Compound 47a (Pel-linker): A flask containing compound 44a (90 mg, 0.12 mmol), 
iron powder (21.5 mg), AcOH (43 μl, 0.76 mmol) and MeOH (1.2 ml) was refluxed for 
2.5 h. After completion, the reaction mixture was cooled to room temperature and 
concentrated. The residue was dissolved in EtOAc-water (1:1) and filtrated. The organic 
layer was separated, washed with water, saturated NaHCO3 and water again, dried over 
Na2SO4 and concentrated. The deprotected amine product (45a) was used to the next 
step without further purification. To a stirring solution of the acid 46 (57 mg, 0.44 
mmol) and catalytic amount of DMF (1 drop) in MeCN (1.0 ml) at 0°C, oxalyl chloride 
((COCl)2 37.3 μl, 0.44 mmol) was added. After stirring at 0°C for 30 min, the white 
suspension was left to stir at room temperature for a further 2 h. The mixture was then 
added dropwise to a solution of the deprotected amine 45a in NMP at 0°C and the 
resulting mixture was stirred for 3 h at 0°C. The solvent was then removed and the 
residue was dissolved in EtOAc-sat. NaHO3. The organic was dried over Na2SO4, 
filtered and concentrated in vacuo to give the crude product. Purification by column 
chromatography (20-100% EtOAc in heptane) gave compound 47a as yellowish oil (76 
mg, 0.094 mmol, 78%). Rf = 0.52 (10% MeOH in DCM).; 
1
H NMR (500 MHz, DMSO) 
δ 9.10 (s, 1H), 8.55 (s, 1H), 8.47 (s, 1H), 7.27 (s, 1H), 7.15 (dd, J = 6.6 Hz, 2.2 Hz, 1H), 
7.09 – 7.02 (m, 1H), 6.96 (m, 1H), 6.26 (d, J = 15.3 Hz, 1H), 4.34 – 4.31 (m, 2H), 3.97 
– 3.93 (m, 2H), 3.77 – 3.66 (m, 6H), 3.59 – 3.54 (m, 6H), 3.12 (d, J = 5.6 Hz, 2H), 2.27 
(s, 6H), 1.45 (s, 18H).; 
13
C NMR (126 MHz, CDCl3) δ 175.10, 164.16, 152.67, 152.36, 
152.17, 151.49, 150.02, 147.26, 135.80, 134.99, 133.58, 126.59, 124.21, 121.37, 
116.72, 113.72, 110.48, 109.16, 88.74, 82.35, 70.57, 70.20, 69.22, 69.02, 68.56, 60.18, 
45.12, 28.04.; HRMS (ESI) 815.3527 [M + H]
+




Compound 47b (Ner-linker): This compound was prepared from compound 44b (90 
mg, 0.11 mmol), iron powder (21.5 mg), AcOH (43 μl, 0.76 mmol) and MeOH (1.2 ml) 
followed by addition of the acid 46 (57 mg, 0.44 mmol), catalytic amount of DMF (1 
drop), oxalyl chloride (37.3 μl, 0.44 mmol) in MeCN (1.0 ml) and the deproetected 
amine 45b in NMP using the method described above for 47a. Purification by column 
chromatography (20-100% EtOAc in heptane) gave the compound 47b as yellowish oil 
(70 mg, 0.077 mmol, 71%). Rf = 0.44 (10% MeOH in DCM).; 
1
H NMR (500 MHz, 
CDCl3) δ 9.12 (s, 1H), 8.55 (dd, J = 4.1 Hz, 0.7 Hz, 1H), 8.46 (s, 1H), 7.76 – 7.69 (m, 
1H), 7.63 – 7.61 (m, 1H), 7.31 – 7.19 (m, 3H), 7.08 – 6.91 (m, 3H), 6.27 (d, J = 15.3 
Hz, 1H), 5.26 (s, 2H), 4.36 – 4.33 (m, 2H), 3.94 (dd, J = 5.1 Hz, 3.7 Hz, 2H), 3.76 – 
3.64 (m, 6H), 3.61 – 3.53 (m, 6H), 3.17 (d, J = 6.0 Hz, 2H), 2.30 (s, 6H), 1.45 (s, 18H). 
13
C NMR (126 MHz, CDCl3) δ 163.88, 156.53, 152.66, 151.82, 152.31, 150.45, 149.08, 
147.14, 142.54, 137.02, 132.51, 128.59, 127.68, 126.19, 125.11, 123.56, 122.73, 
121.25, 116.86, 113.84, 113.31, 109.37, 88.01, 82.32, 70.68, 70.61, 70.21, 69.23, 69.04, 
68.65, 60.03, 45.28, 28.05.; HRMS (ESI) 904.3990 [M + H]
+
, C46H58ClN7O10 requires 
M 903.3934. 
 
3.1.2.5 Synthesis of Bodipy FL 
 
Scheme 3-4: Total synthesis of the “free” acid of Bodipy FL dye. 
 
Compound 50 (Bodipy FL)
155
: Compound 47 (708 mg, 5.76 mmol) and the acid 48 
(800mg, 5.76 mmol) were dissolved in ethanol (150 mL) and then pTsOH (1124 mg, 
5.76 mmol) was added to the mixture.  After 30 min at room temperature, the solvent 
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was removed in vacuo. The residue (compound 49) was then dissolved in DCM (150 
mL), followed by addition of DIPEA (5 mL, 28.8 mmol) and the resulting mixture was 
stirred for 5 min at room temperature. It was then cooled down to 0
o
C and boron 
trifluoride ethyl etherate was added (7 mL, 115.2 mmol). After stirring at this 
temperature for 1h, the mixture was left to slowly warm up to room temperature and 
stirred for another h. The solution was washed with water and brine, the organic layer 
was dried over MgSO4, filtered and concentrated in vacuo to give the crude product. 
Purification by column chromatography (0-20% MeOH in DCM) afforded the product 
as a red solid (771 mg, 2.65 mmol, 46%). The 
1
H NMR data for the compound (50) are 
identical to literature data
156









H NMR (500 MHz, MeOD) δ 7.45 (s, 1H), 7.02 (d, J = 4.0 Hz, 1H), 6.33 (d, 
J = 3.9 Hz, 1H), 6.24 (s, 1H), 3.23 (t, J = 7.7 Hz, 2H), 2.77 (t, J = 7.7 Hz, 2H), 2.53 (s, 
3H), 2.30 (s, 3H). 
 
3.1.2.6 Synthesis of Bodipy 650/665 
 




: To a solution of pyrrole 51 (1.4 ml, 20.16 mmol) in 
DCM (300 ml) at -78°C, PIFA (2.9 gr, 6.74 mmol) and TMSBr (1.34 ml, 10.05 mmol) 
were added.  The reaction mixture was stirred at -78 °C for 2 h before it was left to 
warm up to 0°C. It was then poured into ice-cold saturated NaHCO3 (400 ml) and the 
resulting mixture was stirred at room temperature for 10 min. The organic phase was 
separated and the aqueous phase was extracted with DCM (2 x 350 ml). The combined 
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organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the 
crude product. Purification by column chromatography (0-50% EtOAc in heptane) 
afforded the product as a white powder (200 mg, 1.51 mmol, 52%) which was stored 
under N2 at 4°C. The 
1
H NMR data for the compound 52 are identical to literature 
data
157








H NMR (500 
MHz, CDCl3) δ 8.21 (br s, 2H), 6.76 – 6.75 (m, 2H), 6.24 – 6.19 (m, 4H).
 
 
Compound 54: This compound was prepared from bipyrrole 52 (200 mg, 1.51 mmol) 
and compound 53 (157 mg, 1.51 mmol) using the method described above for 
compound 50. Purification by column chromatography (0-40% EtOAc in heptane) 
afforded the product as a light brown solid (208 mg, 0.77 mmol, 51%).; Rf = 0.37 (20% 









NMR (500 MHz, MeOD) δ 7.18 – 7.12 (m, 4H), 6.96 – 6.91 (m, 2H), 6.35 (dd, J = 3.7 
Hz, 2.7 Hz, 1H), 6.28 – 6.27 (d, J = 4.0 Hz, 1H), 2.59 (s, 3H). 
 
Compound 56 (Bodipy 650/665)
158
: To microwave tube containing compound 54 (200 
mg, 0.74 mmol, 1 equivalent) and the acid 55 (664 mg, 3.69 mmol, 5 equivalents in 
acetonitrile (3 mL) at 0
o
C, acetic acid (0.42 ml, 7.4 mmol, 10 equivalents and 
pyrrolidine (0.62 ml, 7.4 mmol, 10 equivalents were added. The tube was placed in a 
microwave oven and heated up at 85
o
C until completion of the reaction (25 min) using 
consutive 5-min steps. The reaction mixture was then concentrated in vacuo and 
purified by column chromatography (0-50% MeOH in DCM) to afford the product as a 
red solid (118 mg, 0.27 mmol, 36%).; Rf = 0.36 (10% MeOH in DCM); MS (C18, ES
+
) 
434.1 [M + H]
+
, C23H18BF2N3O3 requires M
+
 433.1409; 
1H NMR (500 MHz, MeOD) δ 
7.45 (s, 1H), 7.03 – 7.01 (d, J = 4.0 Hz, 1H), 6.34 – 6.32 (d, J = 4.0 Hz, 1H), 6.24 (s, 






3.1.2.7 Synthesis of tetramethyl 5/6-carboxy-rhodamine 
 
Scheme 3-6: Total synthesis of the “free” acid of tetramethyl 5/6-carboxy-rhodamine dyes. 
 
Compound 59 (tetramethyl 5/6-carboxy-rhodamine)
159
: N,N-Dimethyl-3-
aminophenol 57 (3.0 g, 21.88 mmol) and 1,2,4-benzenetricarboxylic anhydride 58  
(2.10 g, 10.95 mmol) were dissolved in a sealed tube containing propionic acid (10 
mL), followed by addition of a catalytic amount of concentrated H2SO4 (2-3 drops).  
The reaction mixture was refluxed for 16 h and cooled to room temperature.  The 
solvent was removed in vacuo to give the crude product as dark-purple slurry. 
Purification by column chromatography (10-40% MeOH in DCM) gave the mixture 
isomers of TMR (59) as a purple-gold solid (780 mg, 1.81 mmol, 17%). The 
1
H NMR 
data for compound (59) are identical to literature data
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H NMR (500 MHz, MeOD) δ 8.79 (s, 0.5H), 8.26 
(dt, J = 7.8, 1.8 Hz, 1H), 8.16 (d, J = 8.1 Hz, 0.5H), 7.86 (d, J = 1.4 Hz, 0.5H), 7.37 (d, 
J = 7.8 Hz, 0.5H), 7.27 (dd, J = 16.9, 9.5 Hz, 2H), 7.04 (dd, J = 9.5, 2.5 Hz, 2H), 6.93 





3.1.2.8 Coupling of TKIs with dyes 
Inhibitor
Fluorescent dye
Bodiby FL TMR 5 TMR 6 Bodipy 650
Gefitinib Compound 60 Compound 64 Compound 67 Compound 71
Lapatinib Compound 61 Compound 65 Compound 68 Compound 72
Pelitinib Compound 62 --- Compound 69 Compound 73
Neratinib Compound 63 Compound 66 Compound 70 Compound 74
 
Scheme 3-7: Total synthesis of final fluorescent TKIs. 
 
Dye-Inhibitor coupling_General Method (Method A): An excess of trifluoroacetic 
acid was (TFA) added to a solution of the tert-butyloxycarbonyl (BOC) protected TKI-
linker compound (1 equivalent) in DCM and the reaction was stirred at room 
temperature for 1.5-2 h. The solvent was then removed using a steady stream of N2 gas 
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or concentrated in vacuo, affording the deprotected compound (verified by LS-MS). It 
was then dissolved in solvent (DMF, DCM or DMSO), followed by addition of DIPEA 
(2 equivalents). In another flask (F2), the fluorescent dye (1 or more equivalents with 
respect to the TKI-linker compound) was dissolved in solvent (DMF, DCM or DMSO) 
and treated with TSTU (1.5 equivalents with respect to the dye) and DIPEA (1.5 
equivalents with respect to the dye). The reaction mixture was stirred for 2 h at room 
temperature. The content of flask F2 was then added dropwise to the solution of the 
deprotected compound and the resulting mixture was stirred at room temperature 
overnight.  The reaction mixture was then concentrated in vacuo and purified by 
preparative HPLC. 
 
Compound 60 (Gef-Bod FL): This compound was prepared from compound 8 and 
compound 50 using Method A (described above). The crude material was purified by 
preparative HPLC (Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; 
B: acetonitrile) and the product was obtained as a green solid (31%). Rf = 0.50 (10% 
MeOH in DCM); 
1
H NMR (500 MHz, MeOD) δ 8.45 (s, 1H), 8.04 (dd, J = 6.7 Hz, 2.6 
Hz, 1H), 7.73 – 7.67 (m, 2H), 7.29 – 7.22 (m, 2H), 7.16 (s, 1H), 6.91 (d, J = 4.0 Hz, 
1H), 6.24 – 6.23 (d, J = 4.0 Hz, 1H), 6.13 (s, 1H), 4.26 – 4.15 (m, 4H), 3.91 – 3.88 (m, 
2H), 3.75 – 3.69 (m, 6H), 3.65 – 3.45 (m, 10H), 3.10 (t, J = 7.6 Hz, 2H), 2.76 – 2.70 (m, 
2H), 2.52 (t, J = 7.7 Hz, 2H), 2.41 (s, 3H), 2.15 – 2.07 (m, 5H).; HRMS (ESI) 882.3720 
[M + H]
+
, C43H52BClF3N7O7 requires M 881.3662. 
 
Compound 61 (Lap-Bod FL): This compound was prepared from compound 25 and 
compound 50 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a green solid (31%). Rf = 0.45 (10% MeOH in DCM); 
1
H NMR (500 MHz, MeOD) δ  8.68 (d, J = 1.7 Hz, 1H), 8.60 (s, 1H), 8.20 (dd, J = 8.8, 
1.8 Hz, 1H), 7.98 (d, J = 2.6 Hz, 1H), 7.88 – 7.87 (d, J = 8.7 Hz, 1H), 7.70 (dd, J = 8.9, 
2.6 Hz, 1H), 7.50 (td, J = 7.9, 5.9 Hz, 1H), 7.45 – 7.35 (m, 3H), 7.29 (s, 1H), 7.21 (d, J 
= 8.9 Hz, 1H), 7.15 (td, J = 8.5, 2.5 Hz, 1H), 7.00 – 6.99 (d, J = 3.4 Hz, 1H), 6.98 – 
6.97 (d, J = 4.0 Hz, 1H), 6.58 – 6.57 (d, J = 3.4 Hz, 1H), 6.35 – 6.34 (d, J = 4.1 Hz, 
1H), 6.19 (s, 1H), 5.32 (s, 2H), 3.97 (t, J = 5.7 Hz, 2H), 3.86 (s, 2H), 3.65 (t, J = 5.6 Hz, 
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2H), 3.61 – 3.58 (m, 6H), 3.51 (t, J = 5.3 Hz, 2H), 3.45 – 3.42 (m, 2H), 3.24 – 3.16 (m, 
6H), 2.79 (t, J = 5.4 Hz, 2H), 2.56 (t, J = 7.7 Hz, 2H), 2.44 (s, 3H), 2.19 (s, 3H).; HRMS 
(ESI) 1016.3554 [M + H]
+
, C50H54BClF3N7O8S requires M 1015.3488. 
 
Compound 62 (Pel-Bod FL): This compound was prepared from compound 47a and 
compound 50 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a green solid (27%). Rf = 0.21 (10% MeOH in DCM).; 
1H NMR (500 MHz, DMSO) δ 9.54 (s, 1H), 8.98 (s, 1H), 8.42 (s, 1H), 7.17 (s, 1H), 
7.01 – 6.92 (m, 3H), 6.83 – 6.77 (m, 1H), 6.76 – 6.68 (m, 1H),  6.64 (d, J = 4.0 Hz, 1H), 
6.05 (s, 1H), 5.98 (d, J = 3.8 Hz, 1H), 4.25 – 4.23 (m, 2H), 3.97 – 3.94 (m, 2H), 3.80 (d, 
J = 6.7 Hz, 2H), 3.75 – 3.59 (m, 6H), 3.50 – 3.47 (m, 2H), 3.36 (d, J = 5.1 Hz, 2H), 3.15 
– 3.06 (m, 3H), 2.80 (s, 6H), 2.52 – 2.46 (m, 5H), 2.18 (s, 3H).; 13C NMR (126 MHz, 
DMSO) δ 175.10, 164.16, 152.67, 152.36, 152.17, 151.49, 150.02, 147.26, 135.80, 
134.99, 133.58, 126.59, 124.21, 121.37, 116.72, 113.72, 110.48, 109.16, 88.74, 82.35, 
70.57, 70.20, 69.22, 69.02, 68.56, 60.18, 45.40, 45.12, 28.04.; HRMS (ESI) 815.3527 
[M + H]
+
, C40H52ClFN6O9 requires M 814.3468. 
 
Compound 63 (Ner-Bod FL): This compound was prepared from compound 47b and 
compound 50 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a green solid (31%). Rf = 0.25 (10% MeOH in DCM).; 
1
H NMR (500 MHz, CDCl3) δ 9.04 (s, 1H), 8.52 (d, J = 4.3 Hz, 1H), 8.40 (s, 1H), 7.69 
(td, J = 7.7 Hz, 1.7 Hz, 1H), 7.60 – 7.56 (m, 1H), 7.23 – 7.15 (m, 3H), 7.01 – 6.87 (m, 
4H), 6.71 (d, J = 4.0 Hz, 1H), 6.25 (d, J = 15.4 Hz, 1H), 6.12 (d, J = 4.0 Hz, 1H), 6.01 
(s, 1H), 5.22 (s, 2H), 4.26 (dd, J = 4.9 Hz, 3.4 Hz, 2H), 3.87 (dd, J = 5.1 Hz, 3.2 Hz, 
2H), 3.67 – 3.50 (m, 8H), 3.46 – 3.42 (m, 2H), 3.46 – 3.42 (m, 2H), 3.36 – 3.31 (m, 
2H), 3.19 – 3.12 (m, 4H), 2.53 – 2.46 (m, 5H), 2.30 (s, 6H), 2.14 (s, 3H).; HRMS (ESI) 
1000.3877 [M + Na]
+
, C50H55BClF2N9O7 requires M 1000.3872. 
 
Compound 64 & 67 (Gef-TMR5 & Gef-TMR6): These compounds were prepared 
from compound 8 and compound 59 (mixed 5- and 6-isomer of TMR) using Method A. 
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The products were separated and purified by preparative HPLC (Boston C18 
21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) to afford the 
pure 5- (30%) and 6-isomer (21%) as purple solids. 5-isomer (64): Rf = 0.28 (10% 
MeOH in DCM);  
1
H NMR (500 MHz, MeOD) δ 8.62 (s, 1H), 8.43 (d, J = 10.8 Hz, 
2H), 8.05 (d, J = 7.4 Hz, 2H), 7.75 (s, 1H), 7.37 (s, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.00 
(dd, J = 25.7, 8.9 Hz, 4H), 6.61 (d, J = 9.0 Hz, 2H), 6.26 (s, 2H), 4.19 (s, 2H), 3.89 (s, 
2H), 3.79 (d, J = 13.5 Hz, 2H), 3.78 – 3.72 (m, 8H), 3.71 (s, 4H), 3.66 (t, J = 11.7 Hz, 
2H), 3.11 (s, 12H), 2.81 (d, J = 17.4 Hz, 6H), 1.98 (s, 2H).; HRMS (ESI): 1020.4073 
[M + H]
+
, C54H60ClFN7O10 requires M 1019.3996.; 6-isomer (67): Rf = 0.33 (10% 
MeOH in DCM);   
1
H NMR (500 MHz, MeOD) δ 8.46 (s, 1H), 8.35 (s, 7H), 8.23 (d, J = 
7.8 Hz, 1H), 8.10 (d, J = 7.2 Hz, 2H), 7.80 (s, 1H), 7.64 (s, 1H), 7.54 (s, 1H), 7.11 – 
7.00 (m, 4H), 6.65 (d, J = 7.7 Hz, 2H), 6.35 (s, 2H), 4.25 (s, 2H), 3.89 (s, 2H), 3.81 (s, 
4H), 3.71 (dd, J = 5.7, 3.3 Hz, 2H), 3.68 – 3.61 (m, 8H), 3.58 (t, J = 4.9 Hz, 2H), 3.15 
(s, 12H), 2.92 (s, 4H), 2.89 – 2.82 (m, 2H), 2.04 (m, 2H).; HRMS (ESI) 1020.4067 [M 
+ H]
+
, C54H60ClFN7O10 requires M 1019.3996. 
 
Compound 65 & 68 (Lap-TMR5 &Lap-TMR6): These compounds were prepared 
from compound 25 and compound 59 (mixed 5- and 6-isomer of TMR) using Method A. 
The products were separated and purified by preparative HPLC (Boston C18 
21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) to afford the 
pure 5- (30%) and 6-isomer (21%) as purple solids. 5-isomer (65): Rf = 0.36 (10% 
MeOH in DCM);  
1
H NMR (500 MHz, MeOD) δ 9.87 (s, 1H), 8.85 (t, J = 5.5 Hz, 1H), 
8.70 (s, 1H), 8.54 (s, 1H), 8.45 (s, 1H), 8.21 – 8.20 (dd, J = 8.1 Hz, 1.2 Hz, 1H), 8.13 – 
8.11 (m, 1H), 8.02 – 8.01 (d, J = 2.6 Hz, 1H), 7.78 – 7.77 (d, J = 8.7 Hz, 1H), 7.75 – 
7.73 (dd, J = 8.9, 2.5 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.34 – 7.28 (m, 2H), 7.29 – 7.28 (d, 
J = 8.1 Hz, 1H), 7.26 (d, J = 9.0 Hz, 1H), 7.18 (td, J = 8.6, 2.6 Hz, 1H), 7.03 – 7.02 (d, J 
= 3.4 Hz, 1H), 6.53 – 6.52 (d, J = 3.4 Hz, 1H), 6.51 – 6.43 (m, 6H), 5.25 (s, 2H), 3.82 – 
3.79 (m, 4H), 3.59 – 3.55 (m, 8H), 3.48 – 3.45 (m, 2H), 3.40 – 3.25 (m, 4H), 2.99 (t, J = 
6.9 Hz, 2H), 2.92 (s, 12H), 2.70 (t, J = 5.6 Hz, 2H).; HRMS (ESI): 1154.3886 [M + H]
+
, 
C61H61ClFN7O11S requires M 1153.3822.; 6-isomer (68): Rf = 0.22 (10% MeOH in 
DCM);   
1
H NMR (500 MHz, MeOD) δ 9.86 (s, 1H), 8.75 – 8.72 (m, 2H), 8.67 – 8.66 
(m, 1H), 8.58 (s, 1H), 8.18 – 8.13 (m, 2H), 8.09 – 8.06 (m, 1H), 7.81 – 7.77 (m, 1H), 
7.76 – 7.72 (dd, J = 9.3, 2.8 Hz, 1H), 7.65 (s, 1H), 7.50 – 7.44 (m, 1H), 7.37 – 7.27 (m, 
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3H), 7.23 – 7.16 (m, 1H), 7.04 (d, J = 3.7 Hz, 1H), 6.57 – 6.46 (m, 7H), 5.27 (s, 2H), 
3.83 – 3.77 (m, 4H), 3.53 – 3.46 (m, 10H), 3.42 – 3.25 (m, 4H), 3.06 – 3.03 (m, 2H), 
2.94 (s, 12H), 2.79 – 2.77 (m, 2H).; HRMS (ESI) 1154.3899 [M + H]+, 
C61H61ClFN7O11S requires M 1153.3822. 
 
Compound 69 (Pel-TMR): This compound was prepared from compound 47a and 
compound 59 using Method A. The products were separated and purified by preparative 
HPLC (Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: 
acetonitrile) to afford the pure product as purple solid (25%). Rf = 0.24 (40% MeOH in 
DCM).; 
1H NMR (500 MHz, DMSO) δ 8.33 (s, 1H), 8.57 (s, 1H), 8.31 (s, 1H), 8.03 
(dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.26 – 7.19 (m, 1H), 7.14 – 8.03 
(m, 5H),  6.77 – 6.70 (m, 4H), 6.59 – 6.49 (m, 2H), 5.98 (d, J = 3.8 Hz, 1H), 4.21 (m, 
2H), 3.85 (m, 2H), 3.75 – 3.53 (m, 12H), 3.18 – 3.15 (m, 14H), 2.77 (s, 6H).; HRMS 
(ESI) 1027.3905 [M + H]
+
, C55H56ClFN8O9 requires M 1026.3843. 
 
Compound 66 & 70 (Ner-TMR): These compounds were prepared from compound 
47b and compound 59 (mixed 5- and 6-isomer of TMR) using Method A. The products 
were separated and purified by preparative HPLC (Boston C18 21*250mm 10µm, 
mobile phase: A: 0.1 % formic acid; B: acetonitrile) to afford the pure 5- (27%) and 6-
isomer (21%) as purple solids. 5-isomer (66): Rf = 0.30 (30% MeOH in DCM).; 
1
H 
NMR (500 MHz, MeOD) δ 8.63 (s, 1H), 8.46 – 8.44 (m, 2H), 8.10 (s, 1H), 7.96 – 7.92 
(m, 1H), 7.82 – 7.76 (m, 1H), 7.60 – 7.56 (m, 1H), 7.30 – 7.08 (m, 4H), 7.03 – 6.93 (m, 
5H), 6.70 – 6.66 (m, 2H), 6.57 (s, 2H), 6.43 (d, J = 15.6 Hz, 1H), 5.13 (s, 2H), 4.13 – 
4.09 (m, 2H), 3.79 – 3.75 (m, 2H), 3.66 – 3.42 (m, 12H), 3.16 – 3.13 (m, 2H), 3.06 (s, 
12H), 2.52 (s, 6H).; HRMS (ESI) 1116.4379 [M + H]
+
, C61H62ClFN9O10 requires M 
1115.4308. 6-isomer (70): Rf = 0.23 (30% MeOH in DCM).; 
1
H NMR (500 MHz, 
MeOD) δ 8.70 (s, 1H), 8.46 (d, J = 5.0 Hz, 1H), 8.15 (s, 1H), 8.02 (d, J = 8.2 Hz, 1H), 
7.95 (dd, J = 8.1 Hz, 1.6 Hz, 1H), 7.85 – 7.78 (m, 1H), 7.70 (s, 1H), 7.62 – 7.59 (m, 
1H), 7.32 – 7.27 (m, 1H), 7.20 – 7.14 (m, 2H), 7.09 – 7.01 (m, 5H), 6.73 (dd, J = 9.5 
Hz, 2.3 Hz, 2H), 6.63 – 6.62 (m, 2H), 6.51 – 6.45 (m, 1H), 5.15 (s, 2H), 4.18 – 4.15 (m, 
2H), 3.81 – 3.78 (m, 2H), 3.60 – 3.42 (m, 12H), 3.17 – 3.13 (m, 2H), 3.08 (s, 12H), 2.55 
(s, 6H).; HRMS (ESI) 1116.4379 [M + H]
+




Compound 71 (Gef-Bod 650): This compound was prepared from compound 8 and 
compound 56 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a green solid (26%). Rf = 0.64 (20% MeOH in DCM); 
1
H NMR (500 MHz, MeOD) δ 8.47 (s, 1H), 7.81 (dd, J = 6.6 Hz, 2.5 Hz, 1H), 7.55 – 
7.52 (m, 1H), 7.45 (d, J = 8.7 Hz, 2H), 7.42 – 7.37 (m, 2H), 7.13 – 7.12 (m, 2H), 7.08 – 
7.04 (m, 2H), 6.95 (d, J = 4.6 Hz, 1H), 6.93 (dd, J = 3.8 Hz, 1.4 Hz, 1H), 6.89 – 6.87 
(m, 3H), 6.81 – 6.80 (d, J = 4.4 Hz, 2H), 6.74 – 6.73 (d, J = 4.4 Hz, 1H), 6.32 – 6.31 (m, 
1H), 4.46 (s, 2H), 4.22 – 4.20 (m, 2H), 4.12 (t, J = 6.6 Hz, 2H), 3.90 – 3.88 (m, 2H), 
3.72 (dd, J = 5.8 Hz, 3.7 Hz, 2H), 3.67 (t, J = 4.7 Hz, 2H), 3.65 – 3.63 (m, 2H), 3.60 – 
3.53 (m, 6H), 3.49 – 3.46 (m, 2H), 2.52 (t, J = 7.2 Hz, 2H), 2.45 (s, 4H), 2.02 – 1.96 (m, 
2H).; HRMS (ESI) 1023.3935 [M + H]
+
, C52H55BClF3N8O8 requires M 1022.3877. 
 
Compound 72 (Lap-Bod 650): This compound was prepared from compound 25 and 
compound 56 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a green solid (26%). Rf = 0.64 (20% MeOH in DCM); 
1
H NMR (500 MHz, MeOD) δ 8.47 (s, 1H), 8.41 (d, J = 1.7 Hz, 1H), 7.96 (dd, J = 8.7 
Hz, 1.8 Hz, 1H), 7.76 (d, J = 2.4 Hz, 1H), 7.71 – 7.70 (d, J = 8.9 Hz, 1H), 7.50 (dd, J = 
8.8 Hz, 2.5 Hz, 1H), 7.48 (s, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.43 (d, J = 17.1 Hz, 1H), 
7.34 (td, J = 7.9 Hz, 5.9 Hz, 1H), 7.22 – 7.21 (d, J = 7.8 Hz, 1H), 7.18 (d, J = 9.6 Hz, 
1H), 7.13 – 7.09 (m, 2H), 7.01 – 6.93 (m, 4H), 6.90 (s, 1H), 6.89 (d, J = 8.9 Hz, 2H), 
6.83 – 6.81 (m, 2H), 6.75 – 6.74 (d, J = 4.0 Hz, 2H), 6.34 – 6.33 (d, J = 3.4 Hz, 1H), 
6.31 – 6.30 (m, 1H), 5.11 (s, 2H), 4.46 (s, 2H), 3.94 (t, J = 5.5 Hz, 2H), 3.77 (s, 2H), 
3.60 (t, J = 5.3 Hz, 2H), 3.57 – 3.54 (m, 6H), 3.48 – 3.46 (m, 2H), 3.38 (t, J = 6.9 Hz, 
2H), 3.26 (t, J = 5.5 Hz, 2H), 3.18 – 3.16 (m, 2H), 2.72 (t, J = 5.3 Hz, 2H).; HRMS 
(ESI) 1157.3776 [M + H]
+
, C59H57BClF3N8O9S requires M 1156.3703. 
 
Compound 73 (Pel-Bod 650): This compound was prepared from compound 47a and 
compound 56 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
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and the product was obtained as a blue solid (30%). Rf = 0.36 (10% MeOH in DCM).; 
1H NMR (500 MHz, DMSO) δ 9.10 (s, 1H), 8.47 (s, 1H), 8.38 (s, 1H), 7.55 – 7.43 (m, 
4H), 7.27 (s, 1H), 7.17 – 6.83 (m, 12H), 6.79 (d, J = 4.3 Hz, 1H), 6.35 – 6.32 (m, 1H),  
6.22 (d, J = 15.3 Hz, 1H), 4.49 (s, 2H), 4.31 – 4.28 (m, 2H), 3.94 – 3.91 (m, 2H), 3.73 – 
3.68 (m, 4H), 3.62 – 3.49 (m, 8H), 3.12 (d, J = 5.2 Hz, 2H), 2.77 (s, 6H).; HRMS (ESI) 
1030.3783 [M + H]
+
, C40H52ClFN6O9 requires M 1029.3723. 
 
Compound 74 (Ner-Bod 650): This compound was prepared from compound 47b and 
compound 56 using Method A. The crude material was purified by preparative HPLC 
(Boston C18 21*250mm 10µm, mobile phase: A: 0.1 % formic acid; B: acetonitrile) 
and the product was obtained as a blue solid (27%). Rf = 0.33 (10% MeOH in DCM).; 
1
H NMR (500 MHz, CDCl3) δ 9.08 (s, 1H), 8.56 (d, J = 4.5 Hz, 1H), 8.45 (s, 1H), 7.76 
– 7.70 (m, 1H), 7.63 – 7.60 (m, 1H), 7.55 – 7.44 (m, 3H), 7.27 (s, 1H), 7.21 – 7.07 (m, 
5H), 7.01 – 6.82 (m, 9H), 6.78 – 6.77 (m, 1H), 6.25 (d, J = 15.5 Hz, 1H), 6.12 (m, 1H), 
5.24 (s, 2H), 4.46 (s, 2H), 4.31 – 4.27 (m, 2H), 3.94 – 3.91 (m, 2H), 3.73 – 3.64 (m, 
4H), 3.62 – 3.46 (m, 8H), 3.42 (d, J = 6.3 Hz, 2H), 2.50 (s, 6H).; HRMS (ESI) 
1119.4249 [M + H]
+
, C59H58BClF2N10O8 requires M 1118.4189. 
 
3.2 Determination of dissociation constants 
Determination of the dissociation constant of compounds was performed in in 
DiscoveRx (San Diego, USA) using KINOMEscan™ Profiling Service technology. The 
protocol used is described below. 
Kinase assay: For most assays, kinase-tagged T7 phage strains were prepared in an E. 
coli host derived from the BL21 strain. E. coli were grown to log-phase and infected 
with T7 phage and incubated with shaking at 32°C until lysis occured. The lysates were 
centrifuged and filtered to remove cell debris. The remaining kinases were produced in 
HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-
coated magnetic beads were treated with biotinylated small molecule ligands for 30 min 
at room temperature to generate affinity resins for kinase assays. The liganded beads 
were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 
1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-
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specific binding. Binding reactions were assembled by combining kinases, liganded 
affinity beads, and test compounds in 1x binding buffer (20% SeaBlock, 0.17x PBS, 
0.05% Tween 20, 6 mM DTT). All reactions were performed in polystyrene 96-well 
plates in a final volume of 0.135 ml. The assay plates were incubated at room 
temperature, shaking for 1 h and the affinity beads were washed with wash buffer (1x 
PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1xPBS, 
0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room 
temperature, shaking for 30 min. The kinase concentration in the eluates was measured 
by qPCR. 
 
3.3 Spectroscopic measurements of compound spectra 
The excitation spectra were recorded using a Jasco V-630 UV-Vis spectrometer. The 
fluorescence excitation spectra of fluorescent inhibitors (between 100-500 nM in PBS) 
were recorded at various emission wavelengths depending on the fluorophore (Bodipy 
FL: 250 to 620 nm, TMR: 250 to 650 nm and Bodipy 650: 250 to 750 nm). The 




3.4 Glass passivation 
Glass-bottom dishes used herein for seeding cells were treated with one of the following 
treatments as previously described
161
. 
Piranha cleaning: 30% w/v hydrogen peroxide was added to ice-cold concentrated 
sulphuric acid in 3:1 ration and left on ice for 5 min. The glass was treated with the 
mixture for 15 min at room temperature, rinsed with copious amount of water and left to 
dry overnight. 
Basic cleaning: NaOH pellets were dissolved in deionised water to a final concentration 
of 7 M. The solution was further diluted to 0.1 M with deionised water. The glass was 
treated with 0.1 M NaOH for 1 h at room temperature, rinsed and left to dry overnight.  
Bovine Serum Albumin (Sigma) was dissolved in PBS to a final concentration of 1% 
w/v and sterilized by filtration. The glass surface was coated with BSA for 1 h at room 
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temperature, rinsed and used promptly. BSA coating was applied after piranha or NaOH 
cleaning. 
PEG-BSA nanogel: Nanogel was prepared as described by Zanetti-Domingues et al.
161
 
(and references therein) 
 
For single-molecule experiments with fluorescent inhibitors (assessment of the non-
specific binding of fTKIs), glass surfaces were treated with one of the aforementioned 
methods as indicated in section 5.3.3. 
For single-molecule experiments with ECD labelling, glass surfaces were piranha 
cleaned and then coated with 1% BSA. 
 
3.5 Cell Biology 
All reagents, unless otherwise stated, were purchased from Invitrogen, UK. Cells were 
grown in 5% CO2 in air at 37°C. 
 
3.5.1 Cell culture 
Chinese hamster ovary (CHO) cells stably transfected with wild-type EGFR or an 
EGFR mutant (L680N-EGFR, K721A-EGFR and Δ973-EGFR) were grown in phenol-
red free Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% (v/v) 
fetal bovine serum, 2mM glutamine, 1% penicillin-streptomycin, 100 μg/ml 
hygromycin and 100 μg/ml geneticin. 
For confocal experiments, cells were seeded on uncoated 35 mm no. 1.5 glass-
bottomed dishes (MatTek Corporation, USA) with 1.0 x 10
5
 cells and with (stably 
transfected CHO cells) or without (transient transfected CHO cells) 250 ng/ml of 
doxycycline (~4 x10
5
 receptors per cell) per sample. Cells were grown for two days 
before starvation. 
For single-molecule experiments, cells were seeded on 35 mm no. 1.5 (high tolerance) 
glass-bottomed dishes (MatTek Corporation, USA) with 1.0 x 10
5
 cells and with (stably 





 receptors per cell) per sample. Cells were grown for two days 
before starvation. 
 
3.5.2 Transient transfection 
Wild type CHO cells (ECCAC culture collection) were grown in phenol-red free 
DMEM/F12 nutrient mix supplemented with 10% (v/v) fetal bovine serum and 1% 
penicillin-streptomycin. For all experiments, a reverse transfection protocol was 
followed as described below. Briefly, 1 x 10
5
 cells in 2 ml of media were transfected 
(before seeding in glass-bottomed dishes) with 1 μg of either EGFR mutants (L858R or 
L858R/T790M) or ErbB2-4 receptors DNA using ViaFect transfection reagent 
(Promega) at 4:1 reagent:DNA ratio. 
 
3.5.3 Western blot 
Either CHO cells stably expressing wild type EGFR (plus 250ng/ml of doxycycline 
hyclate (Sigma)) or wild type CHO cells reverse transfected with EGFR mutants were 
seeded on 6-well plates at a density of ~1.0 x 10
5
 cells per well, grown to 80% 
confluency and serum-starved for 2 h (for stably expressing CHO cells, the same 
amount of doxycycline hyclate was added). Cells were treated with either the indicated 
concentrations of unlabelled murine-EGF (between 1 nM and 20 nM) or PBS 1x 
(negative control) for 2 h on ice. For the 9G8 nanobody
162
 treatment, cells were treated 
for one h on ice at 4°C with 200 nM nanobody dissolved in PBS. After washing off the 
samples (3×ice-cold PBS), samples were lysed for 5 min on ice with 400 μl pre-heated 
lysis buffer (LDS buffer (Invitrogen) supplemented with 25 mM benzamidine, 1/100 
Protease Inhibitor cocktail (Cell Signaling Technologies), 100 mM NaF, 1 mM Na3VO4 
and 1% DTT). Lysates were cleared by centrifuging at 14000g for 5 min at 4°C. 
Samples were run in parallel on 1.0 mm thick 3-8% Tris-Acetate NuPAGE gels 
(Invitrogen) with HiMark Prestained HMW and Novex Sharp Prestained protein 
standards (Invitrogen) using an XCell apparatus (Invitrogen). Proteins were blotted 
using an iBlot system (Invitrogen) on PVDF membranes, blocked for 1 h 4°C with 5% 
BSA in TBS+0.1% Tween and probed overnight with mouse anti-phosphotyrosine 
4G10 antibody (Millipore). Gels were probed with secondary anti-mouse-HRP antibody 
77 
 
(Jackson ImmunoResearch) and incubated with Supersignal West Pico 
Chemiluminescent Substrate solution (Pierce) for 5 min, then imaged with a BioRad 
ChemiDoc MP system imager. Each blot was stripped with 25 ml stripping buffer (2% 
SDS, 0.75% β-mercaptoethanol, 62.5 mM Tris HCl pH 6.7) for 50 min at 60°C, and re-
probed with an anti-EGFR cocktail composed of anti-EGFR D38B1 (Cell Signalling 
Technologies), anti-EGFR N-Terminal polyclonal ab137660 (abcam) and anti-EGFR 
polyclonal 10005: sc-03 (Santa Cruz Biotechnology), all derived from rabbit. Anti-
rabbit-HRP (Jackson ImmunoResearch) was used for all blots and images were acquired 
as above. 
Densitometry analysis was performed with ImageJ software (NIH)
163
. Bands were 
normalized to the amount of total EGFR. 
 
3.5.4 Labelling of extracellular domain of receptors 
EGF conjugates were custom-conjugated with NHS-ester or SE-ester dyes by 
Cambridge Research Biochemicals. Only 1:1 labelled fractions were used in Single-
Molecule experiments. All Affibodies and nanobodies were conjugated in-house with 
maleimide dyes following manufacturers’ instructions. NRG1β was conjugated in-
house with maleimide dyes following manufacturers’ instructions. ErbB4 Adhiron was 
conjugated in-house with NHS-ester dyes following manufacturers’ instructions.  
Table 3-1: List of ligands and dyes for the conjugates used in the present study 
Ligand (Manufacturer) 
Dyes conjugated with ligand 
(Manufacturer) 
EGF (Peprotech) - Alexa 488 / Molecular Probes 
Invitrogen 
- CF640R / Biotium 
Anti-EGFR Affibody (Abcam) 
Anti-EGFR nanobody EgB4 - gift 
by Dr Paul van Bergen en 
Henegouwen (Utrecht 
University) 




Anti-ErbB2 Affibody ZErbB2:477 
(m) (Affibody Inc.) 
CF640R / Biotium 





Anti-ErbB4 Adhiron - gift by Dr D. 
Tomlinson (University of Leeds) 
 
3.5.5 Cell preparation and labelling 
3.5.5.1 Permeability test of Fluorescent Tyrosine Kinase Inhibitors (fTKIs) 
Wild type CHO cells were seeded on glass-bottomed dishes as described in section 
3.5.1. After two days, the medium was changed to serum-free medium (phenol-red free 
DMEM/F12 nutrient mix supplemented with 1% penicillin-streptomycin) for 2 h. Cells 
were promptly imaged after replacing the medium with 200 nM of fTKIs dissolved in 
serum-free medium. For each fTKI, 20 confocal images of equatorial regions of the 
cells were collected over a period of 30 min from 2 replicates. 
 
3.5.5.2 In vitro binding of fTKIs in live cells 
CHO cells expressing wt EGFR were seeded on glass-bottomed dishes as described in 
section 3.5.1. After two days, the medium was washed thrice and replaced with a range 
of fTKIs’ concentrations (50-400nM) dissolved in 0.1% serum medium (phenol-red free 
Dulbecco’s Modified Eagle medium (DMEM) supplemented with 0.1% (v/v) fetal 
bovine serum, 2mM glutamine, 1% penicillin-streptomycin, 100 μg/ml hygromycin and 
100 μg/ml geneticin) plus 250ng/ml of doxycycline hyclate for 2 h. After starvation, 
cells were washed thrice with PBS and cooled at 4°C on ice for 10 min. Cells were then 
labelled with 20 nM of either anti-EGFR Affibody or EGF (both labelled with either 
Alexa 488 or CF640R) for 1 h at 4°C to inhibit EGF-induced endocytosis. The N-
79 
 
terminus of EGF was labelled at a 1:1 ratio by Cambridge Research Biochemicals 
(Cleveland, UK). The EGFR Affibody was labeled at a 1:1 ratio at its single cysteine 
residue. Cells were rinsed with ice-cold PBS and fixed with 3% paraformaldehyde plus 
0.5% glutaraldehyde for 15 min at 4°C on ice, then for 15 min at room temperature. 10 
confocal images per fTKI from 3 replicates were collected. 
 
3.5.5.3 In vitro binding, binding specificity and dye effect of fTKIs and pre-fixed 
cells 
CHO cells either stably expressing wt EGFR or transfected with any of ErbB2-4 were 
seeded on glass-bottomed dishes as described in section 3.5.1. After starvation, cells 
were washed thrice with PBS and cooled at 4°C for 10 min. For pre-treated cells with 
unlabelled Neratinib (Tocris Bioscience), cells were treated with 1μM of the 
commercial TKI during starvation and it was included during ECD labelling. Then, 
cells were labelled with 20 nM of an extracellular domain ligand (anti-EGFR Affibody, 
EGF, anti-ErbB2 or ErbB3 Affibody, NRG1β and anti-ErbB4 Adhiron, all labelled with 
either Alexa 488 or CF640R) for 1 h at 4°C. Cells were rinsed with ice-cold PBS and 
fixed with either 3% paraformaldehyde plus 0.5% glutaraldehyde or 3% 
paraformaldehyde for 15 min at 4°C, then 15 min at room temperature. Finally, cells 
were permeabilized with 0.05% Triton-X100 (Sigma) for 1 min. Cells were then 
labelled with fTKIs (100nM) dissolved in PBS just before imaging at room temperature 
and the labelling solution was remained in the dish during data acquisition.10 confocal 
images per fTKI from 3 replicates were collected using the microscope and set up 
described above. 
 
3.5.5.4 Quantitative binding analysis 
CHO cells stably expressing EGFR alleles (wt EGFR, L680N and Δ973) or wild type 
CHO transfected with L858R or L858R/T790M were seeded on glass-bottomed dishes 
as described in section 3.5.1. For Gefitinib pre-treatment, cells were treated with 1 μM 
unlabelled Gefitinib (Tocris Bioscience) during starvation and it was included during 
ECD labelling. 
After starvation, cells were washed with PBS, cooled at 4°C for 10 min and then 
labelled for 1 h at 4°C with one of the following: 
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- 50 nM of anti-EGFR nanobody EgB4-Alexa 488 or 20 nM of anti-EGFR 
Affibody-CF640R (basal receptor) 
- Either indicated concentration (1, 10 or 20 nM) of unlabelled EGF plus 50 nM 
of anti-EGFR nanobody EgB4-Alexa 488 plus or 20 nM of EGF-CF640R (EGF-
stimulated receptor) 
- 20 nM of anti-EGFR Affibody-CF640R plus 200 nM of 9G8 (9G8-treated 
receptor) 
Cells were then rinsed with ice-cold PBS and fixed with 3% paraformaldehyde for 15 
min at 4°C, then 15 min at room temperature. Finally, cells were permeabilized with 
0.05% Triton-X100 (Sigma) for 1 min. Cells were then labelled with TMR labelled 
TKIs (100nM) dissolved in PBS just before imaging at room temperature and the 
labelling solution remained in the dish during data acquisition. Forty-five confocal 
images per fTKI from three replicates were collected. 
 
3.5.5.5 Intradimer FRET between fTKIs 
CHO cells expressing wt EGFR were seeded on glass-bottomed dishes as described in 
section 3.5.1. After starvation, cells were washed with PBS, cooled at 4°C for 30 min 
and then fixed with 3% paraformaldehyde for 15 min at 4°C, followed by 15 min at 
room temperature. Cells were then treated with Bodipy FL labelled TKIs (concentration 
between 10 and 400 nM, donor) dissolved in PBS and incubated for 20 min at room 
temperature. The donor labelling medium was then replaced with the acceptor medium 
(Bodipy 650 labelled TKIs at a concentration of either 0.2 or 2 μM). Data were 
collected without removing the acceptor labelling medium after incubation for 20 min. 
Twenty areas per fTKI from 2 replicates were collected. 
 
3.5.5.6 Assessment of non-specific binding on glass surface 
CHO cells expressing wt EGFR were seeded on glass-bottomed dishes as indicated in 
section 5.3.3. After starvation, cells were washed thrice with PBS, cooled at 4°C for 10 
min and labelled for 1 h at 4°C with 4 nM of ECD labelled ligand (same as before) and 
50 nM of fTKI (both dissolved in PBS). Cells were then rinsed with ice-cold PBS and 
fixed with 3% paraformaldehyde plus 0.5% glutaraldehyde for 15 min at 4°C, then 15 




3.5.5.7 Single-particle tracking with fTKIs 
CHO cells expressing wt EGFR were seeded on glass-bottomed dishes as described in 
section 3.5.1. During starvation (2 h at 37°C) cells were treated with a mixture of 
labelled (20 nM) and unlabelled (980 nM) TKIs, both diluted in 0.1% medium. After 
starvation, cells were washed with 0.1% medium (without doxycycline), followed by 
ECD labelling using a mixture of unlabelled and labelled (either Alexa 488 or CF640R) 
ligand (Affibody or EGF). The final concentration of both was 100 nM with 10% of it 
being the labelled ligand. ECD labelling was performed at 37°C for 7 min. 
 
3.5.5.8 Distance of Closest Approach experiments. 
CHO cells stably expressing EGFR alleles (wt EGFR, L680N and Δ973) or wild type 
CHO transfected with L858R or L858R/T790M were seeded on glass-bottomed dishes 
as described in section 3.5.1. For Gefitinib pre-treatment, cells were treated with 1 μM 
unlabelled Gefitinib (Tocris Bioscience) during starvation and it was included during 
ECD labelling. After starvation, cells were labelled with 5 μM C18 Vybrant DiD or left 
in 0.1% medium (control), both without doxycycline, for 10-15 min at 37°C. After this 
step the same procedure described in section 3.5.5.4 was followed up to the fixation 
step. Data were collected at room temperature. 
 
3.5.5.9 Characterisation of EgB4 and Affibody binding 
CHO cells expressing wt EGFR were seeded on glass-bottomed dishes as described in 
section 3.5.1. After starvation, cells were washed with PBS, cooled at 4°C for 10 min 
and labelled for 1 h at 4°C with 50 nM anti-EGFR nanobody EgB4-Alexa 488 or 20 nM 
anti-EGFR Affibody-Alexa488 in the absence or the presence of 200 nM of 9G8 
nanobody. Cells were rinsed and fixed with 3% paraformaldehyde plus 0.5% 
glutaraldehyde as described above. Thirteen confocal images of equatorial regions of 




3.5.5.10 Single-particle tracking for colocalization experiments 
CHO cells stably expressing EGFR alleles (wt EGFR, L680N and Δ973) or wild type 
CHO transfected with L858R or L858R/T790M were seeded on glass-bottomed dishes 
as described in section 3.5.1. For Gefitinib pre-treatment, cells were treated with 1μM 
unlabelled Gefitinib (Tocris Bioscience) during starvation and it was included during 
ECD labelling. After starvation, cells were washed thrice with 0.1% medium, followed 
by ECD labelling using a mixture of either affibodies with two different dyes (Alexa 
488 and CF640R) or EGFs with the two same dyes. For 9G8 nanobody treatment, cells 
were treated for 30 min with 200 nM of 9G8 dissolved in 0.1% medium in the last 30 
min of the starvation step before labelling. The final concentration of the Affibody 
mixture was 14 nM (1:1) and for EGF was 8 nM (1:1). For Affibody labelling, 10 min 
treatment at 37°C was used, whereas EGF mixture was added to cell culture dishes and 
cells were promptly imaged without rinsing steps, in order to minimise internalisation 
during labelling and imaging. 
 
3.5.5.11 Fluorescence Localisation Imaging with Photobleaching (FLImP) 
CHO cells stably expressing EGFR alleles (wt EGFR, L680N and Δ973) or wild type 
CHO transfected with L858R or L858R/T790M were seeded on glass-bottomed dishes 
as described in section 3.5.1. For Gefitinib pre-treatment, cells were treated with 1 μM 
unlabelled Gefitinib (Tocris Bioscience) during starvation and it was included during 
ECD labelling. After starvation, cells were washed thrice PBS, cooled at 4°C for 10 min 
and labelled for 1 h at 4°C with one of the following methods: 
- 4 nM of anti-EGFR Affibody-CF640R (basal receptor) 
- 4 nM of EG -CF640R (EGF-stimulated receptor) 
- 4 nM of anti-EGFR Affibody-CF640R plus 200 nM of 9G8 (9G8-treated 
receptor) 
Cells were then rinsed with ice-cold PBS and fixed with 3% paraformaldehyde plus 
0.5% glutaraldehyde for 15 min at 4°C, then 15 min at room temperature. Data were 






3.6.1 Confocal Microscopy 
Data were acquired at room temperature using a Leica TCS SP8 microscope with an oil 
immersion objective (NA=1.4, Leica) and Leica HyD hybrid detectors. Samples were 
illuminated with 488 nm, 550 nm or 640 nm light from an NKT Extreme 
supercontinuum light source and fluorescence was detected between 495 to 530 nm (for 
488 nm excitation), 565 to 610 nm (for 550 nm excitation) and 650 to 690 nm (for 640 
nm excitation). The pixel size of the confocal images was 76x76 nm. 
 
3.6.1.1 Quantification of fTKIs binding 
A machine learning algorithm (Trainable WEKA Segmentation
164
) plugin for ImageJ
165
 
was used to train a classifier that could reliably distinguish the membrane and non-
membrane regions of the extracellular EGFR label. This classifier was applied to all of 
the imaged areas to exclude non-membrane pixels from the analysis. The pixel values of 
the ECD label channel (anti-EGFR Affibody, anti-EGFR nanobody or EGF) and the 
fTKI channel values were gathered and the fTKI intensity values were sorted by the 
corresponding Affibody channel value. The mean and standard deviation of the 
distribution of fTKI intensity values for each Affibody channel value was plotted. 
 
3.6.1.2 Characterisation of EgB4 and Affibody binding 
The fluorescence intensity values of pixels contributing to cell membranes were 
extracted to create a frequency distribution of membrane pixel intensities for each 
concentration of EgB4- and Affibody-Alexa 488. The median intensity value was 
plotted as a function of concentration, with error bars representing the upper and lower 
quartiles of the distribution. Frequency distributions of membrane pixel intensities 
between 9G8-treated and untreated labelled cells were compared. 
 
3.6.1.3 Assessment of the expression of L858R and L858R/T790M EGFR mutants 
The fluorescence intensity values of pixels contributing to cell membranes were 
extracted to create a frequency distribution of membrane pixel intensities for each 
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EGFR mutant labelled with Affy-CF640R. The median intensity value was plotted as a 
function of concentration, with error bars representing the upper and lower quartiles of 
the distribution. Frequency distributions of membrane pixel intensities between 9G8-
treated and untreated labelled cells were compared. 
 
3.6.2 FLIM-FRET Microscopy 
Data were collected at room temperature using a Nikon Eclipse C1 confocal microscope 
with time-correlated single photon counting electronics (SPC830, Becker-Hickl 
GmbH). Samples were excited with a supercontinuum light source (Fianium SC450-4; 
40 MHz repetition rate). Bodipy FL labelled TKIs (intradimer FRET between fTKIs) or 
ECD ligands with Alexa 488 (DOCA) were excited with 488 nm light and fluorescence 
was detected between 505 to 530 nm using a fast photomultiplier tube (PMC-100; 
Becker-Hickl GmbH). Confocal images of Bodipy 650 labelled TKIs (intradimer FRET 
between fTKIs) or Vybrant DiD (DOCA) were collected by excitation at 640 nm. 
 
3.6.2.1 Lifetime measurements 
Fluorescent intensity decays were best-fitted to a single exponential decay model where 
acceptor was absent and to a bi-exponential model when both donor and acceptor were 
present using SPCImage FLIM analysis software (Becker-Hickl GmbH). Donor 
lifetimes for FRET efficiency calculations were obtained by taking the mean of the 
distribution of the fluorescence lifetimes of pixels. The occurrence of FRET results in a 
decrease in the fluorescence lifetime of the donor τ_D in cells loaded with acceptor 
τ_DA. The FRET efficiency (EFRET) was calculated from fluorescence lifetime data 
using the following formula 





Intradimer FRET between fTKIs. For each cell in the FLIM images, regions of 
interest were drawn to isolate the membrane. Lifetime distribution and the mean 
lifetime and standard deviation from these pixels were used to for the plots in Section 




Distance of Closest Approach experiments. For each cell in the FLIM images, regions 
of interest were drawn to isolate the membrane and the mean lifetime from these pixels 
was used to calculate a mean FRET efficiency. The same region of interest was then 
applied to the corresponding image of Vybrant DiD labelling to determine the 
corresponding mean acceptor intensity. The mean acceptor intensity was converted to a 
density with units of acceptors per R0
2
 using a calibration factor previously determined 
from samples with a known DOCA
136
. A model obtained from Monte Carlo simulations 
of a single donor at different distances above a plane of acceptors was fitted to each 
dataset to estimate the ensemble averaged DOCA for that experiment. 
 
3.6.3 Single-Molecule Microscopy 
Data for all methods used were acquired using Axiovert 200M microscopes with TIRF 
slider (Zeiss, UK) with a NA=1.45 oil immersion objective (100x, α-Plan-Fluar, Zeiss, 
UK) and an EMCCD camera (Andor, UK)
166
. The microscopes are also equipped with a 
wrap-around incubator (Pecon XL S1). 
For single-particle tracking (SPT) (two-colour experiments), samples were excited 
with a Lighthub-6 combiner (Omicron) which contains solid state lasers emitting at 488 
nm (60 mW, Phoxx, Omicron), 561 nm (75 mW, Jive, Cobolt) and 642 nm (140 mW, 
Phoxx, Omicron), which are co-aligned into a polarisation-maintaining single mode 
optical fibre. Samples were imaged at 37
o
C acquiring an image every 0.05 sec for a 
period of 30 sec. Two-color TIRF images of the basolateral surfaces of cells were 
chromatically separated by a beam splitter
166
. 
For fluorophore localisation imaging with photobleaching (FLImP) data, samples 
were illuminated with 640 nm light taken from a diode laser (100mW, Cube, Coherent) 
from a fibre-coupled laser combiner (Andor) or VortranStradus 638 nm diode laser 
(Laser Technology, Inc., USA). Images were collected at room temperature and at 3.57 





3.6.3.1 Data analysis 
Identification of spots, extraction of single particle tracks and registration of two-colour 
TIRF images (for SPT experiments) in order to map the relative positions of the probes 
over the time course of data acquisition were made using custom Bayesian algorithms 
reported  by Rolfe et al
96
. 
Calculation of diffusion coefficient. Mean squared displacement (MSD) curves were 
calculated as MSD(ΔT)=<|ri(T+ΔT)-ri(T)|
2
> where |ri(T+ΔT)-ri(T)| is the displacement 
between position of track i at time T and time T+ΔT and the average value is over all 
pairs of points separated by ΔT in each track. The average instantaneous diffusion 
coefficient (D) for these tracks was calculated by fitting a straight line to the first 2 
points of the MSD curve then calculating D directly from the gradient m of the fit, 
D=m/4. The errors in the MSD curve were calculated by repeating the MSD curve 
calculation 200 times, each time on a different synthetic dataset created by randomly 
resampling with replacement the time points within each track, the tracks present within 
each dataset, and the datasets present (bootstrap resampling). The error in D, σ(D), is 
calculated from the standard deviation of the D fits obtained from each bootstrap-
resampled MSD curve. 
Colocalisation analysis. The fraction of co-localized tracks was reported as tracks in 
which a receptor particle in one channel colocalizes with another particle in the other 
channel, spending at least three 50 ms frames in total moving together within a pixel of 
each other
137
. Coincidental colocalization statistics were calculated for a dataset as 
follows. In each channel, a randomized set of tracks of the same size as the measured set 
was produced, where each track in the random sample was chosen (with replacement) 
from the measured tracks for that channel, recentred at random with uniform probability 
density across the field of view, rotated through a random angle with uniform 
probability density between 0 and 360 degrees, and randomly flipped in x with 
probability 0.5. The random tracks therefore have key properties such as durations and 
path structures representative of the true tracks, but now randomized in distribution and 
orientation. The colocalisation statistics were then calculated for the randomized tracks. 
This was performed a total of 50 times for each dataset, and the colocalisation statistics 
pooled to give a final estimate coincidental colocalisation fraction for that dataset. The 
reported colocalisation fraction is then the fraction for the real data minus the estimated 
coincident colocalisation fraction. The duration of individual events in which a track 
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in one channel moves within a pixel of a track in the other channel and then they move 
apart again was also calculated. To reduce the impact of localization error on these 
results a temporal Gaussian smoothing filter of FWHM 4 frames (200ms) was applied 
to the position traces before the colocalisation analyses. 
FLImP distribution. FLImP analysis is described in detail in Needham et al. (2013)
70
 
and in Zanetti-Domingues et al. (2015)
71
 but will also be briefly explained here. 
The FLImP analysis workflow is shown in Figure 3-1. From total internal reflection 
fluorescence (TIRF) images a two-fluorophore spot is selected. A potentially suitable, 
for FLImP analysis, spot have the following characteristics: two intensity levels of equal 
height separated by a photobleaching step, the lowest level decays to zero intensity after 
photobleaching and each level contains more than 10 frames of data
70,71
. In such a spot 
when one fluorophore bleaches, the centroid position of the spot shifts.  A global least-
squares 7-parameter fit is used to identify the best intensity, x and y positions for each 
fluorophore (6 parameters) and the full width at half-maximum of the point spread 
function(1 parameter), from which the separation between the molecules (𝑟 =
 √(𝑥1 − 𝑥2)2 =  (𝑦1 − 𝑦2)2) can be calculated with a precision determined by the 
localization error. Monte Carlo bootstrap method is used to assess the probability 
distribution of the model parameters and the x and y fluorophore positions converted to 
a distribution of separations. Empirical posterior FLImP distributions were obtained 
based on discrete fluorophore separation measurements that had confidence intervals of 
less than 6-7 nm. 
Calculation of the proportion of FLImP measurements in the tethered-extended 
dimer range (see Figure 6-15). The full FLImP distribution is shown in grey. The 
FLImP distributions for subsets of the measurements whose 69% confidence intervals 
overlap with the ranges of Affibody separations of the expected tethered (4.1 [-1.9 +4.2] 
nm) or extended (12.0 ± 1.6 nm) are shown in green and yellow respectively. Affibody 
separations >12.0+1.6 nm are highlighted in blue. The proportion of the measurements 
corresponding to each of the subsets was calculated, with error bars calculated by 




















In order to develop small-molecule probes for successfully labelling the ICDs of 
EGFR family, the reactive warhead of the probes discussed in Section 1.4.1 must be 
able to recognise the target in a selective manner. Over the years, numerous small-
molecule TKIs have been developed to target and inhibit the TKDs of EGFR family 
receptors with modest to great selectivity and affinity. Therefore, TKIs could be used as 
the recognition element which would afford probes with dual capabilities: probing the 
structure of the receptors and studying TKIs’ properties in a cellular context. 
The most crucial step towards the development of fluorescent tyrosine kinase 
inhibitors (fTKIs) is to choose TKIs that are very selective and exhibit high affinity to 
their target(s). To do this, understanding their binding mode and reviewing the available 
literature is indispensable. Moreover, insight on TKIs would also allow identification of 
a position on their structures where the linker can be attached without affecting the 
binding. Lastly, the selection of cell-permeable and photostable fluorescent dyes for 
tagging the TKIs is also important and will be discussed. 
 
4.2 TKIs for EGFR Family 
The paramount role of the TKD in EGFR activation was discovered in 1987 from 
parallel mutational studies on the ATP binding site which showed the absolute 
dependency on the TKD for tyrosine phosphorylation activity
167,168
. A year later, the 
first compound (Figure 4-1), inspired by natural products
169
, that had the ability to 
inhibit EGFR phosphorylation by binding to TKD was published
170
. This discovery 
gave rise not only to the development of countless compounds for EGFR but also to 




Figure 4-1: Structure of the first published TKI for EGFR. 
 
The need for increase selectivity and potency of EGFR TKIs led to a much more 
complex structure of today’s inhibitors compared to Tyrphostin.  TKIs for the EGFR 
family are ATP-competitive inhibitors which target the ATP binding site located 
between the N- and C- lobe in TKD. The quinazoline scaffold mimics the adenine base 
of ATP and exploits similar interactions within the cleft (Figure 4-2). Diversity around 
the quinazoline core confers selectivity to the target and increases potency for efficient 
displacement of ATP, characteristics which are essential to reduce the side effects of 
treatment. 
 
Figure 4-2: Common characteristics between ATP and EGFR TKIs. The 
quinazoline core (highlighted area) of EGFR TKIs mimics the adenine base of 




, are classified by their generation (first, second and third) and 





 (Figure 4-3). The first generation of EGFR family 
inhibitors includes reversible TKIs such as Gefitinib, Lapatinib and Erlotinib whereas 
the second generation comprises irreversible (covalent) inhibitors and it emerged as a 
solution for overcoming the resistance of EGFR mutants (T790M) to the treatment with 
inhibitors of the first generation
172
. Third generation TKIs were designed to selectively 
inhibit T790M mutation over wild-type (wt) as the irreversible ones, apart from 
Afatinib
173
, were unsuccessful in clinical trials. EGFR TKIs can be further classified by 
their type (I and II). Type I inhibitors such as Gefitinib (first generation), Pelitinib and 




 the active TKD conformation 
whereas Type II (or Type I½
174





 the inactive (further discussion about 
Type I and II in Section 5.3.1). The only difference between the two types lies in the 
para-substituent on the aniline ring (see Section 4.3). 
 
Figure 4-3: Chemical structures of some TKIs and their generation. EGFR TKIs can be divided in three 
generation: reversible (first), irreversible (second) and mutant-selective inhibitors (third). Inhibitors can be further 
classified in type I (target inactive KD) and type II (target active KD) compounds. 
 




, the structure of the 
core of both first and second generation TKIs is the same (anilinoquinazoline scaffold). 
The chemical structure of the third generation TKIs differs from the rest (only the 
pyrimidine core is retained), and from each other, as they have been developed in order 
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to circumvent resistance of the, so-called, “gatekeeper” mutation (T790M) which 
precludes the rigid anilinoquinazoline core from slotting in the ATP-binding cleft. 
Even though ErbB family members are highly homologous, selective binding of 
some TKIs against either EGFR or ErbB2 has been reported. The FDA approved 
Gefitinib and Erlotinib are EGFR-selective compounds
176





 are ErbB2-selective. The rest drugs, either approved or in clinical 
trial, are multi-targeted TKIs with examples of dual (EGFR/ErbB2)
47
 inhibitors, 




) or even 
compounds that bind to all four ErbBs
181
. 
Based on the reported potencies and selectivity profiles of the published compounds 
as well as from studies investigating the binding affinities of various 
compounds
176,182,183
 I have created a map showing the structure-selectivity relationship 
of first and second generation TKIs (Figure 4-4). 
 




Type I reversible (first generation) TKIs are EGFR-selective with affinities against 
the other members which are at least 200-fold higher. Moving to type II by substitution 
of the small halogen with a benzyl (or other 5- or 6-member ring) alcohol (red arrow) 
results in dual EGFR/ErbB2 inhibitors. The affinity against ErbB4 is also increased but 
not at the same levels as for EGFR and ErbB2. A similar increase in potency is also 
found when comparing Type I reversible and irreversible TKIs (blue arrow), this time 
however, the affinity against all three receptors (EGFR, ErbB2 and 4) is at low 
nanomolar levels. Replacement of both structural features (which leads to type II 
irreversible inhibitors – orange arrow) produces compounds which can bind all ErbB 
members with similar potency. The last observation is related to the two ErbB2-
selective compounds mentioned earlier. While the increase in ErbB2 affinity is expected 
when the halogen is replaced by a bulkier group (green arrow), the decrease affinity 
against EGFR is in contrast to what was observed when moving from reversible type I 
to type II. The answer may lie in the more rigid phenol substituent of those two 
inhibitors whereas the extra carbon on the benzyl alcohol ring present in type II 
reversible inhibitors allows it to freely rotate around itself.  
 
4.3 Identification of Labelling Position and Selection of TKIs 
for fTKIs development 
After having understood the structural features that define selectivity but also having 
reviewed the most potent compounds (characteristics essential for the recognition 
element), I then moved to the linker part of the probes’ structure. In order to 
successfully design the fluorescent versions of TKIs it is essential to incorporate the 
linker (and subsequently the fluorescent dye) in a position with no or minimal effect on 
the binding affinity of the inhibitor. 
The binding mode of first and second generation inhibitors, which share the 
anilinoquinazoline core, is common and can be divided into three sections (Figure 
4-5A): the quinazoline core (red) and the aniline substituent (purple) which are placed 
with the ATP-binding site and the R3 and R4 substituents (blue) which point out of the 
pocket. The potency of the inhibitors is mainly due to hydrogen bond interactions 
between the nitrogen atoms (N) of the quinazoline core and nearby residues within the 
hydrophobic pocket
184
. Each ErbBs inhibitor can form up to three different hydrogen 
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bonds, depending on its atoms and its orientation. Furthermore, crystal structures 
showed that one of these interactions, between N3 and a threonine residue within the 
binding pocket (Thr766), is bridged by a water molecule as the distance between them 
is longer than the minimum required to form a direct hydrogen bond. To overcome the 
requirement for the presence of water for this interaction, scientists from Wyeth 
developed two inhibitors, Pelitinib (EKB-569)
138
 and Neratinib (or HKI-272)
181
, in 
which the N3 atom was ingeniously replaced by a carbon atom bearing a cyano-group in 
order to minimize the distance between the nitrogen and Thr766
185
. Apart from the three 
aforementioned interactions, Peng et al.
186
 recently reported an additional hydrogen 
bond interaction (do not occur in anilinoquinazoline-based inhibitors). This novel 
interaction takes place between the Asp residue of the DGF motif, outside the pocket, 
and an amine on some inhibitors’ scaffold which contributed to a 50-fold higher 
potency compared to inhibitors lacking this interaction.  
The aniline ring, which plays a role in the selectivity of TKIs towards ErbB2-4 as 
discussed earlier, is buried deep into the cavity and interact with other residues that 
stabilize the binding. These interactions however are weaker (hydrophobic, π-π and Van 
der Waals interactions) and hence their contribution to the total potency is less 
important compared to hydrogen bond interactions. While the contribution of the 
solvent-exposed R4 substituent to the binding is also minimal, R3 substituent is a key 
element of the irreversible TKIs. 
Second-generation irreversible inhibitors have been designed to form a covalent 
adduct with EGFR, ErB2 and ErbB4 (ErbB3 lacks the required residue in the specified 
position), by exploiting a cysteine residue (Cys773 for EGFR, Cys805 for ErbB2 and 
Cys803 for ErbB4) which resides just outside of the pocket (Figure 4-5B). For this, the 
substituent on the R3 position of the reversible inhibitors was replaced with a Michael 




Figure 4-5: Diagram of common interactions of TKIs within the ATP cleft of the kinase domain (A) and 3-
dimensional view of a TKI in the binding site (B). 
 
The above analysis, together with the examination of all the available crystal 
structures of different anilinoquinazoline-based inhibitors bound to ErbB members 
clearly suggested that the most suitable position for attaching the linker would be on the 
R4 group. R4 substituents points out of the pocket, do not participate in essential 
interactions and in many TKIs the functional group at this place is a methoxy or an 
ethoxy group. This also guided me in the selection of the water-soluble polyethylene 
glycol (PEG) as a linker which would act as an extension of the existing ether groups, if 
present in the parent TKIs. Additionally, PEG linkers are commercially available in 
different lengths and have been used in similar cases
124,143
. 
Of equal importance as the position for the incorporation of linker, and for the same 
reasons, is the length of the linker between the dye and the inhibitor. The ideal linker 
length was calculated by performing molecular modelling (Dr Martyn Winn, STFC) 
using the PDB structure of 2ITY (Figure 4-6). After having screened three different 
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linkers, the tetra-ethylene glycol linker was found to give the optimum distance. This 
occurs when the linker is long enough in order for the dye not to alter the binding of the 
inhibitor but not so long as to result in a very flexible dye. Flexible dyes can potentially 
be a problem when low-nanometer precision is required (single-molecule localization 





Figure 4-6: Molecular modelling for determination of optimum linker length. 
 
The last component of the fTKI structure is the fluorescent dye. Due to their low 
molecular weight (MW), small-molecule probe properties such as permeability, wash-
out kinetics and intracellular distribution have been shown to be greatly dependent on 
the choice of the dye
187,188
. The importance of dyes on dye-EGFR ligand conjugates, as 
well as their fluorescent properties and their suitability for single-molecule studies, have 
been also explored in depth by my co-workers
104,161
. Even though these studies provide 
useful information regarding dyes that one should avoid, depending on the experiment, 
the properties of a novel low-MW conjugate cannot be accurately pre-determined based 
on their results. Cases where a certain dye did not affect the permeability of a probe but 
instead affected other conjugates with different warheads
189–191
 confirm the difficulty in 
predicting the physicochemical properties of a molecule. In view of this fact it was 
decided to select (based on the hydrophobicity and cell permeability of dyes-small-
molecule conjugates) three different fluorescent dyes (green, orange and far-red) for 
labelling the compounds in the last step of the synthesis (Figure 4-7). The variety of 
different dye colours would allow me not only to choose the best conjugate for a certain 




Figure 4-7: Selected fluorescent dyes for TKIs’ labelling. Chemical structure, commercial name and absorption 
and emission maxima (Absmax and Emmax, respectively) of selected fluorescent dyes for labelling EGFR TKIs in this 
study. 
 
The last step before starting the synthesis of the fTKIs was to choose the TKIs for 
developing the fTKIs. In order for the potential inhibitors to be able to turn into probes 
for imaging, the following criteria should be met: 
- the inhibitors must not have substituent on the R4 position or at least have an 
ether group (methyl or ethyl); 
- the structural features and the synthetic route of the inhibitor must allow the 
incorporation of the PEG linker and subsequently of the fluorophore; 
- the inhibitors must be very selective to their primary target (or targets if they 
bind more than one ErbB member);  
- the final list should include Type I and II as well as reversible and irreversible 
TKIs. 
Based on the above criteria I decided upon a set of TKIs which could be potentially 
employed in studying all ErbB family members. They are summarized in the table 
below (Table 4-1). All of these compounds have affinities in the low nanomolar range 
for their targets and great selectivity
176,182
. The fact that I have chosen TKIs from all 
four categories (first and second generation as well as type I and II) will allow me to 
target all the possible conformations as well as to study the differences between them. 






























ErbB1-ErbB4 Second / II Clinical trials 
 
4.4 Synthesis of fTKIs 
The strategy I followed for the fTKIs synthesis of the compounds bearing methoxy 
or ethoxy group at R4 (Gefitinib, Pelitinib and Neratinib) was the same and is depicted 
in Scheme 4-1. Starting from inexpensive starting materials, I prepared the 
anilinoquinazoline core and then demethylated the methoxy group. The free hydroxy 
group was then alkylated with commercial tetraethylene glycol (linker) which had 
previously been functionalized at the other end for later amide coupling with the dye. 
Synthesis of the succinimidyl ester of the dye and coupling with the TKI-linker 




Scheme 4-1: Synthetic strategy for developing fluorescently labelled versions of Gefitinib, Pelitinib and 
Neratinib. 
 
For the synthesis of fluorescent labelled Lapatinib, the strategy was slightly different 
due to a different labelling position compared to other three. The reason for choosing an 
alternative place for incorporating the linker was because Lapatinib does not have any 
substituent at R4 position so introduction of any chemical group might alter specificity 
and/or affinity. Moreover, a structure–activity relationship (SAR) study of Lapatinib 
derivatives
192
 revealed that substitution of the methyl sulfone on the terminal side-chain 
with bulkier chemical groups has only little effect on the potency (Figure 4-8). That 
gave me additional confidence that the fluorescent Lapatinib will retain the affinity and 
selectivity of the parent compound. 
 
Figure 4-8: Sulfone derivates of Lapatinib and their inhibition and cellular efficacy (Adapted from Petrov K. G., 




4.4.1 Preparation of modififed Gefitinib 
The synthesis of Gefitinib modified with the linker began with a relative inexpensive 
starting material which afforded Gefitinib (3) in only one step after refluxing it with 
aniline 2
138
 (Scheme 4-2). For the demethylation step the procedure reported by Wang 
et al.
140
, in their synthesis of radiolabelled Gefitnib as a PET agent, was followed. The 
demethylation reagent used was the widely used LiCl; however, in my hand the reaction 
gave very poor yield despite the prolonged heating. I next sought to attempt to increase 
the yield in a microwave-assisted reaction
141
. Even though both the reaction time and 
the yield were improved, the latter was still very low. Compound 5 was finally obtained 
with very good yield and without the need of further purification using pyridinium 
hydrochloride (pyHCl) in solvent-free conditions
142
 (Scheme 4-2). 
 
Scheme 4-2: Preparation of the demethylated Gefitinib. 
 
Before alkylation of the phenolic hydroxyl group of compound 5 with the linker, the 
one end of the linker was functionalized in order to perform the coupling with the dye at 
the last step. I started from tetra-ethylene glycol di-p-tosylate (6) and replaced one of 
the p-Ts esters with a protected amine as described previously
143
 (Scheme 4-3). Finally, 
attachment of tetraethylene glycol linker (7) took place in mild conditions in an 
overnight reaction which furnished compound 8 (Gef-linker) in moderate yield (Scheme 
4-3). The final step for the synthesis of fluorescently labelled Gefitinib derivatives, as 




Scheme 4-3: Functionalization of tetraethylene glycol linker and coupling with compound 5. 
 
4.4.2 Preparation of Lapatinib-linker compound 
The synthesis of the equivalent Lapatinib-linker (Lap-linker) compound is shown in 
the next three schemes. Ring closure of 5-iodoanthranilic acid (9) in refluxing 
formamide (10) gave 6-iodo quinazolinone (11) which was subsequently chlorinated 
with thionyl chloride
144
 (Scheme 4-4). Condensation of the commercially available 
aniline 13 with 12 afforded 6-iodo anilinoquinazoline 14 in great yield
147
 (Scheme 4-4). 
The precursor (16) of the sulfone Lapatinib derivative was obtained by Suzuki 
palladium-catalysed cross coupling of 14 with 2-furanyl boronic acid (15) as described 
by Mahboobi et al.
145
 (Scheme 4-4). 
 




In order to attach the linker at the preferred position discussed earlier (Section 4.3) a 
hydroxyl group is required to participate in the reaction shown earlier for Gefitinib 
(Scheme 4-2). I therefore examined the crystal structure of Lapatinib bound to wt 
EGFR (Figure 4-9) to get an insight of the orientation of the side-chain. I noticed that 
the methyl group on the sulfone appears to be facing towards the protein surface, even 
though is poorly defined as Wood et al.
47
 found. For that reason I decided to introduce a 
hydroxy group on the sulfone side-chain separated by a spacer of two carbon atoms 
from the sulphur atom.  
 
Figure 4-9: View of the labelling position on Lapatinib’s side-chain (PDB: 1XKK). 
 
The synthesis of the 2-[(2-aminoethyl)sulfonyl]ethanol (19, Scheme 4-5) was 
adapted from described procedures by Seto M. and Ohashi T.
150
. The synthesis started 
with an SN2 displacement of bromide from compound 18 with the thiol group of 2-
mercaptoethanol, followed by oxidation of the thiol to sulfone with 3-chloroperbenzoic 
acid at 0
o
C (Scheme 4-5). The amino-protective group was then cleaved before the 




Scheme 4-5: Preparation of the sulfonyl side-chain and synthesis of the modified Lapatinib. 
 
The selected linker for Lapatinib was slightly shorter (tri-ethylene glycol) than the 
linker used in Gef-linker synthesis as the sulfone side-chain was already extended away 
from the pocket. The preparation of the linker was performed according to the tetra-
ethylene glycol synthesis (Scheme 4-3); however, the yield of the reaction was always 
lower. Even though the yield of the reaction was increased by addition of catalytic 
amount of NaI, it was not at the same levels as previously (compound 24, Scheme 4-6). 
Alkylation of compound 22 with the linker did not proceed in the same conditions as 
Gefitinib did. That was not unexpected as deprotonation of aliphatic hydroxy groups 
require stronger conditions. Therefore the potassium carbonate was replaced with a 





Scheme 4-6: Synthesis of Lap-linker compound. 
 
4.4.3 Preparation of modified irreversible TKIs 
Both selected irreversible inhibitors, Pelitinib and Neratinib, have been developed by 
the pharmaceutical company Wyeth and share the same quinoline-3-carbonitrile core 
(compound 40, Scheme 4-9). Their difference lies on the aniline substituent, as 
mentioned earlier (Section 4.2). This allowed me to carry out a common synthetic route 
up to the point of insertion of the anilines. As discussed in Section 4.4, the synthetic 
strategy for their synthesis is the same as for Gefitnib with the sole variation in the last 
step which in this case is not the attachment of the linker but the incorporation of the 
Michael acceptor. This is due to the high reactivity of the α,β-unsaturated amides, which 
gives them their ability to form covalent bonds with cysteines in cell environment, and 
which might lead to protonation in organic reaction solutions. 
The synthesis was based on published work of the aforementioned TKIs
138,154,181,193
. 
The compounds were designed to carry a methoxy group instead of an ethoxy group, as 
the commercial one, because demethylation (step before attachment of the linker) is 
more efficient and faster with this group. The synthesis started from aniline 26 which 
was protected by acylation (compound 27), followed by palladium-catalyzed reduction 
of the nitro group via hydrogenation to afford compound 28 (Scheme 4-7). The 
precursor (compound 30) of the quinoline-3-carbonitrile (compound 31) was 
synthesized by conjugate addition of the free N to the double bond of (E)-ethyl 2-cyano-
3-ethoxyacrylate (compound 29) in toluene (Scheme 4-7). The last step was the thermal 
cyclization at 250
o
C using a high boiling point solvent (Dowtherm A) in an overnight 
reaction. Despite the fact that the current step has been reported to proceed successfully, 
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I was unable to obtain the desired product (compound 31, Scheme 4-7). Judging by the 
state of the isolated product, it was hypothesized that polymerization may have occurred 
probably due to the amino-protective group. 
 
Scheme 4-7: First attempt towards the synthesis of 4-anilinoquinoline-3-carbonitrile scaffold. 
 
Based on the results above (Scheme 4-7) and on my speculation, an alternative route 
was designed which entailed omitting the amine from the staring material and inserting 
it after the cyclization step. Since amines cannot directly be inserted on aromatic rings, I 
would first nitrate selectively on the same position, according to published procedures 
using exactly the same substrate
138
, and then reduce the nitro group. As hypothesized, 
thermal cyclization took place successfully and with an excellent yield, affording 
compound 34 (Scheme 4-8). Although the nitration (method i, table in Scheme 4-8) 
reaction was allowed to proceed to completion (no reactant detected by LC-MS), both 
1
H NMR and HPLC analysis revealed the presence of two nitro products (compounds 
35 and 36, Scheme 4-8). The same result, with variation on the ratio of the isomers, was 
obtained with all the possible nitration conditions tested (methods ii-v, table in Scheme 
4-8). These isomers (compounds 35 and 36) have identical properties and therefore 
purification and isolation of the desired product at that stage would be impossible. 
Separation at later stage of the synthesis might have been possible however at least half 




Scheme 4-8: Second attempt towards the synthesis of 4-anilinoquinoline-3-carbonitrile scaffold. 
 
Taking into consideration the issues I encountered with both the aforementioned 
strategies (Scheme 4-7 and Scheme 4-8), an alternative synthetic route was designed 
where the amine would not be present before cyclization and the nitro group would be 
on the starting material at the desired position. Due to commercial availability reasons, I 
started from 3-fluoro-4-nitroaniline (compound 37) which was converted to the 
methoxy-substituted compound 38 after aromatic substitution of the fluorine
151
 (Scheme 
4-9). Conjugate addition to compound 29 and thermal cyclization, both steps performed 
as in Scheme 4-8, afforded the desired nitro-compound 36 (Scheme 4-9). In order to 
create an attachment point for the subsequent addition of the anilines that would result 
into Pelitinib and Neratinib derivatives, the nitro-compound 36 was converted into the 




Scheme 4-9: Third attempet and synthesis of irreversible fTKIs’ scaffold. 
 
The following step was the aromatic substitution of the chloride of compound 40 by 
either aniline 2
138
 (earlier used in Gefitinib synthesis, Scheme 4-2) or aniline 41
181
 
which afforded Pelitinib (42a) and Neratinib (42b) derivatives, respectively (Scheme 
4-10).  
 
Scheme 4-10: Condensation of aniline 2 or 41 for synthesis of Pelitinib and Neratinib derivatives. 
 
The remaining synthetic steps towards the irreversible TKI-linker compounds were 
the same for both Pelitinib and Neratinib as shown in Scheme 4-11 and they were 
performed in parallel reactions. The first step was demethylation, carried out using the 
same condition described for Gefitinib (Scheme 4-2). In contrast to demethylation of 
Gefitinib, the reaction on these substrates was extremely fast and no starting material 
was detected after only 3-5 min. The conditions for introducing tetraethylene glycol 
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linker 7 (Scheme 4-3) were also different; catalytic amount of NaI and higher 
temperature (75
o
C instead of 60
o
C) were required to push the reaction to completion 
(compounds 44a-b). Reduction of the nitro group with iron metal resulted in the aniline 
(compounds 45a-b) which was then coupled with the acyl chloride of 46 (which had 
been previously formed in situ with oxalyl chloride) to afford the final products 47a 
(Pel-linker) and 47b (Ner-linker) 
 
Scheme 4-11: Synthesis of irreversible Pelitinib- (47a) and Neratinib-linker (47b) compounds 
 
4.4.4 Synthesis of fluorescent dyes 
Synthesis of the Bodipy dye core (boron-dipyrromethene) can be performed in two 
steps either in a 2- or in a 3-componet reaction
194
 (Scheme 4-12). The former route 
(Scheme 4-12A) requires an 2-acylpyrrole (I) and a pyrrole with an unsubstituted α-
carbon (II). The latter route (Scheme 4-12B) on the other hand requires two α 
unsubstituted carbon and an aldehyde (or acyl chloride) and it is preferred for the 
preparation of the so-called meso-substituted Bodipy dyes (VI). Substitution on the 
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pyrrole rings can be performed before or after the formation of the boron-
dipyrromethene core (III), depending on the chemistry allowed on them. Substituents 
that extend the π-conjugated system (electron delocalization) shift the emission from 
low to high wavelength. This is applicable to all types of dyes. 
 
Scheme 4-12: 2- and 3-component strategies for synthesis of Bodipy dyes 
 
In order to be able to conjugate the dyes (both Bodipy and TMR) I require a free 
carboxylic acid group which would be activated by forming the succinimidyl ester and 
then coupled with the TKI-linker compounds via an amide bond. The synthesis of the 
commercial Bodipy FL® (Bod FL) has been previously reported in two studies
156,195
 (in 
addition to the patent from Molecular Probes®
196
). However, in both studies the 
propanoate group had to be protected at the beginning of the reaction, either by 
esterification or by a trichloroethyl group, and deprotected at the end. As a result, Bod 
FL synthesis requires two more steps than one would expect, based on the general 
scheme above, and also the overall yield of the synthesis drops significantly. 
I attempted an alternative synthesis based on a published procedure by Meltola et 
al.
195
 where the authors synthesized a Bodipy dye with the propanoate group but in a 
different position. Even though the formation of the desired product was indeed 
detected, the yield of the reaction was really low. Therefore, this procedure was 
abandoned. 
The solution was found in a Thesis by Spicka K. J
155
 (Montana State University). He 
managed to eliminate the protection-deprotection step by using para-toluenesulfonic 
acid (p-TsOH) which allowed the reaction to proceed with good yield. The fact that the 
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reaction was successfully applied to a variety of different substrates enhanced my 
confidence. Addition of p-TsOH in the reaction mixture of compound 47 and 48 
instantaneously changed the colour of the solution, indicative of product formation 
(Scheme 4-13). The dipyrromethene 49 was generated in excellent yield (almost full 
conversion to product) and with high kinetic rates. Transformation to the boron complex 
(50) was then performed as reported by Gießler et al156 with a moderate yield. 
 
Scheme 4-13: Synthesis of Bodipy FL 
 
The far-red emission of Bodipy 650/665 (Bod 650) is due to substituents on both the 
right- and the left-hand side pyrroles which extend electron delocalization. On the right-
hand side, there is an α-substitution from another pyrrole ring whereas on the left an α-
substitution from a styryl group. Pyrrole rings can be introduced on the final molecule 
but only on meso-substituted Bodipy dyes
197
 (Scheme 4-12B, VI), therefore the 
bipyrrole 52 was decided to be prepared beforehand. Among the few procedures found 
in literature for synthesising bipyrroles, the one reported by Dohi et al.
157
 not only 
overcomes the issues from which the others suffer, but also proceeds with good product 





cyclization, however the former procedure requires two additional steps. 
The synthesis of Bod 650 (Scheme 4-14) started with the oxidative coupling of the 
pyrrole 51, which generated α-linker bipyrrole 52, followed by formation of Bodipy 
core (compound 54) as described for Bod FL earlier (Scheme 4-13). Finally, a 
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microwave-assisted Knoevenagel-type condensation of the acid 55 with Bodipy 54 
furnished the desired product (compound 56, Scheme 4-14). 
 
Scheme 4-14: Synthesis of the far-red Bodipy dye. 
 
The last fluorescent dye to be synthesized is the tetramethyl carboxyrhodamine. The 
most common approach for the synthesis of rhodamine-based (and fluorescein-based) 
dyes
199
  is between 2 equivalents of aminophenol (VII) and 1 equivalent of phthalic 
anhydride (VIII) in the presence of a Lewis or a protic acid at high temperature 
(Scheme 4-15). The reaction is not regioselective and therefore both 5- and 6- isomer of 
TMR are generated in the mixture. The two isomers can be separated by preparative 




Scheme 4-15: General synthesis of Rhodamine-based dyes 
 
Rhodamine-based dyes, being among the oldest dyes reported
200
, have been well 
explored in order to improve the synthetic efficiency but also to eliminate the use of 
harsh conditions such as concentrated sulphuric acid at 170
o
C. Among the various 
conditions tested
160,201,202
 the procedure reported by Uddin et al.
159
 gave me the best 
results in terms of product yield and ease of purification and isolation. The reaction is 
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shown in Scheme 4-16 and took place in one step by condensation of 3-
(dimethylamino) phenol (compound 58) and phthalic anhydride (compound 58) in a 
weakly acidic solvent in the presence of catalytic amount of sulphuric acid. 
 
Scheme 4-16: Synthesis of tetramethyl 5/6-carboxy-Rhodamine 
 
4.4.5 Coupling of TKI-Linker Compounds with Dyes 
The last part of the synthesis is the coupling of the TKI-linker compounds 
(compounds 8, 25, 47a and 47b) with the fluorescent dyes (compounds 50, 56 and 59) 
through formation of an amide bond. This type of reaction is facilitated by activation of 
the carboxylic acid group before reacting with the amine
203
. The two most widely used 
methods for activation of carboxylic acids are by formation of acyl chloride (Scheme 
4-17A) or by formation of active esters (Scheme 4-17B) such as succinimidyl (NHS) 
esters. The latter is preferred for the protection of the dyes due to its non-acidic 
conditions. 
 
Scheme 4-17: Most commonly used strategies for amide bond formation. 
 
In this synthesis the activated esters were generated and reacted with the amine in 
situ eliminating the need for extra purification and isolation steps
159
. Moreover in this 
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fashion, the overall yield starting from the free carboxylic acid to amide (2 steps) was 
higher as attempts to purify the NHS esters resulted in transesterification of the dye with 
the methanol (which was required for solubilizing the dyes). 
The method used for the TKI-dye coupling was the same for all TKIs and all dyes 
except for the solvent which was chosen based on the solubility of the dye (table in 
Scheme 4-18). The two amino-protecting groups of the TKI-linker compounds (8, 25, 
47a and 47b) were first cleaved using trifluoroacetic acid (TFA) followed by removal of 
unreacted TFA. The residue was then re-dissolved and kept in a separate container (c1). 
In another container (c2), the “free” dye was left to be activated for 2 h using 
tetramethyl-O-(N-succinimidyl) uronium tetrafluoroborate (TSTU) before it was added 
to c1 to generate the fluorescent TKIs (compounds 60-74). This reaction was repeated 
for all the possible combinations between a TKI and a dye (16 reactions), resulting in 15 
TKI-dye products which were purified by preparative HPLC.  
 




In this chapter, the design and synthesis of fluorescently labelled ErbBs’ inhibitors 
was shown. With regards to the selection of the TKIs, an extensive literature review for 
understanding and identifying highly specific inhibitors led to the selection of four 
compounds: Gefitinib, Lapatinib, Pelitinib and Neratinib. The fact these compounds 
belong to different classes (type I or II/reversible or irreversible) could potentially allow 
me to get an insight into their mechanism of action. 
The insertion of the linker (and consequently of the dye) was rationally design in 
such a way in order not to alter (or at least to have the minimum effect) the binding of 
the compounds. Molecular modelling was also performed in order to predict the 
optimum linker length. 
Finally, the synthesis of every compound reported herein (including the dyes) was 
based on previously reported synthesis. Even though some of the literature procedures 
did not work as expected, alternative reactions led to the desirable final compounds. 




5 Evaluation of fTKIs as Imaging Probes and their 
Applications in Imaging Techniques 
 
5.1 Introduction 
The synthesized fluorescent ErbBs inhibitors described in Chapter 4 are shown in 
Figure 5-1. The final “palette” includes TKIs from 4 different categories tagged with 
three different fluorescent dyes each. 
 
Figure 5-1: Overview of the synthesized fluorescent ErbB inhibitors 
 
In order to be able to use the fTKIs as probes for imaging it is critical to evaluate if, 
and to what extent, the conjugation of the linker and the dyes has affected properties 
essential for their function. These properties are: 
i. Binding affinities against the ErbB family members 
ii. Fluorescent properties 
iii. Cell permeability 
iv. Binding/labelling in cells 
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v. Binding specificity 
Following this evaluation, I will explore the suitability for using fTKIs in various 
imaging techniques and described the development of methods that would allow me to 
probe the target receptors and to study the mechanism of action of TKIs.  
 
5.2 Characterization of fTKIs 
The binding affinity of any novel imaging probe (from small-molecule to antibodies) 
is surely the foremost property and could define the ‘fate’ of the probe. Low affinity 
probes would require high concentration for engaging the target which would affect the 
signal-to-noise ratio or might result in high non-specific binding. 
As discussed earlier, the TKIs were selected due to their high specificity to the EGFR 
family. The selectivity profile data I reviewed in the selection process were obtained 
from previous studies investigating the selectivity of various inhibitors against the 
kinome
176,182,183
. The platform used in these studies for screening the compounds 
(KinomeScan®, initially developed and reported by Fabian et al.
183
) is offered by 
DiscoveRx (San Diego, USA), so it was decided to determine the binding affinities of 
the fTKIs using the same assay. An overview of the assay’s principle is shown below. 
 
Figure 5-2: KinomeScan® assay for determination of Kd values of fTKIs (Adapted from DiscoveRx website). 
 
Binding affinities of fluorescently labelled Gefitinib (f-Gef) and Pelitinib (f-Pel) 
were only determined for EGFR (since there are selective to EGFR), whereas for the 
multi-targeted Lapatinib (f-Lap) and Neratinib (f-Ner) affinity for the other members of 
the ErbB family was also assessed (Table 5-1). Furthermore, in order to ascertain that 
the dyes of the conjugates have not contributed to the observed affinity, the dissociation 
constants (Kds) of the modified compounds prior to dye coupling (TKI-linker 
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compounds) was determined. If the dye of a TKI-linker-dye compound binds to the 
target, the Kd of the TKI-linker compound should be higher. However, if the dye does 
not bind, the Kd of the inhibitor without the dye is expected to be lower as attachment of 
the bulky dye should at least slightly affect the affinity of the conjugate. 
Table 5-1: Binding affinities of fTKIs and crucial intermediates. 
 Kd (nM) * 
Compound EGFR ErbB2 ErbB3 ErbB4 
Gefitinib® ** 0.62 3500 790 410 
Gef-linker (8) 4.9 - - - 
Gef-Bod FL 13 - - - 
Gef-TMR 5 39 - - - 
Gef-TMR 6 12 - - - 
Gef-Bod 650 29 - - - 
Lapatinib® ** 2.4 7 5500 54 
Modified Lap (22) 3.3 8.4 - 38 
Lap-Linker (25) 8.9 39 - 290 
Lap-Bod FL 7.9 13 - 140 
Lap-TMR 5 14 8.2 - 230 
Lap-TMR 6 45 38 - 1500 
Lap-Bod 650 18 18 - 340 
Pelitinib® *** 0.44 500 - 21 
Pel-Linker (47a) 5.1 - - - 
Pel-Bod FL 9.3 - - - 
Pel-TMR 6 5 - - - 
Pel-Bod 650 28 - - - 
Neratinib® ** 1.1 6.0 7.7 2.4 
Ner-Linker (47b) 2.9 13 25 8.2 
Ner-Bod FL 4 7.6 23 17 
Ner-TMR 5 7.5 6.6 12 17 
Ner-TMR 6 8.1 14 18 19 
Ner-Bod 650 10 33 58 17 
* Kd determination (in duplicates) was performed in DiscoveRx, for all compounds, except where noted 
** Obtained from Davis et. al., Nat Biotechnol. 2011176 




As reported in Table 5-1, all fTKIs retained low-nanomolar affinities against their 
targets, therefore vindicating the design of the probes. Moreover, the selectivity profile 
of the multi-targeted fTKIs against ErbB family members exhibited the same trend as 
the parent compounds (orange coloured rows). Comparison of the Kd of the TKI-linker 
compounds with their labelled (with any dye) versions clearly indicates that the dyes do 
not interact with the targets. The data also suggests that the affinity of the conjugates is 
affected by the size of the dye. Insertion of the Bod FL, which is 140 Da (Table 5-2) 
lighter than the other two, had the smallest effect on the affinity whereas Bod 650 (only 
3 Da heavier than TMR, but with a larger cross-section) conjugates exhibited the 
highest Kd values. 
Table 5-2: Characteristic of fluorescent dyes 
Fluorescent dye Molecular Weight (Da)  Net charge CLogP* 
Bod FL 305.1307 0 2.868 
TMR 443.4944 0 - 4.467 
Bod 650 446.2569 0 4.979 
* Hydrophilicity (ClogP) of the dyes was calculated from their structures using ChemDraw software 
(CambridgeSoft®) 
 
Overall, the binding affinity data show that the fTKIs have the potential to be used 
for labelling all four ErbB members at the same time by using a f-Ner compound. 
Furthermore, it might be possible to visualize individual members by employing 
unlabelled and labelled compounds using one of the following strategies: 
a. Either f-Gef or f-Pel for EGFR labelling 
b. f-Lap with unlabelled Gefitinib (or other type I TKIs) for ErbB2 specific 
labelling 
c. f-Ner with unlabelled Afatinib (binds to EGFR, ErbB2 and ErbB4) for ErbB3 
labelling 
d. f-Ner with combination of unlabelled Lapatinib (EGFR and ErbB2) and 
Bosutinib (ErbB3) for labelling of ErbB4. 
The next step in the evaluation process was to determine whether the conjugation has 
altered the fluorescent properties of the dyes. For that the excitation spectra of the fTKIs 
were recorded and compared with the ones from the ‘free’ dyes (obtained from the 
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Invitrogen® website). In all three cases, the observed excitation of the fTKIs was 
slightly shifted (due to conjugation) towards longer wavelengths compared to 
commercial unconjugated dyes but without any significant change on the shape of the 
individual spectra. 
 
Figure 5-3: Comparison of excitation spectra of commercial “free” dyes and dyes conjugated to TKIs. 
Excitation spectra of Bodipy FL (A), TMR (B) and Bodipy 650 (C) conjugates and comparison with spectra from the 
free dyes (dotted line), obtained by Invitrogen. 
 
Next, the ability of the fluorescent compounds to permeate the plasma membrane 
was evaluated. The fact that the inhibitors are fluorescent allowed me to assess their 
permeability in real-time (live-cell imaging) rather using assays such as Caco-2 
permeability assay. Confocal microscopy allows optical sectioning of thick samples and 
therefore visualization of intracellular distribution is possible. The experiments were 
performed in live Chinese Hamster Ovary (CHO) cells which do not express 
appreciable levels of EGFR family receptors. CHO cells seeded on glass-bottomed 
dishes were placed on an incubator-equipped microscope pre-warmed at 37
o
C and 
treated with various concentrations of fTKIs. Images were then recorded for 20-30 min 
using the appropriate laser beam for the dye used. 
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Table 5-3: Permeability of fTKIs 
 
Permeable 
Compound Yes No 
Gef-Bod FL √ - 
Gef-TMR - √ 
Gef-Bod 650 √ - 
Lap-Bod FL √ - 
Lap-TMR √ - 
Lap-Bod 650 √ - 
Pel-Bod FL √ - 
Pel-TMR - √ 
Pel-Bod 650 √ - 
Ner-Bod FL √ - 
Ner-TMR √ - 
Ner-Bod 650 √ - 
 
 
Figure 5-4: Example of an impermeable and a permeable fTKI. 
Live CHO cells were treated with fluorescent inhibitors in situ and 
images were recorded for 20 min at 37oC. An example of an 
impermeable fTKI (Gef-TMR) is shown on the left and one of a 
permeable (Gef-Bod FL) is shown on the right. 
 
Out of the 12 different TKI-dye combinations only two fTKIs were not permeable: 
TMR labelled Gefitinib and Pelitinib (red highlighted rows, Table 5-3). Surprisingly, 
TMR did not affect the permeability of Lapatinib and Neratinib conjugates. The 
difference between these two sets of conjugates is that both Lapatinib and Neratinib are 
~100 Da heavier than the other two TKIs and the TMR dye. Taking also into account 
the hydrophilicity of TMR (CLogP: - 4.467, Table 5-2), the permeability results suggest 
that the size of the warhead might be responsible for overcoming the resistance of a 
slightly hydrophilic neutrally charged dye to cross the plasma membrane. These 
considerations can provide an additional guidance for low-MW weight probe 
development in the future. It should be noted that even though Gef-TMR and Pel-TMR 
were not permeable they were used in imaging experiments in pre-fixed cells (see 
below). 
Having assessed the permeability of the compounds, next I investigated the 
binding/labelling in vitro for the permeable ones. For this experiment, CHO cells stably 
transfected with wt EGFR expressing 400.000 receptors per cell were used. Since 
binding of TKIs is a relatively slow process due to their constant competition with ATP, 
the fTKI incubation time was increased to 2 h in order to maximize the chances of 
effective labelling. The receptor was also tagged on its ECD with fluorescently labelled 





EGF) which are known to be specific for EGFR in order to examine their colocalization 
with the fTKIs. After labelling, cells were washed three times to remove unbound 
molecules, fixed with 3% paraformaldehyde (PFA) and 0.5% glutaraldehyde (GA) to 
avoid receptor internalization and imaged with a confocal microscope at room 
temperature (RT). 
 
Figure 5-5: In vitro binding of reversible and irreversible fTKIs in live cells. Live CHO cells expressing wt 
EGFR were pre-treated with fTKIs for 2 h, washed thrice and fixed before imaging. Examples of labelling with a 
reversible (A) and an irreversible (B) fTKI are shown. Top images show intracellular labelling with fTKIs and the 
bottom ones extracellular labelling with EGFR Affibody. 
 
There was not significant membrane labelling from the reversible fTKIs, despite the 
long incubation and high concentration (Figure 5-5A). This, however, was somehow 
expected as even bound molecules would be washed out due to their reversible binding. 
The membrane signal on cells pre-treated with irreversible fKTIs on the other hand was 
clearly present, proportional to ECD labelling and with excellent colocalization (Figure 
5-5B). Therefore, irreversible fTKIs can be used for live cells imaging. 
In parallel to the previous method, reversible fTKI labelling was also attempted to be 
visualized in live cells without removing the fTKI media after the 2 h treatment. 
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However no safe conclusion could be drawn as the presence of the fTKI in the solution 
made it impossible to distinguish between potentially bound molecules and molecules 
on the periphery of non-expressing cells (Figure 5-6). Upon removal of the fTKI media, 
without further washings, the signal on the cell edges immediately dropped to similar 
levels as seen in fixed cells in both expressing and non-expressing cells. 
 
Figure 5-6: Live cell imaging using reversible fTKIs without washing out the labelling media. Live CHO cells 
expressing wt EGFR were pre-treated with fTKIs for 2 h and then imaged without removing the labelling media. Left 
image shows the intracellular labelling with a reversible fTKI and the right one the extracellular labelling with EGFR 
Affibody. 
 
While live cell labelling with fTKIs is very useful for investigating the perturbed 
receptor, it is not suitable for studying the receptor in its unperturbed state (basal or 
activated), which was one of the aims of the current project. Therefore, a different 
labelling method needed to be developed. 
In order for the fTKIs to tag their target without perturbing the system cells have to 
be fixed in advance. Moreover, in order to avoid internalization of the receptors the 
labelling of the ECD was performed at 4
o
C. Cells expressing wt EGFR were therefore 
labelled with either Affibody or EGF and then fixed with 3% PFA and 0.5% GA at the 
4
o
C for 15 min and then at room temperature for another 15 min. They were also briefly 
permeabilized (only for 1 min) using 0.25% Triton X-100 in order to allow ATP release 
and hence faster binding of the inhibitors. The results of this labelling method are 




Figure 5-7: Comparison of fTKIs binding in wt EGFR expressing cells pre-fixed with 3% PFA + 0.5% GA (A) 
or with 3% PFA. CHO cells expressing wt EGFR were labelled with an ECD probe (Affibody or EGF) and then 
fixed as indicated in (A) and (B). Cells were then briefly permeabilized and treated with fTKIs before imaging. For 
both (A) and (B), left images show the intracellular labelling with Gef-TMR and right ones the extracellular labelling 
with EGF. 
 
In contrast to live cell labelling, the labelling efficiency of both reversible and 
irreversible fTKIs in pre-fixed cells was very similar. Another benefit of this method is 
that impermeable Gef- and Pel-TMR probes can also be used. However I noticed that 
the signal on the membrane in the fTKIs channel was not comparable to ECD labelling. 
I speculated that the presence of GA, which is a powerful crosslinker, in the fixative 
might crosslink the ATP binding sites. Such a crosslinking could either prevent the 
release of pre-bound ATP molecules or completely block substrate access. In order to 
test the former hypothesis, cells were first lightly fixed using 1% PFA for 15 min, then 
permeabilized (which could facilitate ATP release) and then fixed for another 15 min 
using 3% PFA+0.5% GA. However, there was no difference in fTKI labelling between 
this method (data not shown) and the method mentioned earlier (fixation with 3% PFA 
and 0.5% GA directly). Consequently I decided to remove GA from the fixative to test 
the latter hypothesis. The labelling method and the concentrations of the probes were 
exactly the same as described above, except for the composition of the fixative. This 
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time the fTKI membrane signal was significantly increased and it was also proportional 
to and colocalized with ECD labelling (Figure 5-7B). Furthermore, the background 
labelling in cells fixed with PFA appears to be lower compared to fixation with 
PFA+GA (same concentration and incubation time of Gef-TMR were used). Even 
though is not possible to define the mechanism by which GA prevents substrate 
binding, these experiments show that GA blocks the ATP sites. 
In the process of developing the method for the labelling of pre-fixed cells I noticed 
that different fluorescent dyes conjugated to the same TKI resulted in fTKIs with 
different intracellular distribution patterns (Figure 5-8). Nevertheless, I do not 
anticipate issues from these differences as I am specifically interested in the 
conformational and signalling dynamics of plasma membrane EGFR whose labelling is 
unaffected. 
 
Figure 5-8: Effect of fluorophore on fTKIs’ intracellular distribution. Pre-fixed wt EGFR expressing cells 
prepared as described in Figure 5-7B were treated with fTKIs and imaged. On the left, the general structures of TKI 
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conjugates are shown. On the middle and right, examples of extracellular and intracellular labelling, respectively, are 
shown. 
 
Out of the three different fluorophores, the conjugates with the highest membrane 
signal-to-background labelling ratio were the TMR labelled compounds (Figure 5-8 & 
Figure 5-9A) whereas the Bod 650 conjugates had the highest background labelling. 
The fact that the same was true for all TKIs tested suggested that it was not an artefact 
of a certain conjugate but a general pattern due to dye properties. In fact, it is known 
that due to their lipophilicity Bodipy dyes have the tendency to accumulate into 
different subcellular organelles
204
 or to form aggregates
205
. Furthermore, Bod 650 
small-molecule conjugates have been previously reported to label the endoplasmic 
reticulum (ER)
187,188
 which is what it was observed. Therefore, I decided to carry out the 
rest of my experiments on pre-fixed cells using the TMR labelled TKIs. 
The next step in the evaluation of the in vitro binding was to determine the binding 
specificity of the fTKIs in the CHO cells. The expression of the receptor in the CHO 
cell lines chosen for this study is induced and controlled by doxycline
206
 and hence 
without it cells do not express any receptor. The same protocol as for pre-fixed cell 
binding but without including doxycycline in the media was therefore followed. 
Labelling with ECD ligand this time serves as a marker for endogenous receptor 
expression, if any.  fTKI concentration and incubation times were exactly the same in 
all experiments. As shown in Figure 5-9B, there was no detectable membrane labelling 
in either the ECD or the ICD channel demonstrating the specificity of the fTKIs to 
EGFR only. 
I also designed another control experiment to investigate the specificity of the 
compounds. This time EGFR expression was induced, as in the test experiments, but the 
cells were treated for 2 h with a saturating concentration of commercial (unlabelled) 
Neratinib prior to ECD labelling and fixation. Being an irreversible binder, Neratinib 
permanently blocks all the available ATP-binding sites and hence fTKIs binding should 
not be possible. As expected, Neratinib treatment completely abolished membrane 




Figure 5-9: In vitro binding specificity of TKI-TMR compounds in pre-fixed cells. Comparison of TKI-TMR 
conjugates treatment in pre-fixed wt EGFR-expressing CHO cells (A) with treatment either in non-expressing CHO 
cells (B) or in EGFR-expressing CHO cells blocked by pre-treatment with an excess of irreversible Neratinib® (C). 
 
The last part of the evaluation was to assess the in vitro binding of the fTKIs against 
the other ErbB family members. As stable cell lines expressing ErbB2-4 receptors are 
not currently in use by my group, I transfected wt CHO cells with the desired plasmid 
using ViaFect (Promega®) and a reverse transfection protocol. 
Among the three receptors, ErbB2 transfection resulted in expression levels similar 
to stably EGFR-expressing CHO cells. For both ErbB3 and ErbB4 the expression levels 
were generally low despite the efforts to improve them. In the following experiments, 
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concentrations of all fTKIs were kept the same as in EGFR experiments in order to 
compare the in vitro specificity with the specificity suggested biochemically (Kd). For 
ECD labelling the following ligands (labelled with fluorescent dyes) were used. 
Table 5-4: List of ligands for ECD labelling of ErbB2-ErbB4 receptors 











Anti-ErbB3 Affibody Non-activating 
ErbB3 






Anti-ErbB4 Adhiron Non-activating ErbB4 
Dr D. Tomlinson 
(University of Leeds) 
 
Starting with ErbB2 expressing CHO cells, fluorescently labelled Lapatinib and 
Neratinib exhibited good labelling efficiency for the receptor, as expected from their 
low-nanomolar affinities. Membrane signal was also observed in cells expressing ErbB2 
after treatment with labelled Gefitinib and Pelitinib, however it was only marginally 
higher than the background labelling (Figure 5-10, blue framework). Among the four 
TKIs conjugates, only f-Ner was expected to bind ErbB3 and that was consistent with 
my in vitro experiments (Figure 5-10, green framework). No detectable signal was 
observed for any of the other fTKIs for either ErbB3 Affibody or NRG1β labelled 
receptors. Lastly, ErbB4 labelling was achieved with three out of four fTKIs. 
Fluorescently labelled Pelitinib and Neratinib showed moderate to good labelling, 
whereas f-Lap labelling was generally low. No membrane signal was detected from f-
Gef treatment (Figure 5-10, red framework). 
Overall, in the evaluation section I showed that the synthetic strategy for developing 
fTKIs yielded probes that retained their low nanomolar affinities and selectivity against 
all ErbB members (both in biochemical assays and in vitro binding studies). I also 
demonstrated that the permeable, irreversible fTKIs can engage and successfully label 
their target in living cells, whereas there is no limitation in the use of any fTKI with the 





Figure 5-10: fTKIs binding in pre-fixed CHO cells expressing ErbB2-4. fTKIs binding visualization by confocal 
microscopy in pre-fixed CHO cells (prepared, by analogy, as in Figure 5-8B) transfected with ErbB2 (blue box), 




5.3 Application of fTKIs 
 
5.3.1 Quantitative Binding Analysis 
As discussed earlier (Section 4.2), one classification of different EGFR TKIs (and 
generally for all kinase inhibitors
22
) is based on their type. Type I inhibitors are 
compounds that bind to the active kinase with a DFG-in conformation whereas type II 
bind to the inactive kinase (an additional pocket is created within the ATP site) with a 
DFG-out conformation
208
.  It is important to note that while EGFR inhibitors such as 
Gefitinib, Erlotinib, Pelitinib and Afatinib (among others) are classified as type I, 
Lapatinib and Neratinib (like the rest of the TKIs with a bulky substituent on the aniline 
ring) meet only one of the two criteria for type II
174,208
 inhibitors despite being 
mentioned as such in literature
209,210
. These two TKIs bind the inactive kinase but with a 
DFG-in conformation which are characterized by some as type II-like TKIs
210
 or  as 
type I½, a terminology which was introduced by Zuccotto et al.
211
. 
The classification of EGFR TKIs, which is based on crystallographic data
25,46,47,212–
214
,  led to the assumption that these TKIs are selective for the state of the kinase 
(inactive or active) they bind. While for type II TKIs this preference is generally 
accepted due to their structural requirement for the additional pocket (red framework, 
Figure 5-11A) created in the inactive receptor, the selectivity of type I inhibitors to the 
active remains controversial.  
Initially, Yun et al.
25
 suggested that Gefitinib and AEE788
175
 (another type I TKI) 
show a preference for the active receptor by demonstrating that both compounds have 
higher affinities against a receptor with an activating mutation (L858R) compared to wt 
EGFR, which was assumed to be in the inactive conformation in the absence of ligand. 
Qiu et al.
215
, and subsequently Wang et al.
216
, later demonstrated (using an assay 
developed in the former’s lab) the preference of Erlotinib for the active (EGF-treated 
receptor) conformation of near full-length EGFR alleles (including wt EGFR) compared 
to the inactive one (Cetuximab-treated receptor). 
On the other hand, many biochemical binding studies using TKDs of wt EGFR and 
activating mutants revealed that both TKI types bind the receptors with similar 
affinities
176,182,183
. Furthermore, Lu et al.
217
 showed that the binding affinities of both 
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Gefitnib and Erlotinib for an EGFR mutant which cannot adopt the active conformation 
(V924R) due to a mutation on the asymmetric dimer interface are comparable with their 
affinities for wt EGFR. It is worth noting that these data constitute the only data that can 
be found in literature regarding the affinity of a compound against an activation-
impaired receptor. Based on this study, Park et al.
218
 performed molecular docking of 
Erlotinib against the V942R mutant and showed that the Glide score (a measure of 
binding affinity for in silico studies) is similar to that obtained by docking Erlotinib 
against the active receptor. Most importantly though, they resolved the crystal structure 
of Erlotinib in complex with V924R which is the only structure where a type I TKI was 
seen bound on an inactive kinase conformation (Figure 5-11C). 
Despite these findings, the question regarding the preference of type I TKIs is still 
not clear
218
. The necessity however for understanding it derives from the clinical need to 
pre-select drugs with the highest possible impact against different EGFR alleles and 
thereby overcoming inhibitor resistance. 
For this purpose, I sought to exploit the fTKIs to unravel the mechanisms of action of 
TKIs. The main advantage over the studies referenced above (biochemical and 
crystallographic) is that the post-fixation fTKI labelling method allows to directly 
monitor the binding of the inhibitors to the receptor in their cell environment. 
 
Figure 5-11: Conformation of the ATP cleft in the inactive and in the active kinase domain and its occupancy 
by TKIs in each state. As crystal structures have revealed, type II TKIs (here Lapatinib in PDB 1XKK, A) require 
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an additional pocket, compared to the active conformation (PDB 2ITY, B), to be formed deep in the cleft in order to 
be accommodated in the ATP-site (inactive conformation). In the wt receptor, both type I and II TKIs fully occupy 
the ATP cleft. On the other hand, binding of type I TKIs in a receptor which is unable to be activated (e.g. V924R) 
leaves the addition pocket present in the inactive conformation unoccupied (C). 
 
In order to determine whether type I TKIs have any such preference or not I 
employed the pre-fixed cells labelling method (Figure 5-9) combined with quantitative 
analysis. It is known that type I TKIs promote, irrespectively of their preference to any 
state, the active conformation
65,217,219
 (similarly, type II promote the inactive one) and 
therefore utilization of this method would allow me to monitor fTKIs binding in either 
the basal (inactive) or the EGF-treated (active) receptor without allowing the inhibitors 
to induce any conformational change that would bias my results, since cells would be 
pre-fixed. 
The experiment I designed was as follows: wt EGFR-expressing cells were left 
untreated (basal-inactive) or were activated with a range of EGF concentration for 1 h in 
at 4
o
C before fixation. Cells were then treated with fTKIs and data was acquired without 
removing the fTKI-containing media for 25 min. The receptor expression levels per cell 
were measured using a nanobody (EgB4
220
, gift of Prof van Bergen en Henegouwen) 
which does not activate the receptor and whose binding is unaffected by EGF binding as 
it binds to a different epitope (ECD sub-domain I)
220
. Labelling with EgB4-CF640R 
was performed simultaneously with (or without) EGF. 
Quantification of the binding was performed using an in-house developed plugin (Dr 
Chris Tynan) for ImageJ. EgB4-AF488 pixel intensity (EGFR expression) and the mean 
intensity of the corresponding pixels in the fTKI channel (inhibitor binding) for EGF 
concentrations in the range 0-20 nM were plotted (Figure 5-12A).  Simple linear 
regression was used to quantify statistical relationships between EGFR expression and 
inhibitor binding. The gradient of the best fit lines for each EGF concentration is plotted 





Figure 5-12: Relationship between EGFR expression and fTKI binding exposed to invreasing EGF 
concentration (A) and the gradient of the best fit lines for each EGF concentration (B). CHO cells stably 
expressing wt EGFR were treated with a mixture of 50 nM EgB4-AF488 (labelling probe) and with or without EGF, 
fixed with 3% PFA and then briefly permeabilized. Cells were then treated with 100 nM Gef-TMR and data were 
collected without removing the labelling media. All experiments were performed in triplicate. (A) EGFR expression 
(EgB4-AF488) and fTKI binding (Gef-TMR) in different EGF concentrations (0-20 nM) were quantified by plotting 
EgB4-AF488 pixel intensity with the mean intensity of the corresponding pixels in the fTKI channel for all four 
conditions. (B) The gradient of the best fit lines from (A) were plotted in order to quantify the statistical relationship 
between EGFR expression and fTKI binding for each EGF concentration. 
 
The data for the Gef-TMR experiments show that Gefitinib binding in wt EGFR-
expressing cells increased with increasing EGF concentration. It is known that the 
activation of the wt EGFR receptor is EGF-dependent and also that receptor activation 
occurs through the formation of an asymmetric dimer in which the individual TKDs are 
in the active conformation. Therefore, the increased fTKI affinity observed in these 


































































more “active” kinases are generated which subsequently leads to higher Gefitinib 
binding. 
In order to validate my interpretation regarding the increasing number of “active” 
kinases with increasing EGF concentration, the phosphorylation levels of the receptor 
when exposed in increasing EGF concentrations were measured by Western Blot (WB). 
The more “active” TKDs in the receptor population, the higher the phosphorylation of 
the receptor should be. The protocol use for the WB was identical to the fTKI method 
mentioned earlier up to the fixation step, at which cells were lysed instead (followed by 
gel electrophoresis and blot development). WB analysis showed that the 
phosphorylation of wt EGFR is increased with increasing EGF concentrations (Figure 
5-13), supporting the hypothesis that the increased Gef-TMR binding is due to 
increasing number of active kinases.  
 
 
Figure 5-13: Western blot measurement of total tyrosine autophosphorylation of wt EGFR in CHP cells 
exposed to increasing EGF concentration. Western blot results using the pan-phosphotyrosine antibody 4G10 and 
an antibody against the EGFR N-terminal tail from CHO cells expressing wt EGFR. EGFR phosphorylation was 
measured in cells treated with increasing EGF concentration (0 (untreated), 1, 10 or 20 nM) as described in Section 
3.5.3. All experiments were performed in triplicate. The phosphorylation signals are normalized to total EGFR signal 
and the mean and standard deviation of three replicates has been plotted 
 
Furthermore, the WB analysis showed that the receptor is phosphorylated even in the 
absence of EGF and that this phosphorylation is ~5-fold lower than signal at 20 nM of 
EGF. The fact that the binding of Gef-TMR in the basal state is only ~2.5-fold lower 
than the binding at 20 nM of EGF indicates that only part of the basal binding can be 
attributed to binding to inactive receptors (monomers or symmetric dimers) as the rest is 

























the inactive kinase is lower compared to the affinity for the active kinases, clearly 
suggesting a preference towards the active conformation. 
Having explored the preference of type I reversible TKIs, I sought to use the type I 
irreversible Pelitinib in order to further understand their mechanism of action. The 
results are shown in Figure 5-14. In contrast to Gefitinib, Pelitinib affinity appears to be 
independent of receptor activation in all the EGF concentrations tested. The covalent 
binding can therefore alter the preference of type I reversible TKIs. This offers an 
insight into the kinetics of TKIs preference. 
 
Figure 5-14: Pel-TMR binding in fixed CHO cells expressing wt EGFR exposed to increasing EGF 
concentration. Cell preparation and data analysis were performed as described in Figure 5-12. All experiments were 
performed in triplicate. 
 
In the context of experiments where factors such as permeability rate, ATP 
competition and ATP-pocket desolvation are eliminated, the binding kinetic models 
could be simplified as illustrated in Figure 5-15A. The affinity of a reversible TKIs 
depends on the ratio of the dissociation (Koff) over the association (Kon) rate of the 
inhibitor towards the target (Kd=Koff/Kon, green rounded rectangle, Figure 5-15A). On 
the other hand, for irreversible TKIs bearing a Michael acceptor the Kd only depends on 
the Kon as after binding and covalent adduct formation they cannot be dissociated (red 
rounded rectangle, Figure 5-15A). 
Even though Pelitinib has not been crystallized with EGFR, the structural similarity 
of its anilinoquinazoline core (which is located within the pocket) to that of Gefitnib 





























binding mode should be very similar
221
. The only difference between them lies in the 
cyano-group of Pelitinib (red bold structure, Figure 5-15B) which has been proposed to 





Figure 5-15: Binding kinetics of reversible and irreversible EGFR TKIs (A) and structural and binding mode 
similarity of Gefitinib with Pelitinib (B). (A) Binding affinity (Kd) of reversible TKIs to the TKD depends on both 
the association (Kon) and dissociation (Koff) rate (green, horizontal). On the other hand, TKIs bearing a Michael 
acceptor covalently bind to the TKD and therefore their binding affinity only depends on the Kon (red, vertical). (B) 
The structural similarity of Gefitinib (left) and Pelitinib (right) cores which are placed within the ATP pocket (blue 




Taking into account the kinetics and the binding similarity of Geftinib and Pelitinib, 
the data suggest that the reduced affinity of type I reversible TKIs against the inactive 
EGFR is due to their faster dissociation (Koff) from the pocket and not due to their 
inability to associate (Kon), otherwise Pelitinib would also have lower affinity in the 
basal state. 
In order to further support my interpretation regarding the dependency of Gefitinib 
binding on the conformational changes occuring with increasing EGF concentrations, I 
employed the type II fTKIs Lapatinib (reversible) and Neratinib (irreversible). As 
discussed earlier, type II TKIs are not expected to bind to the active conformation due to 
their structural restrictions (they cannot be accommodated in the “small” active site) and 
hence the increase in the number of active kinases with increased EGF in my 
experiments should result in reduced bindings compared to untreated cells. 
The results from the experiments with both type II fTKIs, performed using the same 
method as earlier, are shown below (Figure 5-16). In both cases, binding was decreased 
upon treatment with EGF and the decrease became more pronounced when EGF 
concentration was increased. This shows that the affinity of type II TKIs, irrespectively 
of whether they are reversible (Lapatinib, Figure 5-16A) or irreversible (Neatinib, 
Figure 5-16B) binders, is EGF-dependent and that this dependency is inversely 
proportional to receptor activation/phosphorylation, as opposed to type I. Furthermore, 
the fact that both type II inhibitors behaved in the same way in response to EGF 
suggests that the parameter responsible for the reduced binding is the Kon due to steric 





Figure 5-16: Type II fTKIs binding in fixed CHO cells expressing wt EGFR exposed to increasing EGF 
concentration. Determination of f-Lap (A) and f-Ner (B) binding in wt EGFR expressing CHO cells prepared. Cell 
preparation and data analysis was performed as in Figure 5-12. All experiments were performed in triplicate. 
 
In conclusion, using these novel tools and method I was able to show not only that 
type I reversible TKIs do have a conformational preference towards the active kinase 
(higher binding in EGF-treated cells), but also that this preference is due to faster 
release of the inhibitors from the inactive kinase (differences in the binding between 
reversible and irreversible type I fTKIs), despite their ability to associate with it. Even 
though this association is in agreement with the findings from Park et al.
218
 (they 
demonstrated the ability of Erlotinib to bind an inactive receptor by crystallization), the 

























































(type I TKIs bind both conformations with same affinity)
218
. Even though a crystal 
structure of a bound inhibitor is informative for its binding mode and its interactions, it 
does not allow getting an insight into the affinity of a compound. For instance, Gajiwala 
et al.
222
 resolved the structure of Gefitinib with a TKI resistant double EGFR mutant 
(L858R/T790M), for which Gefitinib is known to have very low affinity
176
 and also not 
to be able to inhibit its phosphorylation
223
. If anything, the crystal structure of Erlotinib 
bound to the inactive kinase might suggest a lower affinity compared to its binding to 
the active. An explanation of this view might reside in the fragment-based approach 
used in drug discovery whose strategy is, briefly, to create high-affinity compounds by 
filling in the empty gaps in a binding pocket
224
. The fact that the binding pocket of the 
inactive kinase is not fully occupied by Erlotinib (Figure 5-11C), as in the case of 
Lapatinib (Figure 5-11A), is reminiscent of the concept of this strategy and my data is 
in agreement with this hypothesis. 
Another important outcome from these experiments is that fTKIs can be used as 
reporters of the conformation/activation of the receptor. This would allow me to 
determine the structural-functional relationship of EGFR in cells when combined with 
existing imaging techniques. 
 
5.3.2 Intradimer FRET between fTKIs 
As discussed earlier (Section 1.2), activation of ErbB receptors is inextricably linked 
to dimerization, irrespective of whether oligomerization/clustering of EGFR is also 
involved, as asymmetric dimers are the smallest known signalling units required for 
phosphorylation to occur. For that reason, receptor dimerization was initially thought to 
be an event that only occurs after activation
225
. However, early studies suggested the 
presence of pre-dimers even in the absence of ligand
101,226
. Later independent studies 
also proposed that ErbB family members pre-dimerized
66–68,225
. Furthermore, formation 
of pre-dimers in the basal receptor state has also been suggested to be associated with 
EGFR activation
66,68,227
. While asymmetric dimerization and phosphorylation after EGF 
stimulation is well documented
49,54,63,65,228,229
, the presence of such pre-dimers is still 
controversial
62,65
 (Section 1.2.2). For these reasons, monitoring dimerization events and 
the extent to which they occur is essential for understanding the mechanisms of EGFR 
activation. Furthermore such a method could potentially allow us to assess the 
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The most frequently employed methods for identifying protein interactions are 
FRET-based or biochemical methods involving chemical cross-linking
231
. The main 
disadvantages of using the latter approach are the requirement for cell disruption and the 
inability to preserve all dimeric structures
232,233
. On the other hand FRET experiments 
can be performed in both fixed and live cells and allow the distance between FRET 
pairs to be estimated under carefully controlled conditions. 
FRET-based methods used for studying the dimerization of ErbB family members 
(either before or after activation by ligand) include, steady state FRET (using both 
confocal
234







Labelling of the receptors in these studies has been performed using labelled molecules 
(ligands, antibodies, etc) targeted to the ECD, labelled antibodies for the ICD, or fusion 
with FPs. However, these methods of labelling have drawbacks for studying interactions 
between EGFR receptors. For instance, the large size of antibodies runs the risk of 
producing a FRET signal due to crowding rather than direct interactions. The use of 
labelled ligands such as EGF is not suitable for FRET experiments as the distance 
between ligand binding sites in an ECD dimer exceeds 10nm, a distance where FRET is 
either no longer possible or practically undetectable between available FRET pairs
68
. 
FPs are also large and are usually fused to the ~200 amino acid long and flexible C-
terminal tail which might perturb the functioning of the receptor. 
Having labelled all the TKIs with more than one colour, I sought to measure FRET 
between two fTKIs within dimeric receptors. The advantage of this labelling method 
over the other methods for monitoring EGFR interactions is that the small fTKIs bind to 
the centre of the TKD and that the distances between fluorophores in either the 
symmetric or the asymmetric dimers are within FRET range as measured by molecular 
simulations (Dr Martyn Winn, Figure 5-17). The importance of assessing EGFR 
dimerization by monitoring TKD-TKD interactions is further highlighted by the fact 
that EGFR TKDs haves been suggested to be necessary for receptor pre-
dimerization
225,239
. For these experiments I used Bod FL and Bod 650 labelled TKIs in 
order to avoid crosstalk and bleed-through. A FLIM-FRET setup was preferred over 




Figure 5-17: Illustration of possible structures and fTKIs distances for FRET experiments. 
 
As discussed in Section 1.2.1, the three possible conformations of EGFR TKDs are: 
monomers, symmetric dimers or asymmetric dimers. As shown in Figure 5-13, basal wt 
EGFR is mostly populated by inactive kinases which can either exist as monomers or 
symmetric dimers. Therefore, type II fTKIs that recognise the inactive conformation or 
Pelitinib which binds both inactive and active conformation (Section 5.3.1) would in 
principle be able to detect most of the dimeric structures, if any. However, I selected the 
two irreversible fTKIs for the following experiments as the fact that they cannot be 
dissociated from the ATP site might increase the chances for detecting FRET. 
 I started the experiments using Neratinib conjugates in pre-fixed EGFR-expressing 
cells, as described earlier (Section 5.3.1). After allowing 20 min for Ner-Bod FL to bind 
the receptor, the lifetime (Figure 5-18) of donor only samples labelled with four 
different concentrations of fTKI (10-80nM) was measured. The mean lifetime of the 
membrane signal in all conditions tested was 5.05 ns. Even though this value is different 
from the lifetime of the “free” dye in methanol240(possibly due to the different solvent 
and the binding of the fTKI conjugate
241–243
), it is consistent with the reported lifetime 
of Bod FL conjugated to protein (5.0 ± 0.2 ns)244. Acceptor (Ner-Bod 650) only samples 
were also prepared in order to ensure that direct excitation of Bod 650 with the 488 nm 
laser does not occur (not shown). 
As shown earlier (Figure 5-8), Bod 650 conjugates tend to accumulate in the ER, 
despite their ability to selectively bind the receptor. This tendency effectively reduces 
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the concentration available locally to receptor binding. Moreover, Bod 650 conjugates 
exhibited a ~2-fold decrease in their binding affinity compared to Bod FL labelled TKIs 
(Table 5-1). As a result, the concentration required to obtain detectable membrane 
labelling was much higher than for Bod FL conjugates. A high acceptor concentration is 
also required to reduce the occurrence of donor-donor pairings, which would lower the 
measured FRET efficiency. 
 
Figure 5-18: Donor fluorescent lifetimes in samples with donor (Ner-Bod FL) only and in samples with 
increasing concentration of acceptor (Ner-Bod 650). CHO cells expressing wt EGFR were fixed, after 2 h 
starvation, and briefly permeabilized as described in Section 5.3.1. Cells were then labelled for 20 mins with Ner-Bod 
FL in indicated concentration. In “Donor only” samples, donor lifetimes (μ) were recorded after removing the 
labelling media. In “Donor + Acceptor” samples, the donor labelling media was replaced with acceptor (either 200 or 
2 μM) labelling media, left for 20 mins and then donor lifetimes were recorded without removing the acceptor 
labelling media. All experiments were performed in triplicate. Analysis was performed as described in Section 
3.6.2.1.  
 
Receptor labelling in the “Donor + Acceptor” (D+A) experiments could be 
performed by treating the cells with both donor and acceptor simultaneously, the donor 
first following by acceptor labelling or the acceptor first. However, it was found that by 
treating cells with the donor first (20 min incubation) following by replacement with the 
acceptor media (which remained in the dish during acquisition) the equilibrium between 
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donor and acceptor binding that produced the largest observed donor lifetime reduction 
was reached faster compared to the other methods. In both the simultaneous labelling 
and the sequential labelling with acceptor first, the acceptor membrane labelling was not 
as efficient. The reason for that was probably the slower binding of Bod 650 conjugates 
(compared to Bod FL ones) due lower effective concentration and competition with Bod 
FL conjugates, factors which cannot be easily pre-determined. 
 
Figure 5-19: Comparison of the probability histograms of the mean lifetimes of “Donor only” with 
“Donor+Acceptor” samples for each FRET pair concentration. Histograms derived from the lifetime distribution 
of each condition shown in Figure 5-18. In plots in A-E, the histograms of donor only (red) and donor+acceptor 
(blue) sample for a given donor concentration are compared. 10 nM of donor with 200 nM of acceptor or 2 μM are 
shown in (A) and (B) respectively, 20 nM of donor in (C), 40 nM of donor in (D) and 80 nM of donor in (E). 
Histograms of the average of lifetimes of all donor concentrations without (red) or with acceptor (green for 200 nM 




In the first D+A experiment, 200 nM of Ner-Bod 650 and the lowest donor 
concentration (10 nM) were used. As expected by the relatively low membrane labelling 
(intensity images) of the acceptor (bottom middle, Figure 5-20), the mean lifetime 
across all cell was measured to be only 90 ps lower the donor-only samples (yellow 
box, Figure 5-18). Comparison of its probability histogram with those of the 10 nM of 
donor only samples is also shown in Figure 5-19A. Higher donor concentration also 
tested but completely abolished acceptor binding. Having seen that the acceptor 
concentration used was not sufficient for membrane labelling I decided to increase it by 
a factor of 10 (2 μM). This time acceptor membrane binding was significantly increased 
as shown in Figure 5-20 (bottom right). This increase was also accompanied by a 
modest reduction, ~200 ps, in the donor lifetime (mean lifetime of ~4.8 ns, Figure 
5-18). The same acceptor concentration was also tested with the other three donor 
concentrations (20, 40 and 80 nM) and showed that the observed lifetime reduction was 
retained throughout all the different donor concentrations (Figure 5-18). This time a 
clear shift of the lifetime distribution towards shorter lifetimes was observed for all 
conditions as shown in Figure 5-19B-E (also in the plot with the combined data, Figure 
5-19F). 
 
Figure 5-20: Representative lifetime and intensity images of wt EGFR-expressing cells labelled with either 
Ner-Bod FL only or Ner-Bod FL + Ner-Bod 650. The membrane lifetime of samples labelled with donor only (top 
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left) is uniformly coloured blue (colour-coded between 4.6-5.1 ns) whereas upon addition of the acceptor (middle and 
right) the membrane colour becomes variable (same colour-coding as before). 
 
It is worth noting that when higher donor concentrations (160-400nM) were tested, 
the recorded lifetime of the donor only samples was lower compared to samples with 
donor concentrations 10-80 nM (Figure 5-21A). Since this reduction was not observed 
with lower concentrations it could be attributed to self-quenching of bound donor 
molecules due to high concentration
245
. Addition of 2 μΜ of acceptor in the high donor 
concentration samples did not result in binding in the acceptor channel (right bottom 
image, Figure 5-21B) or any further change in the donor lifetime (Figure 5-21A). This 
suggests acceptor associated drops in donor lifetime are not caused by excess unbound 
inhibitor. 
 
Figure 5-21: Effect of high donor concentration in its lifetime. (A) Donor lifetimes of donor, in the absence and in 
the presence of acceptor, in samples with low (10-80 nM, obtained from Figure 5-18) and high (160-400 nM) Ner-
Bod FL concentrations. Samples for the high donor experiments were prepared as described for the low donor 
concentration (Figure 5-18). All experiments were performed in triplicate. (B) Representative lifetime and intensity 
images of wt EGFR-expressing cells labelled with high Ner-Bod FL concentration without or with Ner-Bod 650. 
 
Further evidence of the correlation between acceptor binding and the reduction in 
donor lifetime is shown in Figure 5-22: when the membrane intensity in acceptor 
channel was increased (by allowing more acceptor molecules to bind the receptor or by 
replacing donor molecules from the binding sites) the donor lifetime was further 
decreased. This suggests that this reduction is indeed due to FRET between donors and 
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acceptors. Because increasing the donor concentration up to 80 nM did not lead to a 
further decrease in donor lifetime, it is unlikely that the acceptor induced reduction in 
donor lifetime is due to bystander FRET. 
 
Figure 5-22: Dependency of FRET to acceptor binding. After replacement of the donor with the acceptor (2 μM) 
media, intensity and lifetime images of the same area were recorded at t=20 min and 18 min afterwards. The increase 
in the acceptor binding was accompanied by a decrease in donor lifetime, indicating the dependency of FRET on the 
increased number of acceptor molecules bound to receptors. 
 
It was also observed that the donor lifetime distribution on the cell membrane of 
D+A samples was not uniform. A close examination revealed that certain areas on some 
cells exhibited lower lifetime compared to the mean lifetime of the whole cell (Figure 





Figure 5-23: Fluctuations of donor lifetime on cell membranes of samples treated with donor only (left) and 
donor+acceptor (right). 
 
Next I attempted to measure FRET using labelled Pelitinib conjugates which, as 
shown earlier (Section 5.3.1) bind both the inactive and the active TKD conformations. 
As shown in Figure 5-24, the mean lifetimes measured in cells labelled with Pel-Bod 
FL, without and with Pel-Bod 650, were remarkably consistent with those of Ner-Bod 
FL from the equivalent experiments (obtained from Figure 5-18). This consistency 
between the type I and II fTKIs indicates that the number dimeric receptors with 
asymmetric configuration is small, if any. 
 
Figure 5-24: Comparison of donor fluorescent lifetimes in samples labelled with Neratinib or Pelitinib 
conjugates. CHO cells expressing wt EGFR were prepared as described in Figure 5-18. Lifetimes of samples 
labelled with Pel-Bod FL (donor) without or with Pel-Bod 650 (acceptor). All experiments were performed in 
triplicate. (A) Comparison of Ner-Bod FL with Pel-Bod FL lifetimes in “Donor only” and in “Donor+Acceptor” 




In conclusion, the present FRET method constitutes the first, to the best of my 
knowledge, example of using small-molecule fluorescence probes for monitoring 
protein-protein interactions. The reduction in donor lifetimes of receptors labelled with 
both donor and acceptor molecules was small (Figure 5-18 and Figure 5-24) and do not 
allow the drawing of strong conclusions. However, the fact that the lifetime of the high 
donor concentration samples (160-400 nM) remained unaffected by the addition of the 
acceptor (Figure 5-21) indicates that the observed FRET in Figure 5-18 and Figure 
5-24 was due to bound fTKIs in close proximity. Previous independent studies assessing 
EGFR dimerization by FRET have shown that in the absence of EGF stimulation, or 
other treatments for inducing receptor dimerization, the receptor is mostly monomeric 
resulting in low FRET efficiencies
230,234,236
. Even though these results are consistent 
with the results presented herein and the weak FRET might be due to low dimerization, 
the lack of evidence of strong FRET signal from all conditions tested indicates that 
further studies are required. Experiments in EGF-stimulated cells or in highly dimeric 
cell lines will be performed in the future in order to assess the validity of the method. 
 
5.3.3 Utilization of fTKIs at Single-Molecule Level 
TIRF microscopy and single-molecule techniques offer insight into the structure and 
the dynamics of biomolecules on the cell surface. My group’s previous experience in 
single molecule methods (in both fixed and live cells)
70,71,104,161
 led me to test the fTKIs 
in these techniques. As discussed in Section 1.3.2, single-molecule methods such as 
SPT and localization-based methods report the distribution of values for a given 
property and allow the complete characterization of a system. In the last part of this 
chapter therefore I discuss the utilization and the challenges of using the small molecule 
probes at single-molecule level.  
The only example available in literature where a small-molecule probe was used for 
single-molecule imaging was reported by Hern et al
246
. In order for the authors to study 
their target of interest (muscarinic receptors) they synthesized two fluorescently labelled 
telenzepine compounds (muscarinic antagonist) which specifically bind the receptor 
with picomolar affinity and employed them in single-particle tracking. The main 
difference between fTKI and these compounds is that the fTKIs bind to the intracellular 
domain of the receptor whereas telenzepine binds to the extracellular domain of 
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muscarinic receptors and therefore does not have to cross the plasma membrane. This 
last feature of telenzepine allowed the authors to incorporate moderate to highly 
negatively charged dyes (hydrophilic) which, as the work from Zanetti-Domingues et 
al.
161
 has shown, are the best for single-molecule experiments due to the smallest 
possible introduction of artefacts. 
Taking into consideration that fTKIs are labelled with hydrophobic dyes and 
previous experience of my group on the importance of surface (glass) passivation
104
 for 
the non-specific binding of dyes (and hence the quality of the data), I sought to find the 
best treatment for the fTKIs. Bovine serum albumin (BSA) coating was employed in all 
four glass treatments tested, it has been demonstrated to reduce the non-specific binding 
of labelled protein molecules
104
. The four treatments tested were: BSA only, acidic 
(piranha) cleaning + BSA, basic (NaOH) cleaning + BSA and nanogel coating (PEG-
BSA). The last one contains BSA and requires acidification and sylane treatment of the 





Figure 5-25: Non-specific binding of fTKIs at single-molecule level with different surface passivation 
treatments of glass surface. Cells expressing wt EGFR were seeded on glass-bottomed dishes passivated with four 
different treatments. After reaching the desired confluence, cell were labelled with Affibody and fTKI, 
simultaneously, for 1 h at 4oC and then fixed. A) On the top row are images of the ECD (green box) whereas images 
in the middle and the bottom rows show the fTKIs labelling, before and after photobleaching. B) Quantification of 
non-specific binding in non-expressing cells. 
 
Cells adhered and grew in all cases. I found that untreated (BSA only) dishes and 
dishes subjected to the basic treatment exhibited the lowest non-specific binding on the 





columns, Figure 5-25A) significantly increased the non-specific binding which 
remained high even after photobleaching (bottom row, Figure 5-25A). Moreover the 
shape of the single-molecule spots in these two treatments was not as sharp as in the 
previous two. Despite the optimization, the signal-to-noise ratio in the fTKI channel 
was always poor compared to ECD labelling, however photobleaching can provide an 
additional strategy for improving the quality of the data. The disadvantage of the 
photobleaching approach is that the fraction of the immobilized molecules will not be 
monitored. An alternative method for imaging single molecules in fixed cells with 
improved signal-to-noise ratio, but still not as good as in ECD channel, was to label the 
receptor with fTKIs after fixation, as previously described for the quantitative analysis 
in the confocal mode. Thus, the incubation time could be significantly reduced as 
sufficient labelling for single-molecule studies could be achieved in 3-5 min. 
Next I attempted to use fKTIs for live cell imaging and specifically for single-
particle tracking (SPT). SPT allows one to study the dynamics of particles and how 
these are affected by different treatments, the confinement of the movement and the 
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frequency, as well as the duration, of particle interactions. As mentioned earlier, live 
cell imaging can be performed only by using irreversible fTKIs, therefore Pelitinib and 
Neratinib conjugates were used in the following experiments. 
Live cell imaging requires cells to be maintained at 37
o
C and hence fTKI labelling 
must also take place at the same temperature. Even though the higher temperature 
negatively affected the non-specific binding, the SPT analysis algorithm
96
 allows, in 
some extend, to distinguish the immobile (non-specific binding on the glass) from the 
mobile fraction of particles. Furthermore, during the optimization of the SPT protocol I 
found that a photobleaching-recovery strategy greatly improved the mobile-to-immobile 
fraction ratio (Figure 5-26A). In order to calculate the time required for single 
molecules to appear in the field of view after photobleaching, and before acquisition, I 
measured the diffusion coefficients of receptors after perturbation with unlabelled 
Neratinib (1 μM for 2 h) in both the basal and the activated state (Figure 5-26B). Given 
their diffusion coefficients and the channel size (80 x 30 μm) I estimated that 2 min are 
enough to allow molecules from surrounding areas to appear in the photobleached area. 
 
Figure 5-26: SPT images of cells labelled with ECD ligand and Ner-Bod FL and the diffusion coefficients of wt 
EGFR. A) Single-molecule images of live CHO cells expressing wt EGFRlabelled with ECD ligand (top image) and 
Ner-Bod FL before (middle image) and after photobleaching (bottom image). All experiments were performed in 





Having optimized the SPT protocol for the irreversible fTKIs I then designed an 
experiment for measuring the diffusion coefficient of the fTKI labelled receptors and 
comparing it with that of the ECD labelled receptors. For that I used a 2-colour SPT 
experiment whereby individual particles labelled with an ECD ligand and a fTKI can be 
tracked simultaneously. For ECD labelling I used either labelled EGFR Affibody for 
tracking the basal receptor or labelled EGF for the active state, both labelled with Alexa 
488 or CF640R depending on the colour of the fTKI used. In order for me to be able to 
compare ECD with fTKI diffusion coefficients I needed to ensure that every receptor, in 
both conditions, has a ligand and an inhibitor bound to it. As single-molecule 
experiments require low labelling, for every labelling reagent cells were supplied with a 
saturating concentration of the equivalent unlabelled reagent. The protocol was as 
follow: cells were treated with 1 μM of inhibitor mixture (labelled and unlabelled) for 2 
h, followed by labelling with ECD ligand mixture for 10 (Affibody) or 4 min (EGF) and 
then imaged at 37
o
C. 
The results (diffusion coefficients) from the SPT experiments are summarized in 
Figure 5-27. Every coloured box within the plot highlights a set of experiments for 
every fTKI used (four in total). The first line in every box represents data obtained from 
fTKI channel in non-expressing cells treated as explained earlier. The second and the 
third lines show data from a two-colour experiment in cells expressing wt EGFR in the 
basal state. Affibody particles are shown in the 2
nd
 whereas fTKI-labelled molecules in 
the 3
rd
. The fourth and the fifth lines depict the equivalent data for receptors in the 




Figure 5-27: Irreversible fTKIs in Single-Particle Tracking. Particle diffusion rates (D) of receptors labelled 
simultaneously with a labelled ECD ligand (Affibody or EGF) and a reversible fTKI (Pelitinib or Neratinib) in CHO 
cells expressing wt EGFR. Cells were treated with a combination of both labelled and unlabelled reagents (ECD 
ligands and fTKIs) in order to ensure that all receptors have a ligand and an inhibitor bound to them. D was 
calculated from single particle tracks as described in Section 3.6.3.1. All experiments were performed in triplicate. 
In each figure panel, one dot reports aggregated results from ~>103 tracks per field of view per dataset. Each point 
shows the estimate of D from a mean-square displacement (MSD) curve of the tracks within a field of view in each 
dataset. 
 
Starting from the data in the 1
st
 line, all fTKIs in the absence of the receptor produce 





). The fact that these particles can be tracked by the SPT algorithm suggests that 
these molecules must be bound or trapped and not freely diffusing. Moreover, since 
TIRF allows imaging of samples within a depth of ~200 nm from the refection 
interface, fTKIs must be in the membrane region. During the evaluation in Section 5.2 it 
was demonstrated that none of the fTKIs produce detectable membrane labelling in non-
expressing cells. Even though this is not yet fully understood, I speculate that a small 
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fraction of fTKIs must be trapped within the membrane bilayer (most likely due to dyes 
properties) while they are in the process of permeating it. 
Despite the overlap between the diffusion coefficients of fTKIs in non-expressing (1
st
 




 lines) cells, I noticed that the presence of the receptor 
on cells alters the dispersion of fTKIs data suggesting that the presence of the receptor 
might play a role. However, safe conclusions can be drawn and further optimization of 
the present method is required in order to minimize or overcome the penetration 







 which has been shown that 
even allowed the delivery of quantum dots
250
. 
Overall in this chapter, the evaluation of fTKIs as imaging probes and their 
applications in different fluorescence imaging techniques were reported. All of the 
synthesised fluorescently labelled compounds exhibited low nanomolar affinity in 
biochemical assays. Apart from the TMR-labelled type I compounds (Gefitinib and 
Pelitinib), the rest fTKIs were cell permeable. As expected, reversible fTKIs (Gefitnib 
and Lapatinib) cannot be used for live cell imaging as there are being dissociated from 
their target. However, all compounds can be used in experiments for labelling the 
receptor after fixation. This post-fixation labelling method was used to study whether 
the type I TKIs are selective against the active EGFR conformation. The present results 
show for the first time that these inhibitors do have preference against the active 
conformation in cell environment. Furthermore, this conformationally selectivity can be 
suggests that fTKIs can be used as reporters for the activity of EGFR in cells. 
Other applications reported herein include EGFR intradimer FLIM-FRET 
experiments as well as experiments at single-molecule level. However, both 




6 Architecture of the Epidermal Growth Factor Receptor on 
the cell surface: A Combinatorial Approach 
 
6.1 Introduction 
As shown in Section 5.3.1, the combination of different fTKIs in quantitative binding 
studies can be used not only as a method to extract information regarding the 
mechanism of action of TKIs but also to understand the conformation of the kinase 
domain. I therefore sought to exploit this novel method in combination with methods 
previously reported by my group that can be used to probe the structure of the ECD to 
better understand both the conformational coupling of the ICD and the ECD and the 
architecture of EGFR on the plasma membrane. 
The three methods I have employed to probe the ECD structure are: i) Distance of 
Closest Approach (DOCA) for measuring the distance between EGFR ligands and the 
membrane
136
, ii) SPT for assessing the degree of non-monomeric complexes
137
 and iii) 
FLImP for determining the geometry of the non-monomeric complexes
70,71,251
. I have 
focused my attempts on determining the architecture of the unliganded basal EGFR in 
its native membrane environment, complementary to recent work towards 




6.2 The Conformation of the ECD of the Unliganded 
Receiver-Impaired Receptor is Extended 
While it is generally accepted that the ECD conformation of the monomeric receptor 
is tethered
36
 (Figure 1-5A), the ECD conformation adopted by the pre-formed inactive 
dimers is still under debate, as it was discussed in Section 1.2.2. On one hand, negative 
stain electron microscopy (EM) images of EGFR from two independent studies, in 
which dimerization was driven either by stabilising the asymmetric kinase dimer 
interface with tyrosine kinase inhibitors
217
 or by fusing the C-termini of the EGFR 
domain IV to dimerising proteins (Fc domain or the dimeric leucine zipper)
252
, revealed 
two tethered ectodomains but with no well-defined interface between them. Moreover, 
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the tethered conformation of EGFR has also been suggested to be present even when 
heterodimerized with ErbB2, which is always extended, in the resting state
72
. 
On the other hand, seminal long-time molecular dynamics (MD) simulations of 
membrane embedded near full-length EGFR predicted that the ectodomains of ligand-
free dimers adopt a back-to-back-like extended conformation
63
. The notion that the 
ectodomains of preformed ligand-free EGFR dimers adopt an extended conformation 
was also proposed by FRET measurements (DOCA) between the N-terminus of the 
ectodomain and the membrane
253,254





) are not the same in both studies (which may be attributed to different 
numbers of pre-formed dimers), both are still longer than the 4.5 nm N-terminal 




In order to investigate the conformation of the ECD of EGFR pre-formed dimers I 
have also employed the DOCA method developed by my group
136,251
. The present 
DOCA method is a lifetime FRET-based assay for measuring the distance between a 
fluorophore (donor) conjugated to EGFR specific ligands and a second fluorophore 
(acceptor) attached to a commercially available membrane probe (Vybrant DiD) on the 
outer leaflet of the plasma membrane (Figure 6-1A). As every donor molecule will 
most likely have more than one acceptor molecules in a distance shorter than 10 nm, the 
measured distance was determined from the variation of the FRET efficiency between 
fluorescent donors and acceptors measured as a function of acceptor surface density, 
based on Monte Carlo simulations
136
. 
In order to eliminate uncertainties that could be derived from measurements of a 
single ECD-membrane distance due to high monomer-dimer ratio (as previously 
discussed) or plasma membrane curvature
251
, I studied the conformation by 
triangulating the separation from two different positions of the ECD to the membrane 
(Figure 6-1B). To achieve this, two fluorescent FRET donors were bound at domain I 
and III respectively in parallel experiments.  One donor was a labelled nanobody 
(EgB4) that binds to domain I
220
 (DI) and the second was a labelled anti-EGFR 
Affibody that binds domain III
256,257
 (DIII).  Both donor probes bind EGFR without 
inducing activation
70,220
 and the dye I used was Alexa 488 (AF488).  By using these two 
probes, if most EGFR ectodomains adopt a tethered conformation, the distance from DI 
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to the membrane will be shorter than that from DIII; if most ectodomains adopt an 
extended conformation, the opposite would be observed (Figure 6-1B). 
 
Figure 6-1: Schematic representation of DOCA principle and distances of ECD domains from the membrane 
in the different conformations. A) Labelling strategy for control FLIM-FRET based observations of labelled ligand-
membrane FRET. A fluorescently labelled EGFR ligand (FRET donor) is bound specifically to the extracellular 
region of ErbB1 and the acceptor (Vybrant DiD) is free to diffuse in the outer leaflet of the plasma membrane. B) 
Illustration of distances of DI (green) and DIII (red) from the plasma membrane in the tethered (right) and the 
extended (left) ECD conformation. When the receptor adopts the tethered conformation DI distance is shorter than 




I started the investigation using wt EGFR-expressing CHO cells, as previously, and 
performed parallel experiments in order to monitor the distances of both DI and DIII. 
Cells were first treated with the membrane probe for 15 min at 37
 o
C followed by 
labelling with either EgB4 or Affibody, both conjugated to AF488, for 1 h at 4
o
C and 
finally fixed. I acquired both confocal images of DiD signal intensity (acceptor channel) 
and lifetime images of ECD probes. 
The average distance of the ECD probes to the membrane (Figure 6-2C) was 
calculated from the plots of the FRET efficiency as a function of acceptor density 
(Figure 6-2 A&B) using the best fits of Monte Carlo simulation as previously 
described
136
. Even though the distances of both DI and DIII are very similar (6.9 ± 0.6 
nm and 6.6 ± 0.6 nm respectively), the fact that DI distance is consistent with a previous 
study suggesting the extended conformation
254
 and that it is also longer than the DI 
distance of tethered monomers predicted by MD simulations
255
 suggest a contribution of 
some receptors which adopt the extended conformation.  
 
Figure 6-2: Determination of the distance of closest approach (DOCA) of EGFR ligands to the cell surface. 
A&B) Plots of FRET efficiency as a function of acceptor density measured in acceptor (DiD)-loaded CHO cells 
expressing wt EGFR.  The receptors were labelled with either EgB4-AF488 (A) or Affy-AF488 (B). All experiments 
were performed in triplicate. The best fits of Monte Carlo simulation results to the data are shown.  The errors from 
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uncertainty in the Monte Carlo model fitting were typically 10-20% of the calculated distance values as previously 
described136. C) Distances between EGFR-bound ligands and the membrane, derived from FRET measurements 
shown in Figure 6-2 A&B. 
 
An explanation for the fact that DI and DIII distances from the membrane are almost 
indistinguishable suggests a mixed population of both tethered and extended 
ectodomains in equilibrium. Furthermore, the results suggest that the extended 
population consists a considerable proportion of the total population, given that 
monomers adopt the tethered conformation
36
 and that the DOCA method does not allow 
distinguishing between monomeric and non-monomeric receptors. The presence of a 
mixed population of ECD conformations is further supported by the fTKI results 
(Section 5.3.1) which showed the presence of both active (binding of f-Gef) and 
inactive (binding of both type II fTKIs) TKD conformers in the basal state of the wt 
receptor. However the fact that type II fTKIs exhibited higher binding of in the basal 
receptor compared to type I suggested that the dominant species in the basal state is 
constituted of receptors with inactive TKDs (monomers and/or symmetric dimers). 
Collectively, the results from these two methods led me to speculate that an unliganded 
extended ectodomain conformation is coupled to an inactive TKD conformation (either 
monomers or symmetric dimers). Although the monomer-dimer ratio in the cell line 
used is not known, the conformational coupling could be ascribed to dimeric receptors 
if the general assumption that EGFR monomers adopt an ECD tethered conformation 
(and of course an inactive TKD) is valid
36
. It is worth noting that this conformational 
coupling between unliganded extended ECD dimers and symmetric TKDs dimers has 
also been predicted by in silico studies
63
. 
In order to further investigate the hypothesis for the conformation coupling of the 
inactive unliganded receptor I sought to determine the conformation of a receptor that 
cannot be activated in order to eliminate the receptor population responsible for f-Gef 
binding (and for the basal phosphorylation, Figure 5-13). For that I employed a 
constitutively inactive EGFR mutant (L680N)
49
 with a single-point mutation on the N-
lobe of the TKD which disrupts the asymmetric dimer formation but not the formation 
of the symmetric dimers (Figure 6-3A). If the above conclusion is true and if inside-out 
signal regulation occurs
217
, the ECD DI distance of such a mutant would be higher than 
6.8 nm as the ratio of tethered-to-extended ECD would be decreased. Moreover, f-Gef 
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binding is expected to be decreased as active kinases would be absent (f-Gef binding 
was shown in Section 5.3.1 to be proportional to active/phosphorylated kinases). 
The experiments were conducted in transiently transfected CHO cells expressing 
L680N EGFR. I first determined the distances of both DI and DIII using the DOCA 
method as described for wt EGFR. As expected, not only the distance of DI from the 
membrane increased by nearly 2 nm compared to wt EGFR (from 6.89 ± 0.6 nm to 8.67 
± 0.64 nm) but also the DI distance was distinctly longer than the DIII distance, which 
only marginally increased (6.97 ± 0.8 nm, Figure 6-3B). These results suggest that the 
predominant ECD conformation of the basal (unliganded) asymmetric dimer-impaired 
receptor is extended. Furthermore, the fact that exclusion of one, out of three possible 
(Figure 6-3A), TKD configurations (the asymmetric dimer) resulted in the “fading” or 
disappearance of an ECD configuration supports the inside-out regulation of ErbB 
receptors. 
 
Figure 6-3: Determination of the ECD and TKD conformation of a constitutively inactive EGFR mutant. A) 
Cartoon representation of feasible conformations of L680N EGFR. B) Determination of DI and DIII distances in the 
basal state of L680N. C) Gef-TMR binding in L680N-expressing CHO cells (red column bars) in both basal (left) and 
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EGF-treated (right) state and comparison with its binding in wt EGFR cells as a control (blue column bars) . All 
experiments were performed in triplicate.  
 
For determining the TKD conformation of L680N I employed the method described 
in Section 5.3.1. The results from the experiments using f-Gef are shown in Figure 
6-3C. In this, as well as in all the following plots, the results from experiments in wt 
EGFR-expressing cells are also included as a control. As expected, disruption of the 
asymmetric dimer interface completely abolished Gefitinib binding in the basal state 
(Figure 6-3C, left plot).   In order to ensure that EGF binding is unable to alter the TKD 
conformation I also performed the experiment in EGF-treated cells and as I expected f-
Gef binding remained unaffected (Figure 6-3C, right plot). 
As opposed to f-Gef, I expected that the other three fTKIs (f-Pel, f-Lap and f-Ner) 
would label L680N with similar efficiency as the basal wt EGFR was labelled since all 
three of them were shown to bind inactive TKDs (Section 5.3.1). However this was not 
the case: compared to wt EGFR-expressing cells a ~5.5-fold decrease was obtained in 
all three cases for both basal and EGF-treated L680N EGFR expressing cells (Figure 
6-4 A-C). Furthermore the fact that the binding of all three fTKIs was equally decreased 
regardless of their generation (reversible or irreversible) and/or type (I or II), but also 
irrespective of ligand binding, shows the reduced ability (compared to wt EGFR) of all 
inhibitors to associate (Kon) with the ATP pocket. Despite this decrease due to altered 
Kon of these fTKIs (discussed below), for all three fTKIs their fluorescence signal on the 
membrane of the L680N EGFR mutant was significantly higher compared to f-Gef 
indicating the presence of only inactive kinases (also consistent with western blot 
analysis reported by Zhang et al.
49
). This last result clearly suggests that the unliganded 
extended ECD (DOCA results of L680N EGFR) is conformationally coupled with the 




Figure 6-4: Type I irreversible and type II (reversible and irreversible) fTKIs binding in L680N EGFR-
expressing cells in basal and EGF-treated cells. Lap-TMR (A), Pel-TMR (B) and Ner-TMR (C) binding in L680N 
EGFR-expressing CHO cells (red column bars) in both basal (left, red outline) and EGF-treated (right, green outline) 
state and comparison with their binding in wt EGFR-expressing cells as a control (blue column bars). Data were 
analyzed as discussed in Section 5.3.1. All experiments were performed in triplicate. 
 
As mentioned in the previous paragraph, the equal reduction in the binding of f-Pel, 
f-Lap and f-Ner (which all bind to the inactive conformation) in L680N EGFR 
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expressing cells is due to their anibility, at least compared to wt receptor, to associate 
with their target. This reduction could be either due to a significantly altered ATP 
pocket conformation or due to inaccessible ATP clefts. 
An alteration of the shape of the ATP-site, which would result in reduced binding 
affinity of TKIs, would mean that the L680N mutant adopts a conformation distinct 
from both inactive and active wt EGFR conformation. However, crystal structures of 
Lapatinib-bound (inactive conformation) wt EGFR (Figure 5-11A), activator-impaired 
(V924R or V948R) EGFR (Figure 5-11C) and receiver-impaired (I682Q, similar to 
L680N) EGFR
258
 have shown that the inactive canonical ATP conformation is 
preserved in all three of them. Nevertheless, in order to further explore the binding of 
Pelitinib and the type II fTKIs against the inactive TKD conformation I employed a 




 is a key residue located within the ATP 
pocket which stabilizes the active conformation of the TKD, after allosteric activation, 
by interacting with a glutamine residue located on the αC-helix which in turn keeps the 
αC-helix in the “in” position53,259. It has been shown that mutating this residue to 
alanine or methionine not only impairs the ability of the receptor to catalyse the transfer 
of the ATP phosphate group to tyrosine residues but also prevents the formation of the 
active TKD conformation in the receiver kinase
53
 (Figure 6-5). Other than these two 
important differences, K721A mutant should behave as the wt receptor.  
 
Figure 6-5: Permitted TKD receiver conformation in the asymmetric dimer configuration of the K721A EGFR 
mutant. Mutation of the catalytic lysine residue located within the ATP pocket allows the formation of an 
asymmetric dimer where both kinases are in the inactive (red outline) conformation (middle dimer) as opposed to the 
canonical dimer where the receiver adopts the active (green outline) conformation. 
 
Since the TKD conformation of K721A EGFR is always inactive and if the inactive 
ATP conformation is not responsible for the reduced fTKI binding, as I previously 
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discussed, then f-Pel and both type II fTKIs should bind the K721A with similar affinity 
as the wt EGFR. The results from the experiments using the K721A EGFR mutant are 
shown below (Figure 6-6). 
 
Figure 6-6: fTKIs binding in K721A-expressing cells in basal (A) and EGF-treated cells (B). fTKIs binding in 
K721A EGFR-expressing CHO cells (red column bars) in both basal (A) and EGF-treated (B) state and comparison 
with their binding in wt EGFR-expressing cells as a control (blue column bars). In both (A) and (B), Gef-TMR data is 
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shown in (i), Lap-TMR in (ii), Pel-TMR in (iii) and Ner-TMR in (iv). Data were analyzed as discussed in Section 
5.3.1. All experiments were performed in triplicate. 
 
Starting with Gefitinib, its binding to K721A was abolished (as in the case of 
L680N) as a result of only inactive kinases in both basal and EGF-treated cells and 
despite the presence of asymmetric dimers (Figure 6-6 A&B, i). The binding to K721A 
was only marginally higher than to L680N, 0.0051 and 0.0027 A.U. respectively. On 
the other hand, Lapatinib membrane signal in K721A-expressing cells was higher 
compared to wt EGFR, in contrast to binding in L680N cells. This increase is consistent 
with the higher number of inactive kinases in the K721A cells after the “replacement” 
of the active kinases from the basal phosphorylated population of the wt EGFR by 
inactive TKDs (Figure 6-6 A&B, ii). Even though I would expect, based on the results 
obtained with Lapatinib, the same increase in the binding of both irreversible fTKIs to 
K721A, both fTKIs exhibited lower affinity, but nevertheless higher than in L680N. 
The answer to this unanticipated result may lay in the structural differences between 
Lapatinib and the irreversible TKIs. Structurally, both Lapatinib and Neratinib (but also 
the smaller Pelitinib) are very similar and show a common binding mode (as 
crystallographic data have shown
47,51,260
). Therefore the reason for the decreased affinity 
of the latter (and Pelitinib) could not be due to any structural restriction related to their 
size (Figure 6-7). Besides, the fact that Lapatinib is able to bind the receptor is a strong 
indication of an inactive ATP conformation.  
 
Figure 6-7: Structural similarities and differences between Neratinib/Pelitinib and Lapatinib. Lapatinib is not 
only structurally very similar to Neratinib and to the smaller Pelitinib (purple superimposed structure) which lacks the 
additional benzyl ring characteristic of type II TKIs, but it also shares the same binding mode as crystal structures 
have shown. The only, yet essential, difference lies on one of the features responsible for a H-bond interaction of all 




As discussed in Section 4.3, both Pelitinib and Neratinib have been developed by 
Wyeth and share a feature which is distinct from the other EGFR anilinoquinazoline 
inhibitors such as Gefitinib, Lapatinib, Erlotinib and etc. This common feature is an 
“extended” nitrogen atom on the cyano-group (red colour, left-hand side molecules in 
Figure 6-7) which directly interacts with a threonine residue, as opposed to Lapatinib 
(and other inhibitors) which requires the presence of a water molecule to bridge the 
interaction between the nitrogen atom on the quinazoline ring (green colour, right-hand 
side molecule in Figure 6-7) and the same threonine. This is the only notable difference 
between Lapatinib and Neratinib/Pelitinib as this feature is involved in one, out of only 
two, H-bond interactions. Taking into account that the mutated residue in the K721A is 
located within the pocket and that there is no difference in the binding between these 
molecules in the wt receptor, I concluded that the reduced affinity of both Neratinib and 
Pelitinib is due to steric hindrance from the presence of the “extended” nitrogen of the 
cyano-group. The fact that Lapatinib binding was increased in K721A indicates that the 
reduced binding against L680N EGFR shown earlier (Figure 6-4A) cannot be due to 
altered ATP conformation of the receptor in the inactive state. 
Inaccessibility of the ATP-sites in the symmetric dimer configuration has been 
proposed by Arkhipov et al.
63
 using long-timescale MD simulations (Figure 6-8A). 
They found that some basic residues on the TKD surface, which are exposed in the 
symmetric but not in the asymmetric dimer, electrostatically interact with the inner 
leaflet of the plasma membrane and that this interaction results in sequestered ATP 
clefts. The interaction of the inactive TKD with the membrane has also been proposed 
by other studies suggesting a model where activation involves release of the kinase 
domains from the membrane
54,261,262
. Such an occlusion of the ATP clefts could explain 
why the Kon of several different TKIs has changed. 
Blockage of the ATP binding site could also result from intermolecular interaction 
between TKDs. Such an interaction was found after examination of the crystal 
structures of both the activator-impaired (V924R) and the receiver-impaired (I682Q) 
EGFR, resolved by Kovacs et al
258
. Apart from the canonical symmetric dimer (Figure 
6-8B), the crystal lattice of both mutants contained an alternative configuration where 
the surface with the ATP-site opening of one kinase is blocked by the backbone of the 
other kinase (Figure 6-8C). Even though such an interaction would be consistent with 
166 
 
the observed reduced fTKI binding, it is unclear whether this configuration is 
biologically relevant (it could be related to higher order oligomers formation, for 
instance), as it is not commented upon by the authors. 
 
 
Figure 6-8: Accessibility of ATP clefts of symmetric KD dimers. A) Illustration of electrostatic interaction beween 
symmetric dimer and plasma membrane (Adapted from Arkhipov et al., Cell, 2013). B) Configuration of symmetric 
dimer found in crystal structures with PDB name 3GT8 and 5CNN. C) Additional interacting species with back-to-
front configuration found in the crystal lattice of both aforementioned crystal structures. 
 
Irrespective of the cause for the sequestered ATP clefts in L680N EGFR expressing 
cells, the fTKIs binding results revealed that the predominant TKD conformation of a 
receptor with disrupted asymmetric dimer interface (L680N) is much less favoured in 
the basal “inactive” wt receptor. This observation is also consistent with the results 
reported by Mi et al.
65
. EM images showed that mutation (T669D/S671D) in the JM 
segment which latches the C-lobe of the activator (similarly to L680N which is located 
167 
 
closer to the C-terminal end of the JM than T669D/S671D) in the asymmetric dimer 
interface promotes symmetric dimerization, a conformation adopted by only ~1/3 of the 
wt EGFR population. If this conformational preference of the receptor is representative 
of the conformations that occur on the cell surface, then my results, in agreement with 
Mi et al., suggest that symmetric dimerization is less favoured when the asymmetric 
dimer interface is intact. Besides, wt EGFR (without perturbation by TKIs) is always 
crystallized in the asymmetric dimer configuration and symmetric dimer crystals can 
only be obtained after introduction of either the N-lobe or the C-lobe mutation. The only 
ErbB member that has been crystallized in the inactive conformation while being in the 
wt form is ErbB4, but even in that case the resolved crystal was monomeric
51
. 
All the above do not necessarily mean that wt EGFR predominantly forms 
asymmetric dimers in the absence of ligand unless asymmetric dimers such as the 
K721M EGFR (mentioned earlier, Figure 6-5) and the wt ErbB2 (reported by 
Aertgeerts et al.
55
), where both kinases are in the inactive conformation, do exist for wt 
EGFR too. This would contradict both the high binding of type II fTKIs (which only 
bind to the inactive kinases) in the basal wt EGFR state (Figure 5-16 A&B) and the low 
basal phosphorylation (Figure 5-13). The high binding of type II fTKIs could be due to 
binding to inactive monomers, to the “inactive” activator on the asymmetric dimers 
(discussed later), or to the slightly tilted symmetric dimers (with partially accessible 
ATP clefts) recently suggested by Bragin et al.
75
 as a result to their coupling with a 
dimeric “inactive” JM structure which is different from what it was previously thought 
(Figure 1-8C). 
In conclusion, I have found that the extended unliganded ECD conformation is 
favoured in the inactive (and presumably non-monomeric) population of the basal 
receptor as a result of its conformational coupling with symmetric dimers. The fact that 
the extended unliganded conformation is an inactive form of EGFR has also been 
proposed by Walker et al.
263
. The authors reported that disruption of the auto-inhibited 
(tethered) ECD conformation, and subsequent promotion of the extended conformation 
in the absence of ligand, by mutation did not result in activation and that this 
conformation is not sufficient for receptor activation as ligand binding is still required. 
Furthermore, both DOCA and fTKI binding experiments indicated that this inactive 
population is not the predominant one in the basal wt receptor. Lastly, the asymmetric 
kinase dimers are present in the basal state in wt EGFR-expressing cells (as both the 
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basal phosphorylation and Gefitinib binding indicated, Figure 5-13 and Figure 5-12 
respectively) and since the ECD unliganded extended conformation can only be coupled 
to one TKD conformation, otherwise regulation of EGFR activation in healthy cells 
would not be possible, by elimination the ECD conformation that remains is 
surprisingly the tethered. 
 
6.2.1 The Unliganded Extended ECD Conformation Promotes 
Non-Monomeric Complexes 
I speculated that if the basal unliganded L680N receptor adopts an extended ECD 
conformation in which the same ECD dimeric interface of the liganded receptor, known 
to promote dimerization, is exposed, it should also promote higher number of non-
monomeric complexes compared to basal wt EGFR. In order to investigate this I sought 
to exploit two-colour SPT to compare the number and the duration of the complexes 
formed. 
Two-colour SPT experiments combined with advanced data analysis algorithms 
allows one to determine the relative (absolute quantification is not possible) frequency 
of pairwise interactions (colocalization) between two single particles (tracks) in two 
channels as well as the duration (Ton) of every interaction
96,137,251
. The basic principle of 
the colocalization experiments is shown below (Figure 6-9). Briefly, live cells were 
labelled with two different fluorescent dyes (always Alexa-488 and CF640R
161
) 
conjugated to either anti-EGFR Affibody or EGF. After acquisition of two-colour TIRF 
images, separated by a beam splitter
73
, over 30 seconds for each area, the two channels 
were registered and single particle tracks were extracted as previously described
96
. In 
order for an event to be regarded as a colocalization event two tracks in different colour 
channels need to spend at least 3 frames (150 ms) moving together while remaining 
within a distance of each other of less than one pixel. The duration of individual events 




Figure 6-9: Two colour single-particle tracking method for determining colocalization frequencies and 
duration (Ton) of colocalized events. Cells expressing the protein of interest were labelled with two different 
fluorescent dyes and data were acquired. The two channels were then registered and single particle tracks were 
extracted as previously described96. Tracks from different channels which colocalize and move together can be 
extracted from which parameters such as colocalization frequency and Ton can be calculated. 
 
For two-colour SPT experiments, cells were maintained at 37
o
C at all times during 
cell preparation and data acquisition and treated with pre-heated labelling solution. In 
order to determine whether the exposure of the ECD dimer interface in basal L680N-
expressing cells promotes non-monomeric complexes I conducted two control 
experiments. In the first I measured the colocalization frequency and Ton of basal wt 
EGFR (labelled with anti-EGFR affibody), while in the second I repeated the 
experiment in EGF-stimulated (8nM) wt EGFR cells (labelled EGF conjugates were 
used as markers). For the basal L680N EGFR experiment, the same conditions as in 
basal wt EGFR were employed. An overview of the distributions of pairwise 




Figure 6-10: Fraction of colocalized tracks (A) and duration of the colocalization events (B) of basal and EGF-
treated wt EGFR cells and basal L680N EGFR cells.  Cells expressing with wt EGFR or L680N EGFR were 
labelled or labelled/stimulated with Alexa-488 and CF640R conjugates of anti-EGFR-Affibody or EGF respectively. 
A) Fractions of tracks in which the features in two tracks in different colour channels spent at least 3 frames (150 ms) 
moving together while remaining within a distance of each other of less than one pixel. B) Duration of the 
colocalisation events from the time a feature in one channel begins to move together within a pixel of a feature in the 
other channel until then they move apart. All experiments were performed in triplicate. 
 
Starting from the control experiments, the data showed that while the wt receptor in 
the basal state (negative control, blue dots) forms only a small number of non-monomer 
complexes (0.9±0.6), EGF stimulation (positive control, green dots) greatly increased 
the fraction of colocalized tracks (~6.5-fold) between the two channels (Figure 6-10A). 
Disruption of the asymmetric dimer interface (L680N mutation), with concomitant 
promotion of the extended ECD conformation, in the basal state however resulted in a 
~3.5-fold increase in the colocalization frequency compared to the basal wt EGFR. I 
also found that L680N EGFR complexes are interacting with each other more strongly 
than the unliganded wt EGFR but less strongly than the EGF-bound wt EGFR 
complexes (Tonwt EGFR-EGF ≈ 2×TonL680N). The latter might be explained by the fact that 
dimerization/oligomerization in L680N EGFR (TKD mutation) is driven only by the 
TKDs with a less favoured (still more favourable than the basal wt receptor), ECD 
conformation (unliganded extended conformation) as predicted by MD simulation
63
. On 
the other hand, EGF binding induces conformational changes that favour the formation 
of complexes which are stabilized from both the outside (crystallographic extended 
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EGF-bound dimer) and the inside (crystallographic asymmetric dimer). Therefore, these 
results support the previous assumption that stabilization of an unliganded extended 
ECD conformation through an inside-out regulation is accompanied by promotion of 
non-monomer complexes. Furthermore, the fact that L680N EGFR forms a higher 
number of non-monomers also agrees with the notion that the dominant TKD 
conformation of L680N EGFR (which is less favoured in the basal wt EGFR-expressing 
cells) is responsible for the decreased fTKIs affinities is the symmetric dimer. 
 
6.3 Geometry of EGFR on the Plasma Membrane 
Even though the DOCA and fTKI data in Section 6.2 suggested that unliganded 
EGFR dimers with an extended ECD and a symmetric TKD conformations are not the 
dominant species in the wt receptor (as in L680N EGFR expressing cells), they do not 
give insight into the existence and the proportion of the different dimeric populations of 
the receptor (the possibility for the presence of a tethered ECD dimer was discussed in 
Section 6.2). In order to be able to detect the two (extended and tethered) dimeric 
conformations I require a method which is capable of achieving sub-6 nm resolution. 
Such a method, namely Fluorophore Localization Imaging with Photobleaching 
(FLImP), has been previously published by my group for reporting lateral separations in 
the 0-60 nm range between identical fluorophores bound to the ECD
70,71,264
. I therefore 
employed this method not only for distinguishing between the two dimeric 
conformations but also for better understanding EGFR’s architecture on cells. 
FLImP allows the measurement of discrete pairwise separations between 
fluorophore-conjugated ligands bound to EGFR complexes.  Unlike the single molecule 
analysis by Kuriyan and colleagues
265
 where the fluorophores were attached to EGFR 
intracellularly, here the fluorophores are positioned extracellularly and the FLImP 
results reflect the extracellular geometry of ligand-bound EGFR complexes. A FLImP 
measurement of the separation of a pair of fluorophore-conjugated  ligands bound to an 
EGFR complex (which is a result of the analysis of two-fluorophore spots based on 
criteria described previously
70,71
) produces an empirical posterior probability 
distribution of the separation
70
. As the separation cannot be negative, instead of a 
Gaussian, the empirical posterior takes the form of an asymmetric Rice distribution
266
.  
The width of the 68% confidence interval of the posterior distribution reflects the 
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precision of each pairwise separation measurement, which ultimately depends on the 
signal-to-noise ratio (Figure 6-11).  The posteriors with 68% confidence intervals 
smaller than the required resolution (typically 4 –7 nm) are retained and pooled into a 
histogram (hereafter referred to as a FLImP distribution), from which one can derive 
structural information of EGFR complexes bound to more than one labelled EGFR 
ligands.  From a FLImP distribution one can estimate the proportion of FLImP 
measurements consistent with particular species of EGFR complexes bound to more 
than one EGFR ligand as an indicator of the relative population of the species (will be 
shown later). 
 
Figure 6-11: FLImP workflow. Steps to determine ligand separations using FLImP:  (1) TIRF images are collected 
from fixed cells; (2) Spots corresponding to individual complexes are tracked to derive intensity vs time traces96;  (3) 
A spot image of a molecular complex containing two fluorophores (each represented by a red dot) features two 
intensity levels and a decay to zero in two bleaching steps;  when one fluorophore bleaches, the centroid position of 
the spot shifts; If more than two steps are present, the lowest two are analyzed  (4) A global least-squares 7-parameter 
fit is used to identify the best intensity, x and y positions for each fluorophore and the full width at half-maximum of 
the point spread function, from which the separation between the molecules can be calculated with a precision 
determined by the localization error; (5) Example systems of a two-ligand EGFR dimer, a two-ligand tetramer, a 
three-ligand tetramer, and a mixture of a dimer and a tetramer;  (6) The FLImP measurement of pairwise ligand 
separations obtained for each example system using FLImP, where the 68% confidence intervals are highlighted.  
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The size of the confidence interval depends on the combined localization errors of the two molecules. The FLImP 
measurements with confidence intervals smaller than the required resolution are pooled into a histogram, generating a 
so-called FLImP distribution that is well fitted by the sum of a discrete number of Rician peaks. 
 
In order to be able to detect and characterize the presence of possibly two different 
(tethered and extended) dimeric populations with FLImP, the knowledge of the 
distances between fluorophore-conjugated ligands bound to both conformations is 
required (assuming that these distances are different). The lateral dimension of the 
unliganded extended ECD dimer is expected to be ~11nm, given the shape similarity of 
the unliganded ECD dimer seen in long-timescale MD simulations
63
 and in EM 
images
252
 with the active (EGF-bound) extended EGFR ECD dimer, for which the 
lateral dimension is ~11nm
34,35
. The ligand I have used for all FLImP experiment herein 
was the anti-EGFR Affibody which binds to the EGF epitope, as I discussed earlier 
(Section 6.2). Given that the estimated separation (based on crystallographic data) 
between the two fluorescent labels each bound to the two EGF in the back-to-back 
EGFR dimers is 12.5 nm
251
, one would anticipate a similar distance between 
fluorophores-conjugated affibodies bound to extended dimers. Furthermore, L680N 
could also be used as a control for the FLImP measurements of the unliganded extended 
dimer since DOCA and SPT results suggested the presence of extended non-monomer 
complexes. While the conformation of the unliganded extended ECD dimer has been 
observed in both long-timescale MD simulations
63
 and in EM images
252
, the 
conformation of a tethered dimer is unknown. Furthermore, an estimation of the 
distance between fluorophores conjugated to ligands (with known epitope such as 
EGFR Affibody) cannot be made as the dimer interface is also unknown (even though 
EM images suggested intermolecular interaction between ECD domain IVs of a EGFR 
receptor where the ECD was fused to a dimeric immunoglobulin Fc domain
252
). 
Therefore, I decided to measure the distribution of separations, using FLImP, between 
labelled ligands of receptors to which the tethered conformation was reinforced.  
Stabilisation of the tethered conformation or prevention of the ECD from adopting 
the extended conformation (or both simultaneously) can be achieved by either treatment 
with reagents targeting the ECD or by mutation. Attempts using the latter approach 
have been previously reported by Burgess and colleagues
263
. The authors mutated two 
key residues located at the centre of the auto-inhibited, intramolecular, interaction of the 
174 
 
tethered conformation (between domain II and IV) to cysteines in order to “lock” the 
receptor via a disulphide bond formation. However, inconsistency between different 
methods for determining the expression levels of this mutant led to the conclusion that 
the receptor might be partially misfolded
263
. On the other hand, treatment of EGFR with 




) or nanobodies (7D12, 
EgA1 and 9G8)
162,268
 has been successfully shown to alter the conformation of the 
receptor. Due to use of ECD probes that bind to either DI (EgB4) or DIII (Affibody and 
EGF) in the imaging experiments, I required a reagent which primarily promotes the 
tethered conformation but does not interfere with the binding of the ECD. Although, 
matuzumab, EgA1 and 9G8 meet both the criteria (matuzumab binds to domain II
24
 
whereas both EgA1 and 9G8 bind to the junction of domain II and III
268
), I selected the 
9G8 nanobody (kind gift from Dr Paul van Bergen en Henegouwen, Utrecht University) 
for my experiments. Apart from the fact that nanobodies, in general, are smaller in size 
than antibodies (and hence produce less interference with other bound molecules), both 
EgA1 and 9G8 have been shown not only to prevent the formation of the extended 
conformation (as matuzumab does) but also to stabilise the tethered conformation
268
. 




As mentioned above, 9G8 binding is not expected to interfere with the binding of the 
ECD probes (EgB4 and Affibody) as it binds to an epitope distinct from both EGF 
(Affibody is an EGF-competitive ligand
256,257
) and EgB4 (binds to DI
220
) epitopes.  
Nevertheless, I sought to characterize the binding of ECD probes by confocal 
microscopy in the absence and in the presence of a saturating concentration (200 nM) of 
9G8 in order to ensure that their binding is not affected by 9G8 binding. For that, wt 
EGFR expressing cells were treated with or without 9G8 during labelling (1 h at 4
o
C) 
with either EgB4-Alexa 488 or Affibody-Alexa 488 and then fixed. The binding of both 
probes to EGFR was assessed by comparing the frequency distributions of membrane 
pixel intensities (obtained by confocal microscopy) of the 9G8-treated with that of the 
untreated cells. As shown in Figure 6-12 (C and D), the binding of both probes was 
unchanged, indicating that 9G8 does not compete with either probe and hence is a 
suitable reagent for my investigation. 
In order to validate that 9G8 treatment generates higher number of tethered receptors 
than wt EGFR (and of course L680N EGFR) in cells I measured the distance of both DI 
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and DIII from the membrane. If more tethered receptors are formed, then the distance 
between ECD DIII and the membrane is expected to be higher than the distance of DI 
and the membrane. As shown in Figure 6-12B, the distance from DI to the membrane 
in 9G8-bound receptors  is 4.6 ± 0.8 nm, which is remarkably consistent with the 4.5 nm 
N-terminus-membrane separation predicted for the tethered conformation by MD 
simulations
255
. The distance from DIII, as expected, is longer (8.4 ± 0.6 nm) indicating 
the predominance of tethered receptors in the samples. 
 
Figure 6-12: 9G8 nanobody binding promotes the tethered conformation. (A) Crystal structures of 9G8 
nanobody bound to the ECD of EGFR in the tethered conformation (PDB: 4KRP). Colours: blue for sub-domain I, 
green for sub-domain II, red for sub-domain III, grey for sub-domain IV and magenta for 9G8. (B) Determination of 
DI and DIII distances (DOCA) in the basal state of wtGEFR pre-treated with 200 nM of 9G8 nanobody. (C) The 
binding of 50 nM EgB4-Alexa 488 to wt EGFR in the absence (green) or in the presence (red) of a saturating 
concentration (200 nM) of the 9G8 nanobody, assessed by the distribution of fluorescence photon counts per pixel of 
membrane (obtained with confocal microscopy).  (D) Assessment of Affibody-Alexa 488 (20 nM) binding as in (C). 
All experiments were performed in triplicate. 
 
As mentioned earlier, comparison of the fTKI and DOCA results between wt and the 
L680N EGFR led me to consider the likelihood of tethered dimers being present in the 





demonstrated that 9G8-treated receptors are predominantly tethered, I then employed 
the FLImP method in an attempt to characterize such tethered dimeric receptors. As a 
control for the extended conformation I used L680N EGFR which was shown earlier to 
form higher number of non-monomer complexes. For the FLImP experiments, cells 
were labelled with Affy-CF640R, similarly to DOCA, and then fixed. 9G8 treatment 
was performed simultaneously with the labelling. 
 
Figure 6-13: Determination of the separations of tethered and extended dimers. FLImP distributions (grey) of 
EGFR labelled with CF640R fluorophore-conjugated Affibody on the surface of CHO cells expressing either wt 
EGFR pre-treated with 200 nM of 9G8 (A) or L680N EGFR (B) labelled with 4 nM Affibody at 4oC, followed by 
chemical fixation. The FLImP distribution was compiled from ~30 FLImP measurements with confidence intervals 
<6 nm. (C) Merged FLImP distribution plots of (A) and (B). All experiments were performed in triplicate. 
 
 The FLImP distributions obtained from these conditions are shown in Figure 6-13. 
Despite their overlap at the dimer range (Figure 6-13C), the shape of their distribution 
revealed two distinct peaks; whereas 9G8-treated receptors (Figure 6-13A) exhibited 
the highest densities at separations <10 nm (green box), L680N EGFR expressing cells 
displayed separations which more frequently appeared in the range of 10-18 nm (yellow 
box, Figure 6-13B). Two separate peaks within these ranges were also recently 
reported
251
 to appear, simultaneously, in the FLImP distribution of pairwise separations 
of basal wt EGFR (Figure 6-14, right panel). The authors further applied a Bayesian 
information criterion in order to determine the decomposition of the FLImP distribution 
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of Affibody separations into 4 (best fit) Rician peak components (Figure 6-14, left 
panel, highlighted by a green box). For the two main peaks, the centre was calculated to 
be at 4.1 (-1.9 +4.2) nm and at 12.0 (±1.6) nm (the smaller peaks at longer distances 
possibly reflect the presence of complexes larger than dimers).  I previously speculated 
that the 4.1 nm separation was associated to the tethered conformation and that the 12 
nm separation may reflect the distance between two Affibody molecules bound to an 
extracellular configuration akin to the back-to-back dimers. Collectively with the 
control experiments for the tethered (9G8-treated cells) and extended (L680N EGFR) 
dimers separations, the data suggest that these peaks represent those two dimeric 
populations. 
 
Figure 6-14: FLImP decomposition into its underlying Rician-peak components (adapted from Needham et al. 
Nat. Commun. 2016251). (Left panel) FLImP distribution (grey) of pairwise Affibody separations on CHO cells 
expressing wt EGFR treated with 4 nM Affibody-CF640R.  (Right panel) Different fits using increasing numbers of 
peak components. The figure shows that increasing or decreasing the number of peaks from 4 (green box) is not 
objectively justified by the data. The distribution is fitted (black line) with a sum of 3-6 Rician peaks (colour lines).  
The number of peaks used was determined using a Bayesian information criterion.  The best-fit positions of the peaks 
and error bars are shown in the inset.  The errors in the fit were calculated as described in Needham et al.251. 
 
In order to be able to correlate the effect of each ECD dimeric population with the 
TKD conformation (and hence receptor activation), their relative proportion in each 
mutant or condition was calculated. To do this, I calculated the percentage of 
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distributions consistent with FLImP measurements in the ranges of either 4.1 (-1.9 +4.2) 
nm (green coloured area) or 12.0 (±1.6) nm (yellow coloured area), based on the ranges 
derived from the peaks of the basal wt EGFR (Figure 6-15). Distributions outside the 
dimer range (>13.6 nm) were also calculated (shown in blue). Hereafter the ranges at 
4.1 (-1.9 +4.2) nm and at 12.0 (±1.6) nm are referred to as tethered and extended 
dimers, respectively. 
 
Figure 6-15: Relative populations of the tethered and extended dimers of basal wt EGFR, 9G8-treated wt 
EGFR and L680N EGFR expressing cells. FLimP results obtained from CHO cells expressing wt EGFR (A) or wt 
EGFR pre-treated with 9G8 (B) or L680N EGFR (C), all labelled with Affy-CF640R. Plots denoted as (i) show the 
FLImP distribution (grey) and the distributions (green, yellow or blue) compiled from the FLImP measurements 
whose ranges of 68% confidence overlap with the ranges of Affibody separations of the expected tethered (4.1 (-1.9 
+4.2) nm, green) or extended (12.0 ± 1.6 nm, yellow) dimer or higher order oligomers (>13.6 nm, blue). Relative 
populations of the tethered and extended dimers determined from the FLImP measurements shown in (i) are 
illustrated in (ii).  For each construct, the tethered percentage is estimated by the ratio of the green integral area to the 
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integral area of all FLImP measurements whose 68% confidence intervals overlaps with the three regions (green, 
yellow and blue). Likewise the extended dimer population is calculated based on the yellow area. Oligomer 
populations are calculated in the same way, using the blue instead of the green integral area. Error bars were 
calculated by bootstrap-resampling the data 1000 times with replacement and repeating the analysis. 
 
As shown in Figure 6-15A, in the basal unliganded wt EGFR both the tethered and 
extended ECD dimers coexist in similar levels on the cell surface. Stabilization of the 
tethered conformation (9G8 binding) or disruption of the asymmetric dimer interface 
(L680N EGFR) significantly alters the relative populations: whereas 9G8 binding to 
unliganded wt EGFR enhances the number of separations consistent with the tethered 
dimer (Figure 6-15B), L680N point mutation favours the formation of extended dimers 
(Figure 6-15C). 
The presence of higher order oligomers in the wt receptor was also observed (Figure 
6-15, blue). The alterations from the wt receptor affected both the overall percentage of 
the oligomers (Figure 6-16) and the frequency of separations at these ranges. Oligomers 
detected in basal wt EGFR appear more frequently at separations which could possibly 
be explained by tetramer (20-30 nm) or hexamer (30-40 nm) formation. By comparing 
9G8 treatment and L680N EGFR the data suggest that Affibody separations consistent 
with the former range appears to be asymmetric dimer-dependent whereas promotion of 
extended ECDs and symmetric dimers (L680N mutant) favours the formation of even 
larger complexes (peak at ~40nm), consistent with SPT results. 
 
Figure 6-16: Relative populations of the higher order oligomers of basal wt EGFR, 9G8-treated wt EGFR and 
L680N EGFR expressing cells. Relative populations of the higher order oligomers determined from the FLImP 




6.4 Outside-in and Inside-out Conformation Coupling of 
Tethered ECD and Asymmetric ICD in the Basal 
Receptor 
In the previous section I showed that 9G8 treatment not only lock the receptor in the 
tethered conformation, in agreement with previously reported data
268
, but also favours 
the formation of tethered dimers which have been also recently visualized by EM
252
. 
Furthermore I showed that these tethered dimers are destabilized when the asymmetric 
dimer interface is disrupted (with concomitant promotion of symmetric dimers). All 
these suggest a linkage between the ECD tethered unliganded dimers with the 
asymmetric TKD dimers present in the basal receptor. In order to investigate this 
conformational coupling in the basal receptor state I used two approaches: 
- Outside-in receptor regulation by promoting the ECD tethered conformation 
- Inside-out signalling by promoting asymmetric dimers 
 
6.4.1 Forcing the Tethered ECD Conformation 
Even though 9G8 treatment was shown by FLImP to favour the formation of tethered 
ECD dimers, the overall relative population of higher order oligomers was significantly 
lower than in untreated cells (25±9% and 41±8% respectively, Figure 6-16). This 
observation could suggest either that promotion of the tethered configuration favours 
dimeric complexes (or disrupts oligomerization) or that the monomer/non-monomer 
ratio is higher than in basal wt EGFR. If the latter is true, then the number of tethered 
dimers will not be notably different between the basal and the 9G8-treated receptors and 
hence the investigation of the TKD conformation might prove difficult. For this reason I 
employed the SPT method described earlier for determining the correlation between the 
tethered conformation and the formation of non-monomer complexes. 
The experiment was performed in the same manner as that described in Section 
6.2.1, but this time in the presence of a saturating concentration (200 nM) of 9G8 
nanobody. The results are shown in Figure 6-17 (basal wt EGFR is also shown for 
comparison). SPT experiments revealed that 9G8 induced a small but significant (p < 
0.05) increase (~1.6-fold) of non-monomer complexes compared to untreated wt EGFR 
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cells (Figure 6-17A). This is especially important considering that FLImP results 
suggest that the non-monomer fraction is mainly populated by dimers. Furthermore, the 
duration (Ton) of these interactions was also increased (Figure 6-17B). These results 
demonstrate that tethered ECDs are able to interact via well-defined extracellular 
interfaces capable of driving dimerization. It is also possible that these dimers gained 
additional stability by the formation of asymmetric kinase dimers, if the tethered ECD 
dimers are indeed coupled to this TKD configuration. 
 
Figure 6-17: Comparison of the fraction of colocalized tracks (A) and duration of the colocalization events (B) 
between basal and 9G8-treated wt EGFR cells.  Cells expressing wt EGFR were labelled with Affibody molecules 
conjugated to Alexa-488 and CF640R in the absence (green) or presence (red) of 9G8 nanobody. All experiments 
were performed in triplicate. 
 
Having showed that 9G8-bound receptors form stable non-monomer complexes I 
then sought to determine the conformation of their TKDs. For that I employed the fTKI 
method. As discussed and demonstrated earlier (Figure 5-12), f-Gef binding is 
increased proportionally with the number of active ATP-clefts (which can only be 
formed after allosteric activation). On the other hand, type II fTKIs (Lapatinib and 
Neratinib) binding is inversely proportional to activation (Figure 5-16). Lastly, f-
Pelitinib binding is conformationally-independent as it was demonstrated to bind both 
inactive and active kinases with the same affinity (Figure 5-14). Therefore, if tethered 
ECD dimers are conformationally coupled to asymmetric kinase dimers then 9G8-
treated cells will exhibit higher membrane signal when labelled with f-Gefitinib and 
lower when type II fTKIs are used, compared to untreated cells. Cells for these 
experiments were prepared as previously described for the basal wt receptor, (Section 
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5.3.1) but in the presence of 200 nM of 9G8 during the ECD labelling step. The results 
are shown below (Figure 6-18) 
 
Figure 6-18: fTKIs binding in CHO cells expressing wt EGFR pre-treated with 200 nM of 9G8 nanobody and 
comparison with untreated cells. fTKIs binding in wt EGFR-expressing CHO cells treated with saturated 
concentration (200 nM) of 9G8 nanobody (red column bars) and comparison with their binding in untreated cells 
(blue column bars). Affy-CF640R was used to label the ECD in both experiments. Gef-TMR (P >0.05) data is shown 
in (A), Lap-TMR (P >0.05) in (B), Pel-TMR (P >0.05) in (C) and Ner-TMR (P >0.05) in (D). Data were analyzed as 
discussed in Section 5.3.1. All experiments were performed in triplicate. 
 
The results from fTKIs binding experiments appear to be consistent with my 
hypothesis: 9G8 treatment led to an increase of f-Gef membrane signal and a decrease 
of both f-Lap and f-Ner binding. Furthermore, the f-Pel binding appears to be 
unaffected. As the changes after 9G8 treatment were relatively small, an unpaired, two 
sample t-test was used to objectively compare the mean fTKI binding intensity ratio of 
the four fTKIs before and after 9G8 treatment (performed using OriginPro). The 
determined P values showed that there was no difference between any of the untreated 
and treated means significant to the 0.05 level (0.29 for f-Gef, 0.26 for f-Lap, 0.78 for f-
Pel and 0.13 for f-Ner) so I consider the results of these experiments to be inconclusive. 
An alternative method for determining whether the number of active TKDs has 
increased as a result of 9G8 treatment is to determine receptor phosphorylation. Western 
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blots analysis of 9G8-treated CHO cells expressing wt EGFR from unpublished data 
(Zanetti-Domingues et al., manuscript in preparation) showed that phosphorylation was 
1.4-fold higher than that of the basal (untreated) receptor. The reason why the observed 
increased in receptor phosphorylation was not able to be detected by the fTKIs could be 
due to the fact that in an asymmetric TKD dimer unit one TKD adopts the inactive and 
one the active conformation (Figure 6-19). 
FLImP analysis of 9G8-treated cells showed that promotion of unliganded tethered 
receptors favours the formation of dimers, probably at the expense of higher order 
oligomers when it is compared to untreated wt EGFR expressing cells (Figure 6-15B). 





 form a daisy chain of asymmetric dimers where the receiver 
kinase of one dimer is also the activator kinase of the following dimer (Figure 6-19A). 
In this arrangement which occurs in EGF-stimulated receptors as recently shown
265
, 
only the activator kinase on one end of the daisy chain adopts the inactive conformation 
(recognized by type II and irreversible type I TKIs) while the rest of the kinases (here 
shown in a tetrameric configuration) are active (recognized only by type I TKIs). In this 
case, type II fTKIs would bind only to ¼ of the population of EGF-stimulated receptors, 
if only tetramers existed as illustrated in Figure 6-19A. On the other hand, TKDs which 
can form a dimeric asymmetric unit but not the daisy chain, as in the case of the 
asymmetric EGFR/ErbB3 heterodimer which cannot form TKD oligomers
269
, half of the 
receptor population would adopt the inactive TKD conformation (Figure 6-19B). Even 
though such a dimeric unit would be phosphorylated, both type I and II fTKIs would be 
able to bind. In cell context, the number of active TKDs of such receptors which exhibit 




Figure 6-19: EGFR asymmetric homodimer daisy chain and EGFR-ErbB3 asymmetric heterodimer. A) In all 
the previously reported crystalized asymmetric kinase dimers (for both EGFR49 and ErbB451 homodimer), the 
molecules form a daisy chain where the receiver of one asymmetric unit is also the activator of the following 
monomer (here is the PDB: 2GS6). In this configuration, all the ATP-cleft form the active conformation. B) In the 
recently resolved EGFR-ErbB3269 crystal structure (PDB: 4RIW), the configuration is absent due to the presence of 
ErbB3 in the activator position. 
 
In conclusion, the data are consistent with the assumption that tethered unliganded 
receptors are conformationally coupled with asymmetric dimers. Most importantly I 
have found that, contrary to expectation in the field, promotion of the tethered ECD 
conformation results in the increase of active kinases (and hence increased 
phosphorylation, Zanetti-Domingues et al. manuscript in preparation) in the absence of 
ligand. A literature search revealed a similar finding for a E578C EGFR mutant in 
which the tethered conformation was promoted by improving the packing of the ECD 
domain II/domain IV interface (intramolecular auto-inhibited interaction of the tethered 
conformation) and resulted in higher basal phosphorylation (which however was not 
commented upon the authors)
263
. “Locking” the ECD conformation to the tethered one 
185 
 
has been proposed as a mechanism for EGFR signalling inhibition due to the 
assumption that tethered receptors would be monomeric and hence inactive
268
. 
Nanobodies such as 9G8 and 7D12 and antibodies such as matuzumab have been 
developed based on that mechanism and in fact these molecules has been shown to 
successfully suppress EGFR phosphorylation after EGF stimulation. However, my data 
suggest that a population of ligand-free receptors might not be actually inhibited. The 
relevance of this finding to cell signalling is not understood. Further studies using such 
molecules and other cell lines need to be conducted to determine whether the effect 
constitutes a general pattern or not. 
 
6.4.2 Promoting EGFR Asymmetric Dimers in the Basal State 
In order to further investigate the presence of unliganded EGFR dimers where the 
ECDs adopt the tethered conformation coupled with the TKDs an asymmetric 
configuration, an alternative approach was employed. As opposed to promoting the 
ECD tethered conformation, I sought to increase the number of the unliganded dimers 
in cells by inducing asymmetric dimerization of the ICDs in the absence of ligand. 





 or FRET measurements
137,230,235
 have shown that cells treated 
with type I TKIs (either reversible or irreversible) exhibited higher number of EGFR 
dimers compared to untreated cells. Furthermore, these receptors were found to form 
asymmetric dimers with their ECDs displaying a conformation more akin to that of the 
tethered monomer in the absence of ligand in EM studies performed on detergent-
solubilized receptors
217
. Therefore I decided to reproduce these experiments in cells to 
further study the conformational coupling between the ECD and the TKD of the 
unliganded receptor seen in 9G8-treated cells (Section 6.4.1). 
All the following experiments on inhibitor-induced dimerization were carried out in 
CHO cells expressing wt EGFR. In order for any inhibitor to induce the associated 
conformational change, receptors need to be treated in live cells with a saturating 
concentration of an unlabelled TKI so that most receptors exist in an inhibitor-bound 
state. Since TKIs in such a concentration inhibit EGFR phosphorylation, the formation 
of asymmetric dimers in cells cannot be verified by WB analysis as previously 
discussed for 9G8 (Section 6.4.1). Therefore the presence of asymmetric dimers can 
186 
 
only be investigated using the fTKI method. However this is a quantitative method 
which is based on the recognition of unoccupied ATP sites (either inactive or active) 
from the fluorescent inhibitors; hence the type I TKI used to induce dimerization needs 
to be reversible so it can be washed out after fixation. Even though any type I reversible 
TKI could in principle be used in the inhibitor-induced dimerization experiments, 
Gefitinib® was chosen as, apart from being the parent compound of my fluorescent type 
I reversible inhibitor, it was also the compound used in the EM study reported by 
Springer and colleagues
65,217
. Inhibitor treatment (1 μM) in the following experiments 
was performed during starvation (2h) as well as during ECD labelling (1 h for methods 
in fixed cells). For live-cell experiments (SPT), the same concentration of the inhibitor 
was kept in the media while acquiring data. 
The results from the fTKI binding experiments for determining the TKD 
conformation of the Gefitinib-treated wt receptors are shown in Figure 6-20. Even 
though, based on previous studies, one would expect that f-Gef membrane signal to be 
higher in inhibitor-treated cells (formation of asymmetric dimers) than in untreated 
basal receptors (Figure 6-20A, red and blue respectively), analysis of the data revealed 
a reduction in f-Gef binding by ⅓ compared to basal receptor. This reduction could be 
either due to a conformation different from the expected, in which more inactive TKDs 
have been generated as a result of Gefitinib treatment, or due to competition of f-Gef 
with residual unlabelled Gefitinib. If the former were true, the binding of both type II 
fTKIs would be increased. However, in both cases the binding was lower compared to 
untreated cells (Figure 6-20 B&D), a result which supports the latter hypothesis and 
demonstrates an increase in the active TKD population. Furthermore, the fact that f-Pel 
binding remained unaffected (Figure 6-20C) indicates that the ATP cleft is fully 
accessible and in a conformation which can be recognized at least by f-Gef (as another 
type I fTKI). Therefore, the reduction of f-Gef binding could be attributed to 




Figure 6-20: Determination of the TKD conformation of wt EGFR pre-treated with Gefitinib®. fTKIs binding 
in CHO cells expressing wt EGFR pre-treated with 1μM of Gefitinib® (red column bars) and comparison with their 
binding in untreated cells (blue column bars). Affy-CF640R was used to label the ECD in both experiments. Gef-
TMR data is shown in (A), Lap-TMR in (B), Pel-TMR in (C) and Ner-TMR in (D). Data were analyzed as discussed 
in Section 5.3.1. All experiments were performed in triplicate. 
 
The fact that f-Pel binding was not reduced by residual unlabelled Gefitinib suggests 
that the concentration of the latter is minimal, which is in agreement with what was 
observed when live-cell labelling with reversible fTKIs was attempted (Section 5.2). 
While competition between reversible compounds (f-Gef and Gefitinib®) is a 
continuous process, displacement of a reversible compound by an irreversible one only 
occurs once. The same differences were also observed in type II fTKIs experiments; 
while f-Lap binding was almost abolished (combination of competition and reduced 
number of inactive kianses), f-Ner membrane signal was reduced by 50%. An 
explanation for the fact that f-Ner binding was not abolished as a result of the formation 
of asymmetric dimers may lie in the presence of mostly dimeric receptors with 
asymmetric TKD dimer configurations which have been promoted due to Gefitinib® 
treatment. As discussed in Section 6.4.1, promotion of the tethered conformation 
favours dimerization. Furthermore, such dimers appear to be conformationally coupled 
to asymmetric dimers (outside-in regulation). If promotion of asymmetric dimers 
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(Gefitinib® treatment) is also accompanied by formation of tethered ECDs as 
previously seen in EM
217
 (inside-out regulation), then Gefitinib-treated cells are 
expected to be highly dimeric (will be also investigated later). If that is the case then 
type II fTKIs would be able to bind to 50% of the total number of receptors which is 
remarkably consistent with the f-Ner result. 
Having found that Gefitinib-treated receptors form higher number of asymmetric 
dimers, the next step was to determine the conformation of the ECD in the same 
conditions. For that, the three methods for probing the ECD structure used earlier, 
(DOCA, SPT and FLImP, were employed. The results are shown in Figure 6-21. 
As in the case of 9G8 experiments (Figure 6-12), DOCA measurements of Gefitinib-
treated wt EGFR expressing cells suggest an increase in the number of tethered 
complexes compared to untreated wt EGFR (Figure 6-21A). However the distance of 
both DI and DIII, as well as the difference between them, were different from those 
obtained from 9G8-bound receptors (6.2 and 7.54 nm as opposed to 4.87 and 8.37 nm 
for 9G8 treatment). A possible explanation for these differences might be due to 
different mechanisms of formation, and hence stabilization, of the ECD conformation. 
9G8 binds to the receptor and “locks” it in the tethered conformation whereas in 
Gefitinib-treated cells the promotion of the tethered conformation is driven from inside 
due to the conformational coupling of asymmetric dimers with the unliganded tethered 
ECD dimers. Another explanation might be due to fluctuations of the tethered ECD 






Figure 6-21: Determination of the ECD conformation and configuration of wt EGFR pre-treated with 
Gefitinib®. DOCA measurement (A), FLImP results (B) and SPT analysis (C) of wt EGFR expressing CHO cells 
pre-treated with 1 μM of Gefitinib®. All experiments were performed in triplicate. 
 
The results from FLImP analysis were also consistent with an increase presence of 
tethered ECD dimers in Gefitinib-treated cells was also confirmed by FLImP analysis 
(Figure 6-21B). In the case of inhibitor-induced dimerization the ratio of the fraction of 
separations consistent with tethered/extended dimers (Figure 6-21B, ii) was increased 
compared to 9G8-treated cells (1.88 and 1.57 respectively). This additional stabilization 
of the tethered dimers when dimerization is driven by the formation of the well-defined 
asymmetric dimer interfaces (Gefitinib treatment) was also confirmed by 2-colour SPT 
colocalization analysis (Figure 6-21C, i). Promotion of asymmetric dimerization 
resulted in a 1.8-fold increase of the mean colocalized fraction of non-monomer 
complexes compared to promotion of tethered conformation (9G8). Despite the 
increased colocalization frequency, the duration of the interactions (Ton, Figure 6-21C, 
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ii) calculated from both treatments was identical which might reflect the absence of 
stable oligomers.  
FLImP distribution and SPT colocalization analysis also suggest that Gefitinib, as 
9G8, favours the formation of dimers within the overall non-monomeric population. 
This observation is in agreement with the previous assumption that receptors treated 
with Gefitinib (and likely other type I TKIs) form asymmetric dimers but, in contrast 
with EGF-stimulated receptors
265
, oligomerization is disrupted, despite the fact that 
TKIs are not expected to affect the interfaces required for oligomerization. The reason 
for this disruption, as the present data suggest, might be due to inability of the receptors 
to form stable higher order oligomers when the ECD adopts the tethered conformation. 
In conclusion, in this section the previously proposed inside-out regulation of 
EGFR
65,103,217
 was exploited to further investigate the conformation coupling of the 
“active” population of the basal receptor seen in 9G8-treated cells. It was found using 
the fTKI method that Gefitinib, a type I TKI, promotes asymmetric dimerization in cells 
consistent with previous results for the solubilized receptor
217
. Furthermore, it was 
shown that this TKD conformation in unliganded receptors promotes the formation of 
tethered ECD dimers, consistent with the data shown in Section 6.4.1. Formation of 
asymmetric kinase dimers appears to be more crucial in stabilizing dimers with a 
tethered ECD configuration than the formation of the tethered conformation itself, or 
the destabilization of the extended conformation, since monomers are believed to be 
tethered
36,65
. A scheme summarizing the findings from Chapter 6 regarding the 
architecture of the basal EGFR in cells is shown below (Figure 6-22). 
Basal wt EGFR exists in equilibrium between three different conformations; inactive 
monomers, inactive extended dimers and active tethered dimers. The two dimeric 
populations were shown to coexist in similar levels when the receptor is unperturbed. 
The extended dimers appear to be associated with higher order oligomers, in agreement 
with what was recently reported by Needham et al.
251
 regarding EGFR oligomerization 
due to interactions between extended ECDs, whereas the tethered dimers disfavour 
higher order oligomers. This may constitute an auto-inhibition mechanism to prevent 
aberrant activation of the receptor in the basal state. Further studies are required to 
determine whether the two dimeric populations are linked and, most importantly, which 









7 Insight into Activation of Non‑Small Cell Lung Cancer 
EGFR Mutants and Drug Resistance 
 
7.1 Introduction 
Physiological regulation of ErbB family members is often disrupted in various cancer 
types, leading to hyperactivation or ligand-independent activation. This deregulation 
could be the result of activating mutations, amplifications or overexpression (usually 
EGFR or ErbB2). 
Activating mutations on all ErbB members have been found in all five structural 











. Unfortunately, the structural basis of the activation of some of 
these mutations which could potentially lead to the design of more effective therapeutics 




 have been 
shown to confer resistance to different TKIs. Herein, I will investigate the role in EGFR 
activation and drug resistance of the two most common mutations occurring in non-
small-cell lung cancer (NSCLC): the primary exon 21 point mutation (L858R or 
L834R) and the secondary exon 20 point mutation (L858R/T790M),. 
 
7.2 Effect of L858R and L858R/T790M on EGFR 
Architecture 
NSCLC constitute the most frequently type of lung cancer
222
 which is often driven 
by mutations on the TKD of EGFR. These somatic mutations are caused by in-frame 

















 is located at the N-terminal region of the A-loop, adjacent to the small helical 
DFG motif, and in the inactive state of the TKD participates in a set of hydrophobic 
interactions which hold the αC-helix outwards. Crystal structures revealed that mutation 
to arginine  results in disruption of these interactions which in turn allows the αC-helix 
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to adopt the position that favours the active conformation
25
 (equivalent mutation has 
been also reported for ErbB3
27
). Furthermore, molecular dynamic simulations suggested 





 is located in the hinge region and is also known as the “gatekeeper” 
residue. Its mutation also involves displacement of the DFG motif and stabilization of 
the active conformation. The double L858R/T790M has been suggested to further 
stabilize the active conformation by reducing the energy barrier for the transition from 
the inactive to the active conformation as well as by stabilizing the αC-helix, and 
subsequently the TKD, in the active conformation
281
. 
Despite these findings, the effect of these TKD mutations on the ECD structure, for 
example through inside-out regulation, and on the geometry of the receptor on cells was 
only recently explored
103
. Valley et al.
103
 showed that L858R adopts an extended 
conformation in the absence of ligand which was also accompanied by increased 
dimerization and aggregation. In order to get a better insight into the mechanism that 
drives the L858R and the L858R/T790M mutations I decided to characterize the 
NSCLC mutants using the methods described in Chapter 6. For these experiments wt 
CHO cells were transiently transfected (optimization of the transfection was also 
performed) with the desired plasmid using ViaFect (Promega®) and a reverse 
transfection as described for ErbB2-4 in Section 5.2. Their expression levels were found 
to be identical as assessed by confocal microscopy.  
 
Figure 7-1: Assessment of expression levels of L858R and L858R/T790M in wt CHO cells. wt CHO cells 
expressing either the L858R (green line) or the L858R/T790M EGFR mutant were labelled with a saturating 
concentration (100 nM) of Affy-CF640R and then fixed. Assessment of the expression of both NSCLC mutants was 




In order to fully characterize the two mutants, the knowledge of their colocalization 
frequency and Tons as well as their basal phosphorylation is imperative. The SPT and 
WB data presented in Figure 7-2 have been acquired by Dr L.C. Zanetti-Domingues 
(Zanetti-Domingues et al., manuscript in preparation). The first two lines in plots 
Figure 7-2 (A) and (B) show the results from basal and EGF-treated wt EGFR 
expressing cells (obtained from Figure 6-10) for comparison. 
 
Figure 7-2: SPT analysis and receptor phosphorylation of the basal L858R and L858R/T790M EGFR 
expressing cells (adapted from Zanetti-Domingues et al., manuscript in preparation).  Cells expressing either 
L858R or L858R/T790M were prepared for both SPT and WB according to the general protocol described herein 
(Sections 6.2.1 and 5.3.1 respectively). Analysis of the SPT data was performed as in Section 6.2.1. 1st and 2nd 
dataset in figures (A) and (B) show the results from experiments in CHO cells expressing wtEGFR with or without 




L858R mutant not only exhibited a significant increase in the colocalization fraction 
compared to basal wt EGFR (1
st
 line), consistent with the results from Valley et al.
103
, 
but its colocalized fraction was comparable with the EGF-stimulated wt receptor 
(Figure 7-2A). The double mutant also showed a 2-fold increase in the formation of 
non-monomeric complexes (similarly to 9G8-treated wt receptors in Figure 6-17) 
however its mean value was 3.5-fold lower compared to the single mutant. This last 
observation was unexpected as the additional mutation (T790M) on a L858R receptor 
has been suggested to enhance stability of the active state
281
, a finding which is also in 
agreement with biochemical studies showing that the double mutant has higher basal 
phosphorylation than the single mutant
282
. In order to ensure that both mutants 
expressed in wt CHO cells show the same trend in phosphorylation as previously 
reported, receptor phosphorylation was also determined (also performed by Dr L.C. 
Zanetti-Domingues). WB analysis confirmed that the double mutant is hyper-
phosphorylated in the absence of ligand (Figure 7-2C). Collectively these results appear 
to be consistent with what was suggested by the experiments in Chapter 6: basal 
phosphorylation of the unliganded receptor is not correlated with a high degree of 
dimerization/oligomerization as opposed to what happens with the liganded receptor 
when treated with EGF concentrations close to physiological levels
234,251,283
. Despite the 
significant difference in the colocalization frequency between the two mutants, Ton of 
L858R was only 1.5-fold higher than that of L858R/T790M, a finding which may 
provide an explanation for the increased phosphorylation. 
In order to better understand the effect of these mutations on the overall receptor 
geometry and ECD conformation, I performed FLImP and DOCA experiments. FLImP 
analysis demonstrated that L858R is highly oligomeric whereas the double mutant is 
mostly dimeric (Figure 7-3 A and B respectively). These results are also consistent with 
the SPT results (Figure 7-2). Attempts to acquire good quality FLIM images were 
unsuccessful due to the low expression of the NSCLC mutants in CHO cells and hence 
low number of photons per pixel. However, Valley et al.
103
 recently showed that L858R 
mutation favours the extended ECD conformation which is consistent, based on the 
model proposed herein, with its high oligomeric fingerprint (Figure 7-3A). 
Unfortunately there are no published data regarding the ECD conformation of the 
L858R/T790M mutant. With regards to the tethered-extended dimer ratio which was 
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shown in Chapter 6 to be correlated with the phosphorylation of the unliganded 
receptor, L858R data (Figure 7-3C) suggest that Affibody separations consistent with 
the tethered dimer conformation are slightly favoured. This is in agreement with its 
basal phosphorylation status, slightly higher than basal wt EGFR, and the model in 
Figure 6-22. On the other hand, the tethered-extended dimer ratio of L858R/T790M 
was unexpected. Even though, based on the results in Section 6.4 (promotion of the 
tethered conformation in the basal receptor is accompanied by an increase in 
phosphorylation), its relatively low non-monomeric fraction, dimeric geometry and high 
basal phosphorylation led me to the assumption that the double mutant would preferably 
form tethered dimers, FLImP analysis revealed that there is not any such preference 
(Figure 7-3C). 
 
Figure 7-3: Determination of the geometry of NSCLC mutants in cells. FLImP results (A & B) of wt CHO cells 
expressing L858R or L858R/T790M EGFR mutants. All experiments were performed in triplicate. The relative 
populations of tethered and extended dimers of both mutants are shown in (C). 
 
The reason why the proposed model presented herein failed to explain 
L858R/T790M hyperactivation may lie on a distinct characteristic of this mutant. Two 
independent studies have shown that a receptor harbouring both point mutations is still 
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phosphorylated even after disruption of the asymmetric dimer interface (either N- or C-
lobe mutation)
282,284
. On the other hand, receptors with either the L858R or T790M are 
entirely dimerization-dependent. Furthermore, Jia et al.
285
 recently showed that cells 
transfected with the activator-impaired version of the L858R/T790M were still able to 
proliferate. Therefore, the double mutation not only stabilizes the active conformation 
but most importantly, as the present data suggest, by-passes the activation mechanism 
followed by both the wt receptor and the constitutively active L858R mutant. 
 
7.3 Drug Sensitivity/Resistance Mechanism of NSCLC EGFR 
Mutants 
The T790M mutation was first identified as a secondary mutation, occurring in 
association with L858R in patients who had been independently treated with two 




). While L858R conferred sensitivity 
to all type I TKIs
288
, the so-called “gatekeeper” mutation, which occurs in many 
kinases
211
, conferred resistant to both type I and II reversible TKIs
213
. It was initially 
though that the resistance mechanism of the T790M relies on the exclusion of the TKIs 
from the ATP site due to steric hindrance from the bulky side chain of 
methionine
212,286,287
. However, Yun et al.
213
 showed that the resistance of this double 
mutant against competitive (reversible) TKIs (which retained low-nanomolar affinity) is 
due to increased affinity to ATP. On the other hand, irreversible TKIs effectively inhibit 
phosphorylation of the double mutant
212
. With the fTKIs in hand I sought to further 
explore the mechanism by which this mutant confers resistance to TKIs. 
All the experiments and analysis were performed as described earlier (Section 5.3.1). 
The results from experiments in basal and EGF-treated cells expressing either L858R or 
L858R/T790M are shown in Figure 7-4. For L858R expressing cells (red columns), I 
found that the membrane signal of both reversible and irreversible type I fTKIs was 
higher compared to wtEGFR in both basal and EGF-treated states (Figure 7-4A & B, i 
and iii). As discussed earlier (Section 5.3.1), any change in f-Pel (irreversible inhibitor) 
binding can only be attributed to alterations in its affinity, therefore the observed ~1.5-
fold increase in Pelitinib binding (in both states) must be due to increased affinity as a 
result of the TKD point mutation. The fact that the structure and binding mode of 
Pelitinib are very similar to Gefitinib (Figure 5-15) suggests that the increased f-Gef 
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membrane signal is mainly due to increased affinity as a result of the L858R mutation 
(part of the increase in the basal state could be correlated to the slightly elevated basal 
phosphorylation). Collectively, the data indicate that the reason behind the increased 
affinity of type I TKIs against L858R EGFR mutant is the altered Kon. 
While the higher affinity of type I TKIs found herein is consistent with previous 
reports
176,182,216
, the increase in f-Lap binding (Figure 7-4A & B, ii) was unexpected. 
The fact that f-Ner binding (Figure 7-4A & B, iv) remained unaffected (which indicates 
that the overall number of inactive kinases has not changed compared to wt EGFR 
expressing cells) suggests that this increase can only be explained by increased 
Lapatinib affinity due to its slower dissociation rate (Koff) from the pocket. Furthermore, 
the type II fTKI data (and in agreement with the WB analysis in Figure 7-2C) indicate 
that the L858R mutation does not itself promote the active conformation by disrupting 







Figure 7-4: Determination of the resistance mechanism of NSCLC EGFR mutants. wt CHO cells expressing 
either L858R or L858R/T790M were prepared and labelled as described earlier for both the basal (A) and EGF-
stimulated (B) receptors. All experiments were performed in triplicate. 
 
This surprising result is in contrast with previous binding studies (where either 
purified EGFR TKD
176,182
 or purified near full-length receptor
216
 were used) which 
showed that Lapatinib binding affinity was decreased as a result of the L858R mutation. 
A L858R crystal structure resolved by Yoshikawa et al.
278
 revealed a novel 
conformation where the ATP cleft is wider and more accessible, which is related to Kon 
of TKIs, than in the wt receptor. Even though this observation could explain the 
increased affinity of type I fTKIs against the L858R mutant, as the authors also 
suggested
278
, the present type II fTKI data (their Kon is not affected) suggest that the 
increased Lapatinib affinity is independent of the reported altered feature of the ATP 
cleft, unless the observed widening also affected the dissociation rate (Koff) of type II 
fTKIs. Even though the exact mechanism behind the increased Lapatinib affinity is not 
understood and requires further studies, I speculate that it might be related either to the 
increased number of non-monomer complexes (Arkhipov et al. postulated that the ATP 
cleft of monomeric receptor is occluded
63
) found by SPT and FLImP (Figure 7-2 and 
Figure 7-3 respectively) or to an alternative intermediate conformation (that is almost 
absent in wt receptor) which was shown by Sutto et al. to be the most stable in the 
L858R mutant (proposed by massive molecular dynamics simulation)
281
. 
Taken together the fTKI data presented herein (Figure 7-4) and the western blot 
analysis obtained from Dr L.C. Zanetti-Domingues (Figure 7-2C) for L858R suggest 
that the sensitization of the L858R EGFR to type I TKIs
25,276
 is not exclusively due to 
constitutive activation, and consequently to increased affinity of type I TKIs, of the 
receptor by the single-point mutation, as previously thought
49
. First of all, the present 
study demonstrated that the L858R mutation in cells is not itself capable of hyper-
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activating the receptor as Zhang et al. proposed
49
. My observation is also in agreement 
with a model recently suggested by Red Brewer et al.
282
 (superacceptor hypothesis) who 
found that lung cancer mutants are more potent when they are co-expressed with the wt 
receptor and forced to adopt the acceptor position, a hypothesis which was also 
confirmed by Ruan et al. for the R776H EGFR mutant
289
. Secondly, the type II 
reversible TKI Lapatinib was also found to possess increased affinity against L858R 
and not reduced. Thus, the mechanism by which cancer cell lines harbouring L858R 
mutation confers sensitivity to type I TKIs may lie in the hyper-activation of the mutant 
(and the reduction of the number of inactive kinases) by another EGFR allele 
(superacceptor model). A similar sensitivity to type I inhibitors has also been shown to 
occur in the EGFR-overexpressing cancer cell line A431 in the basal state despite the 
fact that both type I and II TKIs have similar potencies for the wt receptor (which is the 
only EGFR allele expressed on A431 cells)
290
. By analogy to L858R EGFR expressing 
cancer cell lines, this sensitivity to type I TKIs is likely due to constitutive basal 
phosphorylation of the receptor by an autocrine loop in which cells self-provide the 
receptors with endogenous TGF-α (EGFR ligand)291,292. 
Next, the drug resistance mechanism of the L858R/T790M receptor was examined. 
Both type I and II reversible fTKIs (f-Gef and f-Lap) exhibited a decrease in their 
binding (Figure 7-4A & B, i and ii). In particular f-Lap binding was completely 
abolished as expected for a constitutive active receptor and also consistent with previous 
binding studies
176,182
. On the other hand, from the two irreversible fTKIs (f-Pel and f-
Ner) only the type II f-Ner displayed a decrease in its binding, whereas f-Pel binding 
remained constant (Figure 7-4A & B, iii and iv). The fact that f-Ner still binds the 
receptors suggests that the observed reduction of the type II fTKIs is due to both the 
high number of active kinases as determined by WB (Figure 7-2C) and their previously 
reported reduced binding affinity
176,182
. On the contrary, the reduced f-Gef binding can 
only be associated to a reduction of its binding affinity, since f-Pel membrane signal is 




 demonstrated that the acquired drug resistance of the double mutant to 
reversible inhibitors
293,294
 is due to the higher affinity to ATP and not due to steric 
hindrance from to the bulky methionine residue (which would affect substrate binding 
affinity). Even though in the context of the fTKI experiments the role of the competition 
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of the reversible TKIs with ATP cannot be examined, the present data show for the first 
time, and in contrast to Yun et al.
213
, that the “gatekeeper” mutation also facilitates the 
release of the reversible inhibitors from the pocket. Therefore the role of the secondary 
T790M mutation in the drug resistance mechanism of the receptor is dual; assisting the 
faster release of TKIs from the pocket and also increasing the affinity for ATP. 
Furthermore the data suggest that irreversible type I TKIs would more effectively 




8 General Conclusions and Future Perspective 
This thesis describes the step-by-step development of novel chemical tools for the 
specific labelling of the TKD (intracellular) of ErbB family members and their 
utilization in fluorescent microscopy which aims to investigate, in combination with 
existing methods
70,71,136,137,251
, the drugs mechanism of action and the basal architecture 
of EGFR on cells. 
In order to specifically label the TKD of ErbB family members, EGFR TKIs, which 
bind to the ATP site of the receptors
22
, were chosen to be turned into fluorescent 
imaging probes. The design of the fTKIs was based on the general structure of activity-
based probes
122
. The synthesis of fTKIs (Chapter 4) was carried out using approved 
drugs or TKIs in clinical trials with good selectivity profiles
182,295
 in order to minimize 
the off-target binding in the cellular environment. The final list of selected compounds 
for development of their fluorescent versions includes four TKIs: Gefitinib (type I 
reversible), Pelitinib (type I irreversible), Lapatinib (type II reversible) and Neratinib 
(type II irreversible). The diversity of the different classes of these TKIs allowed me to 
get an insight into their mechanism of action as well as to be able to use them, when 
combined, as reporters of EGFR activity in cells (Chapters 5-7). The synthesis of every 
compound reported herein (including the dyes) was based on previously reported 
synthesis. Even though some of the literature procedures did not work as expected, 
alternative reactions led to the desirable final compounds. Overall 15 final fluorescent 
EGFR inhibitors were synthesised herein. 
Characterization of the affinity and selectivity of the synthesized fTKIs in a 
biochemical assay (KinomeScan®) demonstrated that the initial design and syntheses 
were successful as all compounds retained low nanomolar affinity and selectivity (Table 
5-1). Furthermore, properties such as permeability and in vitro binding and specificity 
were assessed in cells (Section 5.2) and revealed: 
i. the lipophilicity (ClogP) and the net charge of the dyes, as well as the size of the 
pharmacophore, affect the permeability of small-molecule conjugates 
ii. different dyes can have different effects on the intracellular distribution and/or 
the non-specific binding of a conjugate 
iii. reversible fTKIs cannot be used for live cell imaging 
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iv. both reversible and irreversible fTKIs can be used for labelling the receptors in 
pre-fixed cells 
The observations yielded from my characterization could further provide an additional 
guidance for low-MW weight probe development in the future, especially for use in 
fluorescence imaging. 
A key feature of the post-fixation fTKI labelling method is that it could allow one to 
directly monitor the binding affinity of different inhibitors to the receptor without 
perturbing its conformation (which can be induced by TKIs binding
65,217,219
). By 
exploiting this cell-based assay and combining it with quantitative imaging analysis 
(Section 5.3.1), I sought to get an insight into the conformationally selectivity of TKIs 
for the different EGFR TKD conformations. Even though the knowledge of such a 
preference could help the clinical need for better response of targeted therapeutics, the 
question regarding the selectivity of EGFR TKIs remained unanswered
218
. My study 
revealed that TKIs are indeed conformationally selective but also gave me an insight 
into the mechanism for this selectivity (binding kinetics). These findings highlight that 
the clinical success of a drug does not only depend on its binding affinity, determined 
by biochemical assays, but also on the type of the inhibitor (I or II) and the state of the 
TKD of the receptor. Furthermore, the fact that fTKIs do have preference for the 
different TKD conformations means they can be used as reporters of the receptor 
conformation. 
Applications of fTKIs in different fluorescence microscopy techniques were also 
explored (Sections 5.3.2 and 5.3.3). These applications include intra-dimer FRET 
measurements, using FLIM-FRET, for assessing receptor dimerization and SPT using 
TIRF microscopy for studying receptor perturbation at single molecule level. Even 
though the preliminary results from both methods shown in Sections 5.3.2 and 5.3.3 are 
promising, further optimization and studies are required in order to assess their validity. 
The information which could be potentially extracted from these methods could allow: 
1) a better understanding into the mechanism of activation of EGFR-driven cancers 
without EGFR mutations as these cell types are likely to depend on homo- and hetero-
dimerization
230
 and 2) insight into dynamics of receptor inhibition and drug resistance. 
With regards to FLIM-FRET experiments, studies in stimulated cells where, 
presumably, the dimerization is higher is imperative for validating the method. SPT 
experiments require improvement of the SNR, by reducing the non-specific binding of 
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the fTKIs on the glass. In order to overcome this issue, alternative methods for loading 
the cells could be attempted
247–249
. Alternatively, different glass surface coating 
methods, such as polyelectrolyte multilayer coating, could reduce the non-specific 
binding on the glass
296
. 
In Chapters 6, I employed a combinatorial approach in order to investigate the 
architecture of the basal full-length EGFR in its native membrane environment. While 
the ECD and TKD conformations of both the monomeric (inactive) and the EGF-bound 
(activated) dimeric receptor have been more extensively studied, the conformation of 
the pre-formed dimers is unknown. Determining their structure is of importance as it 
would allow scientists to build a model for the inactive-active transition which in turn 
would lead to the design of novel therapeutics agents. 
The combinatorial approach included previously developed methods for probing the 
EGFR ECD structure
70,71,136,137
 and combined with the pre-fixed fTKI labelling method 
reported herein for probing the TKD structure. The data from the study presented herein 
appears to be consistent with the model of the basal receptor illustrated in Figure 6-22. 
According to that model (which does not include higher order oligomers), basal EGFR 
on the cell surface can adopt two different dimeric populations (apart from the inactive 
momoner
36
): inactive dimers where the ECDs adopt the extended conformation and the 
TKDs are in a symmetric configuration and active dimers with tethered ECDs coupled 
to asymmetric TKD dimers. Furthermore, the data indicated that oligomerization of the 
receptor in the basal state is not important for basal phosphorylation. 
These findings further led me to investigate whether the mechanism of activation of 
two constitutively active NSCLC EGFR mutants, L858R and L858R/T790M, are 
consistent with the proposed model as well as the mechanism of drug resistance of these 
mutants (Chapter 7). In terms of the first objective, the data indicated that L858R 
EGFR mechanism of activation appears to be consistent with the model of the wt 
receptor (ligand-dependent activation) when it is not co-expressed with wt EGFR
282
 (or 
perhaps other ErbB members). On the other hand, the double mutant (L858R/T790M) is 
able to “by-pass” the requirement for ligand binding as its kinase domain preferentially 
adopts the active conformation and, as recent studies indicated
282,284,285
, do not require 




- the sensitivity of L858R EGFR to type I TKIs is not only due to conformational 
change by the TKD mutation but also depends on the ability of the mutant to be hyper-
phosphorylated by the wt receptor (super-acceptor hypothesis
282
) 
- the resistance of L858R/T790M to reversible TKIs is a result of both the higher 
affinity of the mutant for ATP
213
 and the higher dissociation rate that reversible TKIs 
exhibit due to the presence of the bulky methionine. 
In addition to this, fTKI data suggested that type I irreversible TKIs could more be 
more effective against such EGFR mutants as they bind both the inactive and the active 
TKD conformations with the same affinity. 
 
The use of small-molecule fluorescence probes in fluorescence microscopy has 
proven a very challenging task, especially at single molecule level, due to the presence 
of the dyes. The properties of such low MW conjugates greatly depend on the net 
charge, lipophilicity and size of the dye. While neutral dyes are essential for the 
permeability of small molecule probes, they introduce artefacts at single molecule level 
due to their non-specific binding on the glass
161
. While labelling of pre-fixed cells can 
be performed at RT with a short incubation time (3-5 min) at low nM concentrations, 
live cell labelling (as in SPT) requires 2 hours incubation at 37
o
C and a relatively high 
concentration. Even though different methods for reducing the non-specific binding 
were attempted (glass cleaning and photobleaching strategy) the SNR was not at the 
desired levels. Optimization of the glass coating method or use of alternative methods 
for loading cells with the probes could allow the use of fTKIs in techniques such as SPT 
and FLImP etc. in order to fully characterize the ICD of EGFR. 
EGFR regulation has been also shown to be associated not only with the other ErbB 
family members
1,297
 but also with other proteins such as c-MET
298
 and G protein-
coupled receptors
299
. Even though fTKIs were successfully used for studying the 
mechanism of action of EGFR drugs in CHO cells, expanding this method in other cell 
lines (which either express wt or other cancer EGFR mutants) would allow painting a 
complete picture of the TKIs mechanism. The method could be further exploited to 
investigate the binding of ErbB2 TKIs in cells. Both Lapatinib and Neratinib are known 
to inhibit ErbB2
300
. Therefore, expanding the method to ErbB2 would allow us get a 







 as well as to study the effect of different dimerization 
partners in TKIs binding. 
In addition to this, another future plan is the investigation of the effect of antibody 
treatment on the binding of different TKI types. Combinatorial treatment of both ECD 
and TKD inhibitors has been suggested as an alternative approach in clinics
18–21
. While 
EGFR inhibition by TKIs occurs by blocking ATP binding, the inhibition mechanism of 
antibodies varies
17,24,267
. Most importantly, it is not known whether antibody binding 
induces conformational changes of the TKD (as shown in Section 6.4, 9G8 appears to 
promote asymmetric dimerization) since methods for probing the TKD conformation 
are not available. If such changes take place and since TKIs affinity depends on the 
TKD conformation (Section 5.3.1), the efficiency of antibody-TKI synergy could be 
affected by antibody binding. Therefore, exploring the effect of antibodies to the 
conformation of the TKD could potential help us to pre-determine which antibody-TKI 
combinations will exhibit the best synergistic effect. 
Following validation of the intradimer FRET method and optimization of the single 
molecule methods (and in particular FLImP), the plans for the long term include the 
expansion of these methods to the other three members of the ErbB family. It has been 
suggested that ErbB family members not only interact with each other when 
activated
1,297
 but also that they heretodimerize in the basal state
66–68,225
. The synthesised 
fTKIs to that can bind all four members in cells with low nanomolar affinity (Table 5-1 
and Figure 5-10). Therefore, fTKIs could in principle enable us to study the extent of 
dimerization when cells express all four members, the heterodimerization preference 
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